Patent application title: PREDICTION OF BARE METAL STENT RESTENOSIS
Inventors:
Conor F. Lundergan (Ellicott City, MD, US)
Harry B. Burke (Glen Allen, VA, US)
Timothy A. Mccaffrey (Silver Spring, MD, US)
IPC8 Class: AC12Q168FI
USPC Class:
435 6
Class name: Chemistry: molecular biology and microbiology measuring or testing process involving enzymes or micro-organisms; composition or test strip therefore; processes of forming such composition or test strip involving nucleic acid
Publication date: 2009-06-04
Patent application number: 20090142756
Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
Usenet FAQ Index |
Documents |
Other FAQs |
Patent application title: PREDICTION OF BARE METAL STENT RESTENOSIS
Inventors:
Harry B. Burke
Conor F. Lundergan
Timothy A. McCaffrey
Agents:
WHITHAM, CURTIS & CHRISTOFFERSON & COOK, P.C.
Assignees:
Origin: RESTON, VA US
IPC8 Class: AC12Q168FI
USPC Class:
435 6
Abstract:
Methods for predicting whether or not a patient is likely to experience
restenosis after the placement of a bare metal stent are provided. The
methods involve detecting and analyzing gene expression patterns of the
cellular components of whole blood, where activation of selected genes
has been found to be indicative of a high probability of restenosis. The
method thus allows the identification, prior to placement of a stent, of
patients who are i) likely to experience restenosis, and thus should
receive a stent that includes anti-restenosis agents; or ii) unlikely to
experience restenosis, and thus should receive a stent without
anti-stenosis agents.Claims:
1. A genomic based profiling method for predicting whether a patient that
is a candidate for a coronary artery stent wil experience restenosis if
he or she receives a bare metal stent, comprising the steps ofi)
obtaining a biological sample associated with a patient that is currently
not suffering from an active infection, and does not have diabetes, a
malignancy, a genetic based disease or a chronic inflammatory disease,
said biological sample being leukocytes present in circulating whole
blood;ii) establishing a gene expression profile from a plurality of
nucleic acids representative of genes expressed in said leukocytes;
andiii) using a trained partial least squares component based regression
model with an accuracy as measured by the receiver operating
characteristic (PLS-ROC) of 0.76 or greater to provide a probability
output for restenosis in said patient based on said gene expression
profilo.
2-4. (canceled)
5. The method of claim 1, wherein said plurality of nucleic acids are expressed from said leukocytes and are selected from one or more molecular pathways or molecular families selected from the group consisting of: molecular target of rapamycin; leukocyte trans-endothelial migration; TGFβ signaling; T cell antigen processing; T cell signaling; mitogen activated protein kinase (MAPK); and cell adhesion molecules.
6. The method of claim 1, wherein said step of determining a gene expression profile is carried out using a whole human genome chip.
7-15. (canceled)
Description:
FIELD OF THE INVENTION
[0001]The invention generally relates to predicting the probability of restenosis in patients receiving bare metal stents in native coronary arteries. In the preferred embodiment, the invention provides methods for predicting whether or not a patient is likely to experience restenosis based on the analysis of gene expression profiles of mRNA-containing components of whole blood, and, based on this prediction, determining whether the patient should receive a bare metal stent or a stent containing anti-restenosis agents.
BACKGROUND OF THE INVENTION
[0002]Coronary artery disease is the most prevalent medical problem in the industrialized world. It accounts for over 40% of all deaths in the United States and Western Europe (1). A primary therapy for coronary artery disease is coronary angioplasty with stent implantation (2).
[0003]Until recently the success of coronary stenting was limited by the process of restenosis, which occurred in 20-40% of cases (3). There have been reports that risk of developing in-stent restenosis appears to depend upon both clinical and procedural factors such as diabetes, length of lesion and location of lesion (4, 5, 6). The clinical and lesion related risk factors for restenosis, however, are very poorly predictive of restenosis. The most recent approach to prevention of restenosis involves local drug delivery to the vessel wall using drug eluting stents (7, 8). Remarkable success has been achieved in reducing restenosis with the use of stents coated with either Sirolimus or Taxol (9).
[0004]Coronary angioplasty with placement of one or more drug eluting stents has become the most common interventional treatment of significant flow limiting coronary artery disease. However, only 2-3 of every 10 patients can be expected to derive an additional benefit beyond that conferred by bare metal stents (10). Bare metal stents are utilized much less frequently compared to drug eluting stents because restenosis is a known problem associated with using bare metal stents. Using a drug-coated stent instead of a bare metal stent is associated with excess costs. Also, although drug-eluting stents would appear to be a significant step forward in the treatment of coronary artery disease, there is concern regarding the long term risk of sub-acute thrombosis associated with drug eluting stents (11). This may occur at an annual rate of 0.2-0.6% and may result in significant excess morbidity and mortality (11). Of note, seventy to eighty percent of patients derive no clinical benefit from drug-eluting stents (10). Therefore, it would be of value to have a test that would be predictive of low risk of restenosis with bare metal stents thereby reducing the indiscriminate use of drug eluting stents with their associated long term risks.
[0005]Despite the length of time that restenosis has been an issue and has been the subject of research no current technology exists for reliably determining whether an individual patient is likely to experience restenosis if given a bare metal stent rather than a drug coated stent, i.e., whether the drug coated stent is truly required to prevent restenosis. In addition to the excess costs associated with drug eluting stents, other associated clinical problems may be introduced by indiscriminately using drug coated stents for some patients who might have similar outcomes with a bare metal stent. These include an excess risk of bleeding associated with the need for long term anti-platelet agents in those individuals receiving drug elution stents and the risk of sub-acute stent thrombosis, a particularly severe adverse event associated with 40% mortality rate, in those individuals who may be non-compliant with the prescribed regimen or required to stop anti-platelet agents for other non-related surgical procedures. A method of identifying individual patients who may be equally well treated with a bare metal stent compared to a drug coated stent, from the perspective of whether restenosis is a risk for the patient, would be highly desirable. A gene expression test that accurately predicts bare metal stent restenosis would reduce the need for drug eluting stents and thus reduce long term excess morbidity, costs and mortality associated with drug eluting stents. In light of the vast numbers of patients receiving drug coated stents on a world wide basis, the introduction of simple, rapid and highly predictive gene expression test for prediction of the need for a drug coated stent would have significant beneficial public health consequences.
[0006]It has been suggested that restenosis of bare metal stents is due to individual genes. Walter et al (12) reported on 650 consecutive patients receiving non-drug eluting coronary stents and demonstrated a significant association of platelet glycoprotein IIIa gene polymorphism, risk of restenosis and statin therapy. Carriers of the P1A2 allele (A1/A2 heterozygotes) demonstrated a significantly increased restenosis rate, and this difference was largely eliminated by the addition of statin therapy. Walter et al concluded that, "statins interfere with the functional consequence of a genetically determined platelet mediated risk factor". Bauters et al. (13) presented data which supported the involvement of an I/D polymorphism of angiotensin-converting enzyme as a risk factor for coronary restenosis. Their results, however, were not confirmed by Momotte et al (14). de Maat et al. (15) suggested that a common promoter variant of the human stromolysin-1 gene confers a genotype specific response to medication in determining clinical event free survival and the risk for clinical restenosis after angioplasty and, therefore, may serve as a predictor of clinical restenosis. Specifically, patients with the 5A6A or 6A6A variant of the promoter region of this gene had significantly fewer events when treated with the lipid lowering drug pravastatin compared to placebo treated patients. Those with the 5A5A variant did not experience event reduction regardless of treatment assignment. Kastrati et al. (16) demonstrated that the presence of allele 2 of the interleukin receptor antagonist gene is associated with a lower risk of both angiographic and clinical restenosis. A clear gene dose effect was noted as patients homozygous for allele 2 had a lower incidence of in-stent restenosis than heterozygotes. Zohlnhofer et al. (17) demonstrated up-regulation of FK506-binding protein-12 (FKBP12) in neointimal specimens obtained by atherectomy post angioplasty. This is of interest in that FKBP12 is a target (receptor) for Sirolimus, an agent recently found to significantly reduce restenosis when applied to coronary stents. None of the above-mentioned studies of single-genes have been replicated or confirmed.
[0007]The expression of an individual gene may not be reliably associated with an outcome. It has been observed that, for the same disease, with similar inclusion and exclusion criteria, and employing the same gene array platform, multiple studies provide dissimilar sets of differentially expressed genes. The reasons for the unreliability of the association between an individual gene and an outcome include: 1) intra-patient and inter-patient variability; 2) small patient sample sizes; 3) low predictive power of most genes; 4) gene microarray platform variance due to their extremely high sensitivity to noise and 5) to bias in sample collection, handling, and pre-processing; 6) variation in processing reagent batch, decay in reagents over time 7) to differences in reading chip wells and 8) in multivariate analysis, the correlation of individual genes.
[0008]The prior art has thus far failed to provide a reliable method for assessing the risk of restenosis in individual patients slated for stent placement.
SUMMARY OF THE INVENTION
[0009]The invention provides a method of predicting the probability of occurrence of restenosis following placement of a bare metal stent in a native coronary artery of a patient, and methods to predict whether any given patient should receive a bare metal stent or a stent that contains anti-restenosis agents. The invention is based on a heretofore unknown association between overall increased gene activation/up-regulation in the mRNA-containing compartment of whole blood and the likelihood of restenosis. According to the invention, gene expression profiles of the RNA containing compartment of whole blood are used to detect gene activation, and this information is correlated with a probability of the occurrence of restenosis. The ability to predict which patients are at risk for or predisposed to restenosis and which patients are not permits the selective choice of stent type, i.e. bare metal stent vs drug eluting stent: patients with a low risk (less than or equal to a probability output of 50% as determined herein) can receive bare metal stents, thereby decreasing costs and the risk of major adverse clinical events attributable to use of drug eluting stents and the necessary use of long term anti-platelet agents, whereas patients with a high risk (probability output greater than 50% as determined herein) can receive stents that include anti-restenosis agents.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010]FIG. 1. Schematic representation of the method of the invention.
[0011]FIG. 2. Results of mRNA expression profiling demonstrating difference between non-restenosis (x-axis) and restenosis (y-axis) patients.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION
[0012]The present invention is based on the following discoveries:
1) Non-restenosis following native coronary artery stenting with a bare metal stent is a highly predictable event.2) Expression profiling using mRNA derived from the mRNA containing component of circulating whole blood may be used prospectively to identify individuals who, with a high degree of certainty, will not experience restenosis within 6 months following native coronary artery stenting with a bare metal stent.3) Increased transcription or decreased inactivation of the components of molecular pathways responsible for multiple cellular functions, including but not limited to T cell function, wound healing, cellular proliferation and migration, prospectively identify patients at high risk for restenosis following bare metal stent implantation who may benefit from the use of drug eluting stents to reduce their probability of restenosis.4) Subjects who do not exhibit activation of molecular pathways described herein have a high likelihood of non-restenosis and would not be expected to derive benefit from drug eluting stents.5) Activation of specific molecular pathways as described herein appear to be singular instances of a more generalized phenomena of activation of a plurality of the entire human genome found in the mRNA containing compartment of circulating whole blood, which itself is predictive of restenosis following native coronary artery stenting with bare metal stents.
DEFINITIONS
[0013]All scientific and technical terms used herein are understood to have the same meaning as commonly used in the art to which they pertain unless specified otherwise.
[0014]The present invention relates to the occurrence of coronary artery restenosis following coronary artery angioplasty with a device referred to as a bare metal stent. "Restenosis" herein means luminal re-narrowing within the confines of the bare metal stent or in the area of the immediately adjacent coronary artery tissue following a percutaneous stenting procedure. Restenosis is defined: i) quantitatively as a narrowing of at least a 50% vessel diameter reduction in the lumen of the stented vessel segment or in the immediate adjacent native vessel relative to a normal appearing non-stented portion of the same human native coronary artery which is located proximally to the stented segment. Restenosis is further defined as a process which fulfills the criteria of i) and; ii) is documented to have occurred within 6 months following placement of a coronary artery bare metal stent.
[0015]"Predicting" or "prediction" refers to the likelihood of a prespecified outcome i.e., a probabilistic determination. In this context, a likelihood outcome does not necessarily mean that the prediction will be correct in each instance of each individual for whom a prediction is made.
[0016]The phrase "gene expression system" or "gene expression platform" refers to any system, device or means to detect gene expression and is inclusive of diagnostic agents, oligonucleotide sets and/or probe sets used to carry out detection of candidate gene set of interest.
Methods for Determination of Gene Expression Levels
[0017]The increased gene activity on which the present invention is based was detected by mRNA expression profiling, i.e. by the elucidation of which genes in a sample were actively producing mRNA. Those skilled in the art will recognize that there are several methods by which gene expression can be detected or measured. Typically, expression of a gene is accompanied by an increase in mRNA transcribed from the gene. If the gene encodes a protein, gene activation is usually also accompanied by increased expression of the protein or peptide translation product from the mRNA. Those of skill in the art will recognize that either of these two entities (mRNA or protein) may be detected as indicators of gene expression. In addition, those skilled in the art will also recognize that nucleic acid sequences in particular are generally interconvertible, e.g. mRNA is readily converted to cDNA which may be converted to cRNA, etc., and any of these molecules may be detected as an indicator of gene expression. Thus, for the purposes of the present invention, gene expression may be assessed by detecting any suitable molecule (i.e. a "target" molecule), so long as the presence of the molecule in a sample is correlated with expression of a gene in a gene set of interest. Further, both the presence and the quantity of a target molecule must be detected/measured. In one embodiment of the invention, the gene expression profile is an mRNA expression profile. In another embodiment of this invention, DNA profiling may be used. In yet another embodiment of this invention, expression at the level of protein products of gene expression may be used.
[0018]In the context of the invention, a gene expression profile for a plurality of genes in a gene set of interest is obtained. A "plurality of genes" is at least two and frequently more than two genes. For example, representative gene sets will typically contain a plurality of genes in a range of from two to several hundred, or from two to several thousand, and may include all known human genes. In a preferred embodiment of the invention, the gene set that is analyzed contains one or more of the groups of genes presented in Tables 1-7 of the Examples section below. In another embodiment, the gene set that is analyzed comprises all known human genes the results of which are shown in Table 12a. In another embodiment of this invention, the gene set that is used in the method of the invention may contain any number of genes, so long as the results obtained from an analysis of this gene set is predictive of a probability of restenosis as described herein.
[0019]The choice of a particular set of genes for analysis may be based on any of several criteria, including but not limited to commonality of function. In this case, the genes in a gene set of interest may, for example, encode proteins that participate in one or more particular biochemical pathways, or that are expressed in a particular location (e.g. within a certain type of cell or tissue), or that are in some other manner related to one another. Alternatively, genes in a gene set of interest may be chosen simply due to convenience and/or feasibility (e.g. the ready availability of devices for detecting expression of a particular set of genes, or the genes being highly expressed and readily and unambiguously detectable); or selected at random. In the practice of the present invention, any suitable set, group, or category of genes may be analyzed, so long as the results obtained predict either restenosis or non-restenosis to a high degree of reliability, i.e., low false positive rate of predicting restenosis/non-restenosis and possess a high degree of reproducibility. In the context of the invention the phrases "predictive gene set", "candidate gene set" or "molecular signature" may also be used to describe the set of selected genes that are targeted for detection and analysis.
[0020]In a preferred embodiment of the invention, the level of gene expression of the genes in a gene set of interest is quantified by determining the mRNA expression profile of the mRNA containing compartment of whole blood, i.e. the intracellular mRNA from whole blood. Such a determination may include both the identification of which genes in the set are expressed and/or the quantification of the mRNA produced from each gene. Those of skill in the art are well-acquainted with the various methods available for establishing a gene expression profile, which include but are not limited to: 1) isolation of mRNA from a sample and separation via gel electrophoresis for subsequent northern hybridization and determination of gene derived mRNA; 2) slot-blots or dot-blots in which mRNA is labeled and hybridized to oligonucleotides derived from a gene set of interest for subsequent quantification of the hybridized product according to standard techniques, and; 3) methods involving: polymerase chain reaction (PCR) and/or reverse transcriptase-PCR (RT-PCR), Fluorescence Resonance Energy Transfer detection, or hybridization to an oligonucleotide array. Additional methods include but are not limited to hybridization to a cDNA array, Taq Man analysis, hybridization to a liquid micro-array, hybridization to a micro-electric array, cDNA sequencing, clone hybridization, cDNA fragment fingerprinting, Serial Analysis of Gene Expression (SAGE) methodology, subtractive hybridization, differential display or screening, and molecular beacon monitoring.
[0021]In another preferred embodiment of the invention, DNA microarrays are used to carry out the gene expression profiling. A DNA microarray (also commonly known as gene or genome chip, DNA chip, or gene array) is a collection of microscopic DNA "spots" representing single genes, arrayed on a solid surface. The DNA in a spot of the array usually consists of oligomer probes that are homologous to a target gene. The oligomer probes are typically about 25 to 60 nucleotides in length and are capable of hybridizing with nucleic acids (such as mRNA, cDNA or cRNA) whose sequences are based on (i.e. complementary to) the target gene. Many DNA microarrays of varying styles and designs are known to those of skill in the art, and any suitable DNA microarray may be used in the practice of the present invention. For example, in some microarrays, a single gene may be presented by multiple probes of differing sequences; homologous probes may be paired with non-homologous, non-hybridizing probes to provide negative hybridization controls; etc. As used herein, the phrase "probe set" refers to the probes present in a microarray that represent (i.e. are designed to detect or confirm the presence of) a gene set of interest. Any given gene in a gene set of interest is usually represented by at least one and frequently more than one probe. Thus, the number of probes in a probe set is usually greater than the number of genes in the gene set of interest that the probe set represents.
[0022]In one embodiment of the invention, a gene chip such as the Affymetrix U133+2 Genechip® gene chip, which contains 54,675 probe sets and is described as representing in excess of 33,000 genes plus other transcripts, may be used. However, those of skill in the art will recognize that many other alternatives exist or can be developed and used in the same or a similar manner in the practice of the present invention. Examples of alternatives include but are not limited to, for example, bead arrays which are used to simultaneously quantify expression of multiple sequences (e.g. LabMap 100, Luminex, Corp, Austin, Tex.). Electric arrays may be used to quantify the expression of multiple sequences (e.g., e-Sensor, Motorola, Inc. Chicago, Ill) or various other nanochip technologies may be used (e.g., Nanogen Inc, San Diego, Calif.). Those of skill in the art will recognize that the selection of a suitable microarray may depend in part on the particular candidate (predictive) gene set that is being examined, although all possible gene sets represented on a microarray need not be analyzed or taken into account, even if such data is available. For example, when the Affymetrix U133+2 Genechip® is utilized, the gene expression profile of all genes that are represented on the microarray may be analyzed. Alternatively, data representing only selected subsets of genes of interest (e.g. those belonging to a candidate or predictive gene set as described herein) may be selected for analysis.
[0023]In a preferred embodiment of the invention, the sample that is obtained from a patient is "whole blood". However, those of skill in the art will recognize that the practice of the present invention need not be limited to the analysis of whole blood. For example, individual cellular (e.g., lymphocyte, reticulocytes or megakaryocyte) or non-cellular components (e.g., platelets) may be examined with regards to expression profiling. The term leukocyte refers to any nucleated blood cell that is not a nucleated erythrocyte. There are two classes of leukocyte including granulocytes (e.g., neutrophils and basophils) and mononuclear cells (e.g., monocytes and lymphocytes).
[0024]In the preferred embodiment of this invention expression profiles are evaluated by detecting mRNA. A multitude of techniques are available for the isolation of mRNA from whole blood. Any method that allows for isolation of mRNA from cells can be utilized. Peripheral blood is drawn from a subject into one or more sterile tubes containing an anti-coagulant such as heparin, EDTA, citrate and or a fixative. In the context of this invention the preferred medium for collection of whole blood is PaxGene® (Quiagen, Inc). The sample is divided into two portions. One portion is frozen and stored for future use and the other is processed by one of a variety of methods for isolation of RNA. A 8 milliliter sample of whole blood usually yields approximately 5-20 μg of total RNA, which is generally a sufficient quantity for labeling and hybridization to a probe array. Labeled target molecules are prepared from the subjects RNA using standard methods. cDNA may be synthesized from RNA using a poly T primer incorporating a T7 polymerase sequence. cRNA may then be transcribed while incorporating biotinylated nucleotides. In the preferred embodiment of this invention the preferred method is the use of the Affymetrix IVT reaction. The resulting pool of labeled cRNA may be purified and fragmented to allow individual transcripts to hybridize to gene probes representing genes of interest located on e.g., micro-arrays. In some instances the amount of RNA extracted is inadequate for processing and amplification of the RNA may be required. Amplification may be performed by 1) increasing the efficiency of labeling or; 2) by amplifying the RNA sample prior to labeling.
[0025]In another embodiment of this invention cDNA may be used for expression profiling. In this embodiment 8 milliliters of whole blood usually yields approximately 5-20 μg of RNA. Labeled target molecules are made from the subjects' sample of RNA using standard methods. cDNA is synthesized from total RNA using a poly T primer and labeled with fluorescent or radioactive nucleotides. The resulting labeled cDNA is hybridized to probes corresponding to known genes or expressed sequence tags and expression data is generated.
[0026]Alternatively, in the context of this invention, expression at the level of protein products of gene expression may be performed using proteomics. Proteins are detected in samples of subjects' serum or from whole blood cell or particulate components. Serum may be prepared by centrifugation of whole blood by standard methods. Cellular protein is obtained by standard methods known to those experienced in the art and include but are not limited to Trizol (Invitrogen Life Technologies). Those practiced in the art will recognize that the following methods, among others, may be used for this purpose: 1) Western analysis; 2) mass spectrophotometry; 3) two dimensional gel analysis; 4) chromatographic separation; 5) protein-fusion reporter constructs; 6) calorimetric assays; 7) binding to a protein array and; 8) characterization of polysomal mRNA. One embodiment involves binding of labeled protein expression products to an array of antibodies specific for protein products of a candidate gene set of interest. Details concerning a variety of immunological and/or immunoassay procedures relevant to this invention may be found in standard texts of biochemistry methodology. Alternative approaches use systems for performing spectrometery. Available systems include Ciphergen Biosystems, Inc (Freemont, Calif.). ProteinChip® arrays approaches also provide arrays for detection of protein expression. Also available are methods which employ affinity reagents such as small molecules and/or antibodies which recognize epitopes of a protein product of interest.
Exemplary Embodiments of the Invention
[0027]FIG. 1 illustrates various aspects of the invention. A sample such as a whole blood sample is obtained from a patient in a pre-specified manner e.g., collection in PaxGene® blood RNA collection tubes. Obtaining a whole blood sample from a patient may be practiced according to usual blood sampling methods known in the art. Using the obtained sample mRNA may be processed according to standard techniques known to those practiced in the art such that labeled target mRNA, cDNA or cRNA is produced. Labeled target is then hybridized to a microarray platform, e.g., to the Affymetric U133+2 GeneChip® which contains oligonucleotide sequences representative of all known human genes which function as probes to detect homologous cRNA. Target molecules hybridized to probes on the chip are then quantified, at least in part, by standard scanning techniques using a summary measure such as RMA (Robust Multiarray Average) in the case of the Affymetrix U133+2 GeneChip® (18).
[0028]In particular, the mRNA expression profile of a gene set of interest consists of background corrected, log transformed, variance normalized, summarized intensity profiles of the probe sets representing a gene set of interest. The likelihood of the occurrence of restenosis is evaluated by determining the probability output of a trained Partial Least Squares component based regression model derived from all the probe set or gene set intensity profiles of the gene set of interest.
[0029]The analysis of the data obtained as described herein has resulted in the development of criteria for establishing two prognosis profiles. The first prognosis profile is that of an individual whose probability output for one or more gene sets of interest is ≦50%. It has been found that such individuals are unlikely to develop restenosis after stent placement, i.e. individuals fitting this profile have a low probability of restenosis and can safely receive a bare metal stent. The second profile is that of an individual whose probability output is >50%. Such individuals are likely to develop restenosis, i.e. individuals fitting this profile have a high probability of restenosis and should receive a stent that includes anti-restenosis agents.
[0030]The invention is further illustrated by the following non-limiting examples.
EXAMPLES
Example 1
Assessment of mRNA Expression in Patients Receiving Bare Metal Stents and Incidence of Restenosis
[0031]Summary: One hundred twelve (112) non-diabetic patients were enrolled in a prospective clinical trial designed to test the hypothesis that an mRNA expression profile can accurately predict which patients will restenose after bare metal stent placement. Peripheral blood samples were collected prior to coronary angioplasty in all patients. Fifty-six (56) patients were found to have significant coronary artery disease and received at least one bare metal stent. All patients had follow-up angiograms 6 months post stent placement. Twenty-three patients experienced restenosis within 6 months of stent placement. Whole blood mRNA expression profiling was performed using the Affymeytrix U133+2 GeneChip®. Putative molecular pathways and functional molecular families responsible for bare metal stent restenosis were pre-specified prior to analysis. A partial least squares algorithm was used to select components for a logistic regression model that predicted bare metal stent restenosis. The ability of the model to discriminate between patients with and those without restenosis was assessed by the receiver operator characteristic (ROC) and misclassification rate (MR).
[0032]The results demonstrated that: 1) restenosis following coronary angioplasty with a bare metal stent can be accurately predicted using mRNA expression profiling of the cellular components of whole blood; 2) biological pathway activation predicts which patients will restenose after placement of a bare metal stent and; 3) generalized transcriptional activation or decreased degradation of the mRNA product of gene transcription of the human genome predicts individual patient risk of restenosis.
Patients
[0033]One hundred twelve (112) sequential patients undergoing elective coronary angiography were enrolled. Clinical inclusion criteria for study entry were: 1) age≧21 years; 2) ability to provide informed consent and; 3) availability for 6 month follow-up angiography. Exclusion criteria were: 1) diabetes mellitus; 2) myocardial infarction within previous 30 days; 3) concurrent infection or inflammatory disease; 4) malignancy; or 5) genetic-based disease process. Angiographic inclusion criteria included: 1) a≧50% diameter stenosis in a native coronary artery suitable for stenting. Fifty eight (58) patients met clinical as well as angiographic inclusion criteria and received at least one coronary artery bare metal stent in at least one native coronary artery. Six (6) of these fifty-eight patients underwent coronary stent placement in more than a single coronary artery. Two patients refused follow-up angiography. Fifty-six patients were available for analysis. Demographic data were collected on all patients including: age, gender, histories of hypertension, tobacco use and hypercholesterolemia. Laboratory data collected included: Complete blood count with differential leukocyte count, blood urea nitrogen, creatinine and liver chemistry including hepatic transaminase enzyme levels, lipid analysis, high sensitivity C-reactive protein (hsCRP) and homocysteine.
Angiography
[0034]All patients underwent coronary angiography according to standard techniques for quantitative coronary angiography. Briefly, 1) the diagnostic coronary catheter of known diameter was utilized as a calibration signal; 2) all images for quantitative analysis were collected in the center of the imaging field in order to minimize "pin cushion" distortion; 3) each coronary artery stenosis of interest was imaged for at least 2 cardiac cycles in order to optimize opportunity for selecting the optimum diastolic image for quantification and; 4) the angiographic view which demonstrated (qualitatively) the greatest degree of stenosis in the opinion of the clinical cardiologist investigator was selected for quantitative analysis. Follow-up angiography, 6 months post stent placement was done according to standard procedures as for initial angiography.
[0035]The Sanders Quantitative Coronary Angiographic Analysis System was used for quantitative coronary artery analysis. Pre-procedure angiographic analysis included: 1) Lesion percent diameter stenosis; 2) minimum lumen diameter of the lesion and; 3) minimum lumen diameter of a normal reference segment. Post-procedure angiographic analysis included: 1) Lesion minimum lumen diameter; 2) lesion percent diameter stenosis and; 3) reference segment minimum luminal diameter. Six months post procedure repeat coronary angiography was done to determine the presence or absence of in-stent restenosis. Data collected at that time included 1) percent diameter stenosis of the previously stented lesion (in-stent restenosis); 2) minimum luminal diameter of the in-stent segment; 3) minimum luminal diameter of a normal reference segment and; 4) late lumen loss (defined as post procedure in-stent minimum luminal diameter minus follow-up in-stent minimum luminal diameter). A single angiographic image reader analyzed all the images.
[0036]In-stent restenosis was defined in a binary (yes/no) manner with the threshold being a greater than 50% diameter stenosis in the stented segment relative to a normal reference segment. Patients who received stents in more than one coronary vessel at the time of the index procedure were classified as patients with restenosis if at least one of the stented vessels demonstrated greater 50% stenosis in the stented segment at the follow-up coronary angiogram.
mRNA Expression Profiling
[0037]Blood samples were collected into PaxGene (PreAnalytix, Inc.) tubes on the day of angiography prior to patient arrival in the cardiac catheterization laboratory. The samples were stored at room temperature for two hours, transferred to -20 degrees C. for two hours and subsequently maintained at -70 degrees C. until shipped frozen to the Core Laboratory (Core Genomics Laboratory, The George Washington University Medical Center, Washington, D.C.) on dry ice. All samples arrived at the Core Laboratory frozen. All sample processing was performed at the Core Laboratory. The samples were stored until there was a sufficient number available for processing and then batch processed. The samples were processed into RNA immediately upon thawing. RNA was purified as specified by the PaxGene manufacturer. The RNA (approximately 8 μg/2.5 ml whole blood) was further purified and concentrated with Affymetrix Blood RNA Concentration Kit. Globin messages were suppressed by peptide-nucleic acid primers annealing to the 3' end of globin messages (globin reduction protocol). The RNA was labeled by reverse transcription with the Affymetrix one-cycle cDNA reaction and an oligo-dT primer incorporating a T7 polymerase sequence. cRNA was transcribed while incorporating biotinylated nucleotides using the Affymetrix IVT reaction. The resulting pool of labeled cRNA was repurified and fragmented to allow an individual transcript to hybridize to the multiple gene probe sets. The labeled probe was hybridized overnight to the Affymetrix U133+2 Genechip®. The hybridized chip was washed, stained with streptavidin-phycoerythrin (SAPE), and amplified with biotinylated anti-SAPE and additional SAPE staining. The array was scanned, deconvolved into gene probe sets, and quality control performed to insure that detection sensitivity and noise were within pre-determined limits. Gene probe sets were summarized into transcript levels using, in part, the RMA algorithm (18).
Pathways
[0038]Genes and/or gene probe sets were grouped according to pre-specified molecular pathways and functional molecular families. The components of each pathway and family were a set of pre-specified genes. The genes comprising these molecular pathways and functionally related molecules chosen for analysis were derived from the Kyoto Encyclopedia of Genes and Genomics (19) and included:
1) Molecular target of rapamycin (Table 1),2) Leukocyte trans-endothelial migration (Table 2),3) TGFβ signaling (Table 3),4) T cell antigen processing (Table 4),5) T cell signaling (Table 5),6) Mitogen activated protein kinase or "MAPK" (Table 6),7) Cell adhesion molecules (Table 7),8) A group of 100 probe sets selected in a non-systematic manner (Table 8).
TABLE-US-00001 TABLE 1 Pathway 1: Molecular Target of Rapamycin Gene Symbol Probe Set ID Gene Title MAPK1 1552263_at mitogen-activated protein kinase 1 MAPK1 1552264_a_at mitogen-activated protein kinase 1 AVO3 1552734_at TORC2-specific protein AVO3 FLJ39075 1553130_at hypothetical protein FLJ39075 ULK2 1554112_a_at unc-51-like kinase 2 (C. elegans) PRKAA1 1555177_at protein kinase, AMP-activated, alpha 1 catalytic subunit RHEB 1555780_a_at Ras homolog enriched in brain AKT2 1560689_s_at V-akt murine thymoma viral oncogene homolog 2 MAPK1 1562283_at Mitogen-activated protein kinase 1 RPS6KA3 1568448_at Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 RPS6KA3 1568449_at Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 PIK3R2 1568629_s_at phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) RPS6 200081_s_at ribosomal protein S6 /// ribosomal protein S6 HIF1A 200989_at hypoxia-inducible factor 1, alpha subunit RPS6 201254_x_at ribosomal protein S6 EIF4E 201435_s_at eukaryotic translation initiation factor 4E EIF4E 201436_at eukaryotic translation initiation factor 4E EIF4E 201437_s_at eukaryotic translation initiation factor 4E RHEB 201451_x_at Ras homolog enriched in brain RHEB 201452_at Ras homolog enriched in brain RHEB 201453_x_at Ras homolog enriched in brain FRAP1 202288_at FK506 binding protein 12-rapamycin associated protein 1 PIK3R3 202743_at phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) DDIT4 202887_s_at DNA-damage-inducible transcript 4 RPS6KA1 203379_at ribosomal protein S6 kinase, 90 kDa, polypeptide 1 VEGFB 203683_s_at vascular endothelial growth factor B AKT2 203808_at v-akt murine thymoma viral oncogene homolog 2 AKT2 203809_s_at v-akt murine thymoma viral oncogene homolog 2 RPS6KA3 203843_at ribosomal protein S6 kinase, 90 kDa, polypeptide 3 PIK3CD 203879_at phosphoinositide-3-kinase, catalytic, delta polypeptide ULK2 204062_s_at unc-51-like kinase 2 (C. elegans) ULK2 204063_s_at unc-51-like kinase 2 (C. elegans) RPS6KB1 204171_at ribosomal protein S6 kinase, 70 kDa, polypeptide 1 STK11 204292_x_at serine/threonine kinase 11 (Peutz-Jeghers syndrome) PIK3CA 204369_at phosphoinositide-3-kinase, catalytic, alpha polypeptide PDPK1 204524_at 3-phosphoinositide dependent protein kinase-1 BRAF 206044_s_at v-raf murine sarcoma viral oncogene homolog B1 PIK3CG 206369_s_at phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 206370_at phosphoinositide-3-kinase, catalytic, gamma polypeptide INS 206598_at insulin FIGF 206742_at c-fos induced growth factor (vascular endothelial growth factor D) PIK3R2 207105_s_at phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) AKT1 207163_s_at v-akt murine thymoma viral oncogene homolog 1 PRKAA2 207709_at protein kinase, AMP-activated, alpha 2 catalytic subunit MAPK1 208351_s_at mitogen-activated protein kinase 1 RPS6 209134_s_at ribosomal protein S6 ULK1 209333_at unc-51-like kinase 1 (C. elegans) TSC1 209390_at tuberous sclerosis 1 EIF4E2 209393_s_at eukaryotic translation initiation factor 4E member 2 IGF1 209540_at insulin-like growth factor 1 (somatomedin C) IGF1 209541_at insulin-like growth factor 1 (somatomedin C) IGF1 209542_x_at insulin-like growth factor 1 (somatomedin C) PGF 209652_s_at placental growth factor, vascular endothelial growth factor-related protein PRKAA1 209799_at protein kinase, AMP-activated, alpha 1 catalytic subunit VEGFC 209946_at vascular endothelial growth factor C VEGF 210512_s_at vascular endothelial growth factor VEGF 210513_s_at vascular endothelial growth factor PIK3CD 211230_s_at phosphoinositide-3-kinase, catalytic, delta polypeptide AKT2 211453_s_at v-akt murine thymoma viral oncogene homolog 2 VEGF 211527_x_at vascular endothelial growth factor IGF1 211577_s_at insulin-like growth factor 1 (somatomedin C) RPS6KB1 211578_s_at ribosomal protein S6 kinase, 70 kDa, polypeptide 1 PIK3R3 211580_s_at phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) RPS6 /// LOC392358 211690_at ribosomal protein S6 /// ribosomal protein S6 EIF4B 211937_at eukaryotic translation initiation factor 4B EIF4B 211938_at eukaryotic translation initiation factor 4B MAPK3 212046_x_at mitogen-activated protein kinase 3 VEGF 212171_x_at vascular endothelial growth factor PIK3R1 212239_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3R1 212240_s_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3R1 212249_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) MAPK1 212271_at mitogen-activated protein kinase 1 AKT3 212607_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) AKT3 212609_s_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) PIK3CB 212688_at phosphoinositide-3-kinase, catalytic, beta polypeptide PIK3R4 212740_at phosphoinositide-3-kinase, regulatory subunit 4, p150 RHEB 213404_s_at Ras homolog enriched in brain RHEB 213409_s_at Ras homolog enriched in brain EIF4E2 213570_at eukaryotic translation initiation factor 4E member 2 EIF4E2 213571_s_at eukaryotic translation initiation factor 4E member 2 PRKAA1 214917_at protein kinase, AMP-activated, alpha 1 catalytic subunit ULK2 215154_at Unc-51-like kinase 2 (C. elegans) PGF 215179_x_at Placental growth factor, vascular endothelial growth factor-related protein FRAP1 215381_at FK506 binding protein 12-rapamycin associated protein 1 TSC2 215735_s_at tuberous sclerosis 2 PIK3R4 216436_at Phosphoinositide-3-kinase, regulatory subunit 4, p150 PIK3R4 216752_at Phosphoinositide-3-kinase, regulatory subunit 4, p150 PIK3CB 217620_s_at phosphoinositide-3-kinase, catalytic, beta polypeptide AKT3 219393_s_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) PIK3R5 220566_at phosphoinositide-3-kinase, regulatory subunit 5, p101 GBL 220587_s_at G protein beta subunit-like EIF4EBP1 221539_at eukaryotic translation initiation factor 4E binding protein 1 PDPK1 221944_at 3-phosphoinositide dependent protein kinase-1 AKT3 222880_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) AKT3 224229_s_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) MAPK1 224621_at mitogen-activated protein kinase 1 PDPK1 224986_s_at 3-phosphoinositide dependent protein kinase-1 AKT2 225471_s_at v-akt murine thymoma viral oncogene homolog 2 raptor 225715_at raptor PRKAA1 225984_at protein kinase, AMP-activated, alpha 1 catalytic subunit PRKAA1 225985_at protein kinase, AMP-activated, alpha 1 catalytic subunit AVO3 226310_at TORC2-specific protein AVO3 AVO3 226312_at TORC2-specific protein AVO3 RPS6KA3 226335_at ribosomal protein S6 kinase, 90 kDa, polypeptide 3 BRAF 226391_at V-raf murine sarcoma viral oncogene homolog B1 RPS6KB1 226660_at ribosomal protein S6 kinase, 70 kDa, polypeptide 1 EIF4E2 226734_at Eukaryotic translation initiation factor 4E member 2 RHEB 227633_at Ras homolog enriched in brain PIK3R5 227645_at phosphoinositide-3-kinase, regulatory subunit 5, p101 PRKAA2 227892_at Protein kinase, AMP-activated, alpha 2 catalytic subunit AVO3 228248_at TORC2-specific protein AVO3 PIK3R2 229392_s_at Phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) MAPK1 229847_at Mitogen-activated protein kinase 1 STK11 231017_at serine/threonine kinase 11 (Peutz-Jeghers syndrome) STK11 231019_x_at Serine/threonine kinase 11 LOC283874 /// 232050_at Hypothetical protein LOC283874 /// Hypothetical LOC124216 LOC124216 TSC1 233570_at Tuberous sclerosis 1 RICTOR 237330_at Rapamycin-insensitive companion of mTOR EIF4E 237718_at eukaryotic translation initiation factor 4E ULK1 238042_at Unc-51-like kinase 1 (C. elegans) RPS6 238156_at Ribosomal protein S6 PRKAA2 238441_at Protein kinase, AMP-activated, alpha 2 catalytic subunit PRKAA2 238489_at Protein kinase, AMP-activated, alpha 2 catalytic subunit HIF1A 238869_at Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-factor) PRKAA2 240349_at protein kinase, AMP-activated, alpha 2 catalytic subunit AKT3 240568_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) RPS6KA3 241460_at Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 AKT3 242876_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) AKT3 242879_x_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) RHEB 243008_at Ras homolog enriched in brain BRAF 243829_at v-raf murine sarcoma viral oncogene homolog B1 PIK3R1 244181_at Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) EIF4E2 244302_at Eukaryotic translation initiation factor 4E member 2 PDPK1 32029_at 3-phosphoinositide dependent protein kinase-1 STK11 41657_at serine/threonine kinase 11 (Peutz-Jeghers syndrome)
TABLE-US-00002 TABLE 2 Pathway 2: Leukocyte trans-endothelial migration Gene Symbol Probe Set ID Gene Title ITGB1 1553530_a_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 ITGB1 1553678_a_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 RASSF5 1554834_a_at Ras association (RalGDS/AF-6) domain family 5 RAP1A 1555339_at RAP1A, member of RAS oncogene family RAP1A 1555340_x_at RAP1A, member of RAS oncogene family ITGB2 1555349_a_at integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1 RHOA 1555814_a_at ras homolog gene family, member A CDC42 1556931_at Cell division cycle 42 (GTP binding protein, 25 kDa) PECAM1 1559921_at platelet/endothelial cell adhesion molecule (CD31 antigen) ROCK2 1563329_s_at Rho-associated, coiled-coil containing protein kinase 2 RAC1 1567457_at Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein RAC1 1567458_s_at ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein PIK3R2 1568629_s_at phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) ROCK1 1569981_at Rho-associated, coiled-coil containing protein kinase 1 RHOA 200059_s_at ras homolog gene family, member A /// ras homolog gene family, member A RAP1B 200833_s_at RAP1B, member of RAS oncogene family CD99 201028_s_at CD99 antigen CD99 201029_s_at CD99 antigen GNAI2 201040_at guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 GNAI3 201179_s_at guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 GNAI3 201180_s_at guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 GNAI3 201181_at guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 RAP1A 202362_at RAP1A, member of RAS oncogene family PIK3R3 202743_at phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) ROCK2 202762_at Rho-associated, coiled-coil containing protein kinase 2 ITGB2 202803_s_at integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1 PTK2B 203110_at PTK2B protein tyrosine kinase 2 beta PTK2B 203111_s_at PTK2B protein tyrosine kinase 2 beta PIK3CD 203879_at phosphoinositide-3-kinase, catalytic, delta polypeptide /// phosphoinositide-3-kinase PIK3CA 204369_at phosphoinositide-3-kinase, catalytic, alpha polypeptide RHOH 204951_at ras homolog gene family, member H VAV2 205536_at vav 2 oncogene VAV2 205537_s_at vav 2 oncogene RAPGEF4 205651_x_at Rap guanine nucleotide exchange factor (GEF) 4 ITGAM 205785_at integrant, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) /// integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) ITGAM 205786_s_at integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) /// integrin, alpha M (complement component receptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) ITGA4 205884_at integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) ITGA4 205885_s_at integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) VAV1 206219_s_at vav 1 oncogene PIK3CG 206369_s_at phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 206370_at phosphoinositide-3-kinase, catalytic, gamma polypeptide TXK 206828_at TXK tyrosine kinase PIK3R2 207105_s_at phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) RAC2 207419_s_at ras-related C3 botulinum toxin substrate 2 (rho family) RAC1 208640_at ras-related C3 botulinum toxin substrate 1 (rho family) RAC1 208641_s_at ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) CDC42 208727_s_at cell division cycle 42 (GTP binding protein, 25 kDa) CDC42 208728_s_at cell division cycle 42 (GTP binding protein, 25 kDa) PECAM1 208981_at platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1 208982_at Platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1 208983_s_at platelet/endothelial cell adhesion molecule (CD31 antigen) CXCR4 209201_x_at chemokine (C-X-C motif) receptor 4 GNAI1 209576_at guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 RAPGEF3 210051_at Rap guanine nucleotide exchange factor (GEF) 3 CDC42 210232_at cell division cycle 42 (GTP binding protein, 25 kDa) PIK3CD 211230_s_at phosphoinositide-3-kinase, catalytic, delta polypeptide ITK 211339_s_at IL2-inducible T-cell kinase ROCK2 211504_x_at Rho-associated, coiled-coil containing protein kinase 2 PIK3R3 211580_s_at phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) CXCR4 211919_s_at chemokine (C-X-C motif) receptor 4 /// chemokine (C-X-C motif) receptor 4 ITGB1 211945_s_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen) MYL6 212082_s_at myosin, light polypeptide 6, alkali, smooth muscle and non-muscle PIK3R1 212239_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3R1 212240_s_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3R1 212249_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3CB 212688_at phosphoinositide-3-kinase, catalytic, beta polypeptide PIK3R4 212740_at phosphoinositide-3-kinase, regulatory subunit 4, p150 ROCK1 213044_at Rho-associated, coiled-coil containing protein kinase 1 ITGA4 213416_at integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) RAC2 213603_s_at ras-related C3 botulinum toxin substrate 2 (rho family) MYL6 214002_at myosin, light polypeptide 6, alkali, smooth muscle and non-muscle CDC42 214230_at cell division cycle 42 (GTP binding protein, 25 kDa) ROCK1 214578_s_at Rho-associated, coiled-coil containing protein kinase 1 ITGB1 215878_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29) ITGB1 215879_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29) RHOH 216166_at Ras homolog gene family, member H RHOH 216168_at Ras homolog gene family, member H ITGB1 216178_x_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29) ITGB1 216190_x_at integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29) PIK3R4 216436_at Phosphoinositide-3-kinase, regulatory subunit 4, p150 ROCK1 216621_at Rho-associated, coiled-coil containing protein kinase 1 ROCK1 216625_at Rho-associated, coiled-coil containing protein kinase 1 PIK3R4 216752_at Phosphoinositide-3-kinase, regulatory subunit 4, p150 CXCR4 217028_at chemokine (C-X-C motif) receptor 4 PIK3CB 217620_s_at phosphoinositide-3-kinase, catalytic, beta polypeptide VAV3 218806_s_at vav 3 oncogene VAV3 218807_at vav 3 oncogene PIK3R5 220566_at phosphoinositide-3-kinase, regulatory subunit 5, p101 RASSF5 223322_at Ras association (RalGDS/AF-6) domain family 5 VAV3 224221_s_at vav 3 oncogene VAV2 226063_at vav 2 oncogene CDC42 226400_at Cell division cycle 42 (GTP binding protein, 25 kDa) PIK3R5 227645_at phosphoinositide-3-kinase, regulatory subunit 5, p101 GNAI1 227692_at guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 ITGB2 229040_at Homo sapiens, clone IMAGE: 5205388, mRNA /// Integrin, beta 2 (antigen CD18) ITGB2 229041_s_at Homo sapiens, clone IMAGE: 5205388, mRNA /// Integrin, beta 2 (antigen CD18) PIK3R2 229392_s_at Phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) CD99 230161_at CD99 antigen ROCK1 230239_at Rho-associated, coiled-coil containing protein kinase 1 RAP1B 231127_at RAP1B, member of RAS oncogene family ROCK1 235854_x_at Rho-associated, coiled-coil containing protein kinase 1 RHOH 236293_at Ras homolog gene family, member H ITGB2 236988_x_at integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1 RAP1A 240215_at RAP1A, member of RAS oncogene family RHOA 240337_at Ras homolog gene family, member A RHOA 241097_at Ras homolog gene family, member A MYL6 241662_x_at Myosin, light polypeptide 6, alkali, smooth muscle and non-muscle MYL6 241664_x_at Myosin, light polypeptide 6, alkali, smooth muscle and non-muscle RHOH 242929_at Ras homolog gene family, member H ITGA4 243685_at Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) PIK3R1 244181_at Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) ITGA4 244599_at Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
TABLE-US-00003 TABLE 3 Pathway 3: Transforming Growth Factor Beta (TGFβ) signaling Gene Gene Symbol Probe Set ID Title MAPK1 1552263_at mitogen-activated protein kinase 1 MAPK1 1552264_a_at mitogen-activated protein kinase 1 ACVR1C 1552519_at activin A receptor, type IC SP1 1553685_s_at Sp1 transcription factor ZFYVE16 1554638_at zinc finger, FYVE domain containing 16 RBL1 1555003_at retinoblastoma-like 1 (p107) RBL1 1555004_a_at retinoblastoma-like 1 (p107) ZFYVE16 1555011_at zinc finger, FYVE domain containing 16 TGFB3 1555540_at transforming growth factor, beta 3 RHOA 1555814_a_at ras homolog gene family, member A ZFYVE16 1555982_at Zinc finger, FYVE domain containing 16 CREBBP 1559295_at CREB binding protein (Rubinstein-Taybi syndrome) RBL1 1559307_s_at retinoblastoma-like 1 (p107) MAPK1 1562283_at Mitogen-activated protein kinase 1 SMAD4 1565702_at SMAD, mothers against DPP homolog 4 (Drosophila) SMAD4 1565703_at SMAD, mothers against DPP homolog 4 (Drosophila) LTBP1 1566267_at Latent transforming growth factor beta binding protein 1 LTBP1 1566268_at Latent transforming growth factor beta binding protein 1 ROCK1 1569981_at Rho-associated, coiled-coil containing protein kinase 1 RHOA 200059_s_at ras homolog gene family, member A /// ras homolog gene family, member A SKP1A 200711_s_at S-phase kinase-associated protein 1A (p19A) SKP1A 200718_s_at S-phase kinase-associated protein 1A (p19A) SKP1A 200719_at S-phase kinase-associated protein 1A (p19A) THBS1 201107_s_at thrombospondin 1 THBS1 201108_s_at thrombospondin 1 THBS1 201109_s_at thrombospondin 1 THBS1 201110_s_at thrombospondin 1 PPP2CB 201374_x_at protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform PPP2CB 201375_s_at protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform ID2 201565_s_at inhibitor of DNA binding 2, dominant negative helix-loop-helix protein ID2 /// ID2B 201566_x_at inhibitor of DNA binding 2, dominant negative helix-loop-helix protein DCN 201893_x_at decorin CREBBP 202160_at CREB binding protein (Rubinstein-Taybi syndrome) E2F4 202248_at E2F transcription factor 4, p107/p130-binding MYC 202431_s_at v-myc myelocytomatosis viral oncogene homolog (avian) SMAD4 202526_at SMAD, mothers against DPP homolog 4 (Drosophila) SMAD4 202527_s_at SMAD, mothers against DPP homolog 4 (Drosophila) LTBP1 202728_s_at latent transforming growth factor beta binding protein 1 LTBP1 202729_s_at latent transforming growth factor beta binding protein 1 SMAD2 203075_at SMAD, mothers against DPP homolog 2 (Drosophila) SMAD2 203076_s_at SMAD, mothers against DPP homolog 2 (Drosophila) SMAD2 203077_s_at SMAD, mothers against DPP homolog 2 (Drosophila) THBS2 203083_at thrombospondin 2 ZFYVE16 203651_at zinc finger, FYVE domain containing 16 TFDP1 204147_s_at transcription factor Dp-1 RPS6KB1 204171_at ribosomal protein S6 kinase, 70 kDa, polypeptide 1 THBS4 204776_at thrombospondin 4 SMAD7 204790_at SMAD, mothers against DPP homolog 7 (Drosophila) BMPR1A 204832_s_at bone morphogenetic protein receptor, type IA ZFYVE9 204893_s_at zinc finger, FYVE domain containing 9 SMAD5 205187_at SMAD, mothers against DPP homolog 5 (Drosophila) SMAD5 205188_s_at SMAD, mothers against DPP homolog 5 (Drosophila) ACVR1B 205209_at activin A receptor, type IB BMP2 205289_at bone morphogenetic protein 2 BMP2 205290_s_at bone morphogenetic protein 2 RBL1 205296_at retinoblastoma-like 1 (p107) SMAD3 205396_at SMAD, mothers against DPP homolog 3 (Drosophila) SMAD3 205397_x_at SMAD, mothers against DPP homolog 3 (Drosophila) SMAD3 205398_s_at SMAD, mothers against DPP homolog 3 (Drosophila) BMP5 205430_at bone morphogenetic protein 5 BMP5 205431_s_at bone morphogenetic protein 5 SMURF2 205596_s_at SMAD specific E3 ubiquitin protein ligase 2 COMP 205713_s_at cartilage oligomeric matrix protein BMP6 206176_at bone morphogenetic protein 6 SMAD9 206320_s_at SMAD, mothers against DPP homolog 9 (Drosophila) AMH 206516_at anti-Mullerian hormone GDF5 206614_at growth differentiation factor 5 (cartilage-derived morphogenetic protein-1) AMHR2 206892_at anti-Mullerian hormone receptor, type II TGFBR1 206943_at transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa) SMAD6 207069_s_at SMAD, mothers against DPP homolog 6 (Drosophila) TNF 207113_s_at tumor necrosis factor (TNF superfamily, member 2) TGFBR2 207334_s_at transforming growth factor, beta receptor II (70/80 kDa) CDKN2B 207530_s_at cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) CUL1 207614_s_at cullin 1 ID3 207826_s_at inhibitor of DNA binding 3, dominant negative helix-loop-helix protein BMP8B 207865_s_at bone morphogenetic protein 8b (osteogenic protein 2) BMP8A 207866_at bone morphogenetic protein 8a SKP1A 207974_s_at S-phase kinase-associated protein 1A (p19A) SMAD1 208015_at SMAD, mothers against DPP homolog 1 (Drosophila) ACVR1B 208218_s_at activin A receptor, type IB ACVR1B 208219_at activin A receptor, type IB ACVR1B 208222_at activin A receptor, type IB ACVR1B 208223_s_at activin A receptor, type IB MAPK1 208351_s_at mitogen-activated protein kinase 1 ZFYVE9 208446_s_at zinc finger, FYVE domain containing 9 PPP2CA 208652_at protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform ID1 208937_s_at inhibitor of DNA binding 1, dominant negative helix-loop-helix protein TGFBR2 208944_at transforming growth factor, beta receptor II (70/80 kDa) ID4 209291_at inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 209292_at Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 209293_x_at inhibitor of DNA binding 4, dominant negative helix-loop-helix protein DCN 209335_at decorin THBS3 209561_at thrombospondin 3 BMP7 209590_at Bone morphogenetic protein 7 (osteogenic protein 1) BMP7 209591_s_at bone morphogenetic protein 7 (osteogenic protein 1) TGFB3 209747_at transforming growth factor, beta 3 SMAD6 209886_s_at SMAD, mothers against DPP homolog 6 (Drosophila) SMAD6 209887_at SMAD, mothers against DPP homolog 6 (Drosophila) TGFB2 209908_s_at Transforming growth factor, beta 2 TGFB2 209909_s_at transforming growth factor, beta 2 BMPR2 209920_at bone morphogenetic protein receptor, type II (serine/threonine kinase) BMPR2 210214_s_at bone morphogenetic protein receptor, type II (serine/threonine kinase) BMPR1B 210523_at bone morphogenetic protein receptor, type IB SMAD1 210993_s_at SMAD, mothers against DPP homolog 1 (Drosophila) CHRD 211248_s_at chordin BMP7 211259_s_at bone morphogenetic protein 7 (osteogenic protein 1) BMP7 211260_at bone morphogenetic protein 7 (osteogenic protein 1) BMP4 211518_s_at bone morphogenetic protein 4 RPS6KB1 211578_s_at ribosomal protein S6 kinase, 70 kDa, polypeptide 1 CREBBP 211808_s_at CREB binding protein (Rubinstein-Taybi syndrome) DCN 211813_x_at decorin DCN 211896_s_at decorin MAPK3 212046_x_at mitogen-activated protein kinase 3 MAPK1 212271_at mitogen-activated protein kinase 1 TFDP1 212330_at transcription factor Dp-1 RBL2 212331_at retinoblastoma-like 2 (p130) RBL2 212332_at retinoblastoma-like 2 (p130) SMURF1 212666_at SMAD specific E3 ubiquitin protein ligase1 SMURF1 212668_at SMAD specific E3 ubiquitin protein ligase1 ROCK1 213044_at Rho-associated, coiled-coil containing protein kinase 1 ACVR1B 213198_at activin A receptor, type IB SMAD6 213565_s_at SMAD, mothers against DPP homolog 6 (Drosophila) BMPR1A 213578_at bone morphogenetic protein receptor, type IA ID2 /// ID2B 213931_at inhibitor of DNA binding 2, dominant negative helix-loop-helix protein ROCK1 214578_s_at Rho-associated, coiled-coil containing protein kinase 1 SP1 214732_at Sp1 transcription factor BMP6 215042_at bone morphogenetic protein 6 SMURF1 215458_s_at SMAD specific E3 ubiquitin protein ligase 1 SMURF1 215589_at SMAD specific E3 ubiquitin protein ligase 1 PPP2CA 215628_x_at Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform THBS1 215775_at Thrombospondin 1 ROCK1 216621_at Rho-associated, coiled-coil containing protein kinase 1 ROCK1 216625_at Rho-associated, coiled-coil containing protein kinase 1 RBX1 218117_at ring-box 1 SMAD3 218284_at SMAD, mothers against DPP homolog 3 (Drosophila) TGFB2 220406_at transforming growth factor, beta 2 TGFB2 220407_s_at transforming growth factor, beta 2 E2F5 221586_s_at E2F transcription factor 5, p130-binding BMP8B 221615_at bone morphogenetic protein 8b (osteogenic protein 2) CHRD 221674_s_at chordin E2F5 222051_s_at E2F transcription factor 5, p130-binding DGAT2 224327_s_at diacylglycerol O-acyltransferase homolog 2 (mouse) MAPK1 224621_at mitogen-activated protein kinase 1 SP1 224754_at Sp1 transcription factor SP1 224760_at Sp1 transcription factor TGFBR1 224793_s_at transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa) BMPR2 225144_at bone morphogenetic protein receptor, type II (serine/threonine kinase) SMAD5 225219_at SMAD, mothers against DPP homolog 5 (Drosophila) SMAD5 225223_at SMAD, mothers against DPP homolog 5 (Drosophila) DGAT2 226064_s_at diacylglycerol O-acyltransferase homolog 2 (mouse) SMAD2 226563_at SMAD, mothers against DPP homolog 2 (Drosophila) RPS6KB1 226660_at ribosomal protein S6 kinase, 70 kDa, polypeptide 1 ID4 226933_s_at Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein BMPR1A 227273_at Bone morphogenetic protein receptor, type IA SMURF2 227489_at SMAD specific E3 ubiquitin protein ligase 2 SMAD1 227798_at SMAD, mothers against DPP homolog 1 (Drosophila) TGFB2 228121_at Transforming growth factor, beta 2 CREBBP 228177_at CREB binding protein (Rubinstein-Taybi syndrome) MAPK1 229847_at Mitogen-activated protein kinase 1 ROCK1 230239_at Rho-associated, coiled-coil containing protein kinase 1 SMURF2 230820_at SMAD specific E3 ubiquitin protein ligase 2 BMPR1A 230979_at Bone morphogenetic protein receptor, type IA E2F5 231237_x_at E2F transcription factor 5, p130-binding NOG 231798_at Noggin BMPR2 231873_at bone morphogenetic protein receptor, type II (serine/threonine kinase) SMURF2 232020_at SMAD specific E3 ubiquitin protein ligase 2 DCN 234104_at Decorin THBS1 235086_at Thrombospondin 1 BMP8B 235275_at Bone morphogenetic protein 8b (osteogenic protein 2) SMAD5 235451_at SMAD, mothers against DPP homolog 5 (Drosophila) PPP2CA 235502_at Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform SMAD2 235598_at SMAD, mothers against DPP homolog 2 (Drosophila) SMAD4 235622_at SMAD, mothers against DPP homolog 4 (Drosophila) SMAD4 235725_at SMAD, mothers against DPP homolog 4 (Drosophila) ROCK1 235854_x_at Rho-associated, coiled-coil containing protein kinase 1 CREBBP 235858_at CREB binding protein (Rubinstein-Taybi syndrome) CDKN2B 236313_at cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) SMURF1 236370_at SMAD specific E3 ubiquitin protein ligase 1 TGFBR2 236419_at Transforming growth factor, beta receptor II (70/80 kDa) TGFBR1 236561_at Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa) BMP8B 237473_at Bone morphogenetic protein 8b (osteogenic protein 2) SMURF1 237723_at SMAD specific E3 ubiquitin protein ligase 1 SMURF2 238391_at SMAD specific E3 ubiquitin protein ligase 2 BMPR2 238393_at Bone morphogenetic protein receptor, type II (serine/threonine kinase) SMURF2 238394_at SMAD specific E3 ubiquitin protein ligase 2 CUL1 238509_at Cullin 1 BMPR2 238516_at bone morphogenetic protein receptor, type II (serine/threonine kinase) PPP2CA 238719_at Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform PPP2CA 239094_at Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform SMAD2 239271_at SMAD, mothers against DPP homolog 2 (Drosophila) THBS1 239336_at Thrombospondin 1 TGFBR1 239605_x_at Transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa) BMPR1B 240331_at Bone morphogenetic protein receptor, type IB RHOA 240337_at Ras homolog gene family, member A DCN 240556_at Decorin LTBP1 240858_at Latent transforming growth factor beta binding protein 1 RHOA 241097_at Ras homolog gene family, member A BMP6 241141_at Bone morphogenetic protein 6 TFDP1 242538_at Transcription factor Dp-1 DCN 242605_at Decorin TFDP1 242939_at transcription factor Dp-1 BMPR1A 243275_at Bone morphogenetic protein receptor, type IA CUL1 243286_at Cullin 1 MYC 244089_at V-myc myelocytomatosis viral oncogene homolog (avian) TFDP1 244550_at Transcription factor Dp-1 E2F4 38707_r_at E2F transcription factor 4, p107/p130-binding
TABLE-US-00004 TABLE 4 Pathway 4: T cell antigen processing Gene Symbol Probe Set ID Gene Title CD8B1 1553562_at CD8 antigen, beta polypeptide 1 (p37) HLA-DOB 1554984_a_at major histocompatibility complex, class II, DO beta TAPBP 1555565_s_at TAP binding protein (tapasin) KLRC4 /// 1555691_a_at killer cell lectin-like receptor subfamily C, KLRK1 EEF1A1 1557120_at WD repeats and SOF1 domain containing HSPCB 1557910_at heat shock 90 kDa protein 1, beta NFYC 1558782_a_at Nuclear transcription factor Y, gamma NFYC 1559218_s_at nuclear transcription factor Y, gamma CD74 1567627_at CD74 antigen (invariant polypeptide of major histocompatibility complex CD74 1567628_at CD74 antigen (invariant polypeptide of major histocompatibility complex TRIM24 1569316_at Tripartite motif-containing 24 HSPCB 200064_at heat shock 90 kDa protein 1, beta /// heat shock 90 kDa protein 1, beta CANX 200068_s_at calnexin /// calnexin HSPA9B 200690_at heat shock 70 kDa protein 9B (mortalin-2) HSPA9B 200691_s_at heat shock 70 kDa protein 9B (mortalin-2) HSPA9B 200692_s_at heat shock 70 kDa protein 9B (mortalin-2) HSPA1A 200799_at heat shock 70 kDa protein 1A HSPA1A /// 200800_s_at heat shock 70 kDa protein 1A /// heat shock 70 kDa protein 1B HSPA1B PSME1 200814_at proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) CTSB 200838_at cathepsin B CTSB 200839_s_at cathepsin B HLA-E 200904_at major histocompatibility complex, class I, E HLA-E 200905_x_at major histocompatibility complex, class I, E CALR 200935_at calreticulin HLA-DPB1 201137_s_at major histocompatibility complex, class II, DP beta 1 LGMN 201212_at legumain IFI30 201422_at interferon, gamma-inducible protein 30 PSME2 201762_s_at proteasome (prosome, macropain) activator subunit 2 (PA28 beta) B2M 201891_s_at beta-2-microglobulin CTSL 202087_s_at cathepsin L NFYC 202215_s_at nuclear transcription factor Y, gamma NFYC 202216_x_at nuclear transcription factor Y, gamma TAP1 202307_s_at transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) HSPA1B 202581_at heat shock 70 kDa protein 1B CTSS 202901_x_at cathepsin S CTSS 202902_s_at cathepsin S RFX5 202963_at regulatory factor X, 5 (influences HLA class II expression) RFX5 202964_s_at regulatory factor X, 5 (influences HLA class II expression) HLA-DQA1 203290_at major histocompatibility complex, class II, DQ alpha 1 complex. CD4 203547_at CD4 antigen (p55) /// CD4 antigen (p55) HLA-DMB 203932_at major histocompatibility complex, class II, DM beta complex. NFYA 204107_at nuclear transcription factor Y, alpha NFYA 204108_at nuclear transcription factor Y, alpha NFYA 204109_s_at nuclear transcription factor Y, alpha CREB1 204312_x_at cAMP responsive element binding protein 1 CREB1 204313_s_at cAMP responsive element binding protein 1 CREB1 204314_s_at cAMP responsive element binding protein 1 TRIM24 204391_x_at tripartite motif-containing 24 HLA-DRB1 204670_x_at major histocompatibility complex, class II, DR beta 1 TAP2 204769_s_at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) TAP2 204770_at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) HLA-F 204806_x_at major histocompatibility complex, class I, F EEF1A1 204892_x_at eukaryotic translation elongation factor 1 alpha 1 CIITA 205101_at class II, major histocompatibility complex, transactivator HLA-DOB 205671_s_at major histocompatibility complex, class II, DO beta CD8A 205758_at CD8 antigen, alpha polypeptide (p32) /// CD8 antigen, alpha polypeptide (p32) KLRK1 205821_at killer cell lectin-like receptor subfamily K, member 1 HLA-DOA 206313_at major histocompatibility complex, class II, DO alpha EEF1A1 206559_x_at eukaryotic translation elongation factor 1 alpha 1 KLRC1 /// 206785_s_at killer cell lectin-like receptor subfamily C KLRC2 LTA 206975_at lymphotoxin alpha (TNF superfamily, member 1) CCR5 206991_s_at chemokine (C-C motif) receptor 5 KIR3DL2 207313_x_at killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 KIR3DL2 207314_x_at killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 KLRC3 207723_s_at killer cell lectin-like receptor subfamily C, member 3 KLRD1 207795_s_at killer cell lectin-like receptor subfamily D, member 1 KLRD1 207796_x_at killer cell lectin-like receptor subfamily D, member 1 IFNA8 207932_at interferon, alpha 8 IFNA4 207964_x_at interferon, alpha 4 CD8B1 207979_s_at CD8 antigen, beta polypeptide 1 (p37) KIR2DS3 208122_x_at killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3 KIR2DL3 208179_x_at killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 IFNA14 208182_x_at interferon, alpha 14 KIR2DS1 208198_x_at killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1 KIR2DS5 208203_x_at killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5 IFNA10 208261_x_at interferon, alpha 10 HLA-DRB1 208306_x_at Major histocompatibility complex, class II, DR beta 3 IFNA13 208344_x_at interferon, alpha 13 IFNA1 208375_at interferon, alpha 1 KIR2DL4 208426_x_at killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 TAP2 208428_at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) RFXAP 208492_at regulatory factor X-associated protein IFNA6 208548_at interferon, alpha 6 PDIA3 208612_at protein disulfide isomerase family A, member 3 HSPA8 208687_x_at heat shock 70 kDa protein 8 HLA-B 208729_x_at major histocompatibility complex, class I, B HLA-C 208812_x_at major histocompatibility complex, class I, C TAPBP 208829_at TAP binding protein (tapasin) CANX 208852_s_at calnexin CANX 208853_s_at calnexin HLA-DRA 208894_at major histocompatibility complex, class II, DR alpha /// class II, DR alpha HLA-B 209140_x_at major histocompatibility complex, class I, B HLA-DRB1 209312_x_at major histocompatibility complex, class II, DR beta 1 /// class II, DR beta 1 HLA-DQB1 209480_at Major histocompatibility complex, class II, DQ beta 1 /// class II, DQ beta 1 CD74 209619_at CD74 antigen (invariant polypeptide of major histocompatibility complex class II) HLA-DRB4 209728_at major histocompatibility complex, class II, DR beta 4 /// MHC class II, DR beta 4 HLA-DQB1 209823_x_at major histocompatibility complex, class II, DQ beta 1 HSPA1L 210189_at heat shock 70 kDa protein 1-like HSPCA 210211_s_at heat shock 90 kDa protein 1, alpha TAPBP 210294_at TAP binding protein (tapasin) HSPA8 210338_s_at heat shock 70 kDa protein 8 HLA-G 210514_x_at HLA-G histocompatibility antigen, class I, G KLRD1 210606_x_at killer cell lectin-like receptor subfamily D, member 1 KLRC4 210690_at killer cell lectin-like receptor subfamily C, member 4 HLA-DQB1 210747_at major histocompatibility complex, class II, DQ beta 1 KIR2DL1 210890_x_at killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1 CIITA 210925_at class II, major histocompatibility complex, transactivator HLA-DRA 210982_s_at major histocompatibility complex, class II, DR alpha HLA-DOA 211142_x_at major histocompatibility complex, class II, DO alpha IFNA21 211145_x_at interferon, alpha 21 KIR2DL4 211242_x_at killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 KIR2DL4 211245_x_at killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 NFYC 211251_x_at nuclear transcription factor Y, gamma IFNA2 211338_at interferon, alpha 2 KIR3DL1 211389_x_at killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 IFNA17 211405_x_at interferon, alpha 17 KIR2DL5A 211410_x_at killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5A HLA-G 211528_x_at HLA-G histocompatibility antigen, class I, G HLA-G 211529_x_at HLA-G histocompatibility antigen, class I, G HLA-G 211530_x_at HLA-G histocompatibility antigen, class I, G KIR2DS2 211532_x_at killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 HLA-DQB1 211654_x_at major histocompatibility complex, class II, DQ beta 1 /// MHC class II, DQ beta 1 HLA-DQB1 211656_x_at major histocompatibility complex, class II, DQ beta 1 /// MHC class II, DQ beta 1 KIR3DL1 211687_x_at killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail. KIR3DL1 /// 211688_x_at killer cell immunoglobulin-like receptor, three domains, KIR3DL2 long cytoplasmic tail. NFYC 211797_s_at nuclear transcription factor Y, gamma HLA-C 211799_x_at major histocompatibility complex, class I, C CIITA 211884_s_at class II, major histocompatibility complex, transactivator HLA-B 211911_x_at major histocompatibility complex, class I, B /// MHC class I, B HSPA5 211936_at heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) HSPCA 211968_s_at heat shock 90 kDa protein 1, alpha HSPCA 211969_at heat shock 90 kDa protein 1, alpha HLA-DPA1 211990_at major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 211991_s_at major histocompatibility complex, class II, DP alpha 1 HLA-DQA1 /// 212671_s_at major histocompatibility complex, class II, DQ alpha 1 HLA-DQA2 /// MHC class II, DQ alpha 2 CALR 212952_at Calreticulin CALR 212953_x_at calreticulin HLA-DQB1 212998_x_at major histocompatibility complex, class II, DQ beta 1 /// MHC class II, DQ beta 1 HLA-DQB1 212999_x_at Major histocompatibility complex, class II, DQ beta 1 /// MHC class II, DQ beta 1 CTSB 213274_s_at cathepsin B CTSB 213275_x_at cathepsin B TRIM24 213301_x_at tripartite motif-containing 24 EEF1A1 213477_x_at eukaryotic translation elongation factor 1 alpha 1 HLA-DPA1 213537_at major histocompatibility complex, class II, DP alpha 1 EEF1A1 /// 213583_x_at eukaryotic translation elongation factor 1 LOC387845 /// LOC389223 /// LOC440595 /// LOC441032 EEF1A1 213614_x_at eukaryotic translation elongation factor 1 alpha 1 HLA-DQA1 213831_at major histocompatibility complex, class II, DQ alpha 1 HLA-A 213932_x_at Major histocompatibility complex, class I, A CALR 214315_x_at calreticulin CALR 214316_x_at Calreticulin HSPCA 214328_s_at heat shock 90 kDa protein 1, alpha HSPCB 214359_s_at heat shock 90 kDa protein 1, beta HLA-C 214459_x_at major histocompatibility complex, class I, C CREB1 214513_s_at cAMP responsive element binding protein 1 IFNA5 214569_at interferon, alpha 5 HLA-DRB1 215193_x_at major histocompatibility complex, class II, DR beta 1 HLA-A 215313_x_at major histocompatibility complex, class I, A CD8B1 215332_s_at CD8 antigen, beta polypeptide 1 (p37) HLA-DQB2 215536_at major histocompatibility complex, class II, DQ beta 2 HLA-DRB4 215666_at major histocompatibility complex, class II, DR beta 4 HLA-DRB4 215669_at major histocompatibility complex, class II, DR beta 4 NFYA 215720_s_at nuclear transcription factor Y, alpha B2M 216231_s_at beta-2-microglobulin CD4 216424_at CD4 antigen (p55) HLA-C 216526_x_at major histocompatibility complex, class I, C KIR3DL3 216676_x_at killer cell immunoglobulin-like receptor, three
domains, long cytoplasmic tail, 3 KIR3DL2 216907_x_at killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 HLA-DOA 216946_at major histocompatibility complex, class II, DO alpha HLA-DOA 217001_x_at major histocompatibility complex, class II, DO alpha KIR2DS1 217296_at Killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1 KIR3DL2 /// 217318_x_at killer cell immunoglobulin-like receptor, three domains, KIR2DL5A /// long cytoplasmic tail, 2 KIR3DL3 /// /// killer cell immunoglobulin-like receptor, two domains, KIR3DP1 /// long cytoplasmic tail, 5A KIR2DL5B /// killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 3 /// killer cell immunoglobulin-like receptor, three domains, pseudogene 1 /// killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5B HLA-G /// 217436_x_at HLA-G histocompatibility antigen, class I, G HLA-H /// major histocompatibility complex, class I, H (pseudogene) HLA-E 217456_x_at major histocompatibility complex, class I, E HLA-DMA 217478_s_at major histocompatibility complex, class II, DM alpha NFYB 218127_at nuclear transcription factor Y, beta NFYB 218128_at nuclear transcription factor Y, beta NFYB 218129_s_at nuclear transcription factor Y, beta HLA-DRB1 /// 221491_x_at major histocompatibility complex, class II, DR beta 1 HLA-DRB3 /// /// major histocompatibility complex, class II, DR beta 1 HLA-DRB4 /// major histocompatibility complex, class II, DR beta 3 /// major histocompatibility complex, class II, DR beta 3 /// major histocompatibility complex, class II, DR beta 4 /// major histocompatibility complex, class II, DR beta 4 HLA-F 221875_x_at major histocompatibility complex, class I, F HSPA8 221891_x_at heat shock 70 kDa protein 8 HLA-F 221978_at major histocompatibility complex, class I, F HSPA8 224187_x_at heat shock 70 kDa protein 8 TAP2 225973_at transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) HLA-DOA 226878_at major histocompatibility complex, class II, DO alpha PDIA3 227033_at protein disulfide isomerase family A, member 3 EEF1A1 227708_at eukaryotic translation elongation factor 1 alpha 1 CTSB 227961_at cathepsin B RFXAP 229431_at regulatory factor X-associated protein HSPA5 230031_at heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) CD8B1 230037_at CD8 antigen, beta polypeptide 1 (p37) HSPA9B 232200_at heat shock 70 kDa protein 9B (mortalin-2) CTSS 232617_at cathepsin S HLA-DQA1 236203_at Major histocompatibility complex, class II, DQ alpha 1 CTSS 237104_at Cathepsin S CANX 238034_at calnexin NFYC 238231_at Nuclear transcription factor Y, gamma HLA-DRB1 /// 238900_at major histocompatibility complex, class II, DR beta 1 HLA-DRB3 /// major histocompatibility complex, class II, DR beta 3 NFYC 241630_at Nuclear transcription factor Y, gamma HSPA9B 241840_at Heat shock 70 kDa protein 9B (mortalin-2) CD74 241849_at CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) KLRK1 242873_at Killer cell lectin-like receptor subfamily K, member 1 CTSB 243157_at Cathepsin B CREB1 243625_at CAMP responsive element binding protein 1 NFYB 244704_at nuclear transcription factor Y, beta
TABLE-US-00005 TABLE 5 Pathway 5: T cell signaling Gene Symbol Probe Set ID Gene Title PTPRC 1552480_s_at protein tyrosine phosphatase, receptor type, C CD8B1 1553562_at CD8 antigen, beta polypeptide 1 (p37) PAK6 1555310_a_at p21(CDKN1A)-activated kinase 6 ZAP70 1555613_a_at zeta-chain (TCR) associated protein kinase 70 kDa RHOA 1555814_a_at ras homolog gene family, member A CDC42 1556931_at Cell division cycle 42 (GTP binding protein, 25 kDa) BCL10 1557258_a_at B-cell CLL/lymphoma 10 PPP3CA 1557637_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) PAK2 1559052_s_at p21 (CDKN1A)-activated kinase 2 FYN 1559101_at FYN oncogene related to SRC, FGR, YES KRAS 1559203_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 1559204_x_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog PPP3CA 1560552_a_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) AKT2 1560689_s_at V-akt murine thymoma viral oncogene homolog 2 CARD11 1562368_at caspase recruitment domain family, member 11 PPP3R1 1565810_at Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform PPP3R1 1565811_at Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform PPP3CA 1566201_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) PPP3CA 1566202_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) PIK3R2 1568629_s_at phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) PTPRC 1569830_at Protein tyrosine phosphatase, receptor type, C NFKB1 1570362_at Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) RHOA 200059_s_at ras homolog gene family, member A /// ras homolog gene family, member A JUN 201464_x_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 201465_s_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 201466_s_at v-jun sarcoma virus 17 oncogene homolog (avian) NFKBIA 201502_s_at nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha CDK4 202246_s_at cyclin-dependent kinase 4 PPP3CA 202425_x_at protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) PPP3CA 202429_s_at protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) PPP3CB 202432_at protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta) PPP3CA 202457_s_at protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) NRAS 202647_s_at neuroblastoma RAS viral (v-ras) oncogene homolog PIK3R3 202743_at phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) PLCG1 202789_at phospholipase C, gamma 1 PAK4 203154_s_at p21(CDKN1A)-activated kinase 4 NCK2 203315_at NCK adaptor protein 2 CD4 203547_at CD4 antigen (p55) /// CD4 antigen (p55) AKT2 203808_at v-akt murine thymoma viral oncogene homolog 2 AKT2 203809_s_at v-akt murine thymoma viral oncogene homolog 2 PIK3CD 203879_at phosphoinositide-3-kinase, catalytic, delta polypeptide /// phosphoinositide-3-kinase. NFKBIE 203927_at nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon KRAS 204009_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 204010_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog PIK3CA 204369_at phosphoinositide-3-kinase, catalytic, alpha polypeptide PPP3R1 204506_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform PPP3R1 204507_s_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform NCK1 204725_s_at NCK adaptor protein 1 LCK 204890_s_at lymphocyte-specific protein tyrosine kinase LCK 204891_s_at lymphocyte-specific protein tyrosine kinase MAP3K8 205027_s_at mitogen-activated protein kinase kinase kinase 8 MAP3K14 205192_at mitogen-activated protein kinase kinase kinase 14 BCL10 205263_at B-cell CLL/lymphoma 10 LCP2 205269_at lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa) LCP2 205270_s_at lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa) CD3E 205456_at CD3E antigen, epsilon polypeptide (TiT3 complex) VAV2 205536_at vav 2 oncogene VAV2 205537_s_at vav 2 oncogene RASGRP1 205590_at RAS guanyl releasing protein 1 (calcium and DAG-regulated) CD8A 205758_at CD8 antigen, alpha polypeptide (p32) /// CD8 antigen, alpha polypeptide (p32) NFATC4 205897_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 PAK2 205962_at p21 (CDKN1A)-activated kinase 2 VAV1 206219_s_at vav 1 oncogene TEC 206301_at tec protein tyrosine kinase PIK3CG 206369_s_at phosphoinositide-3-kinase, catalytic, gamma polypeptide PIK3CG 206370_at phosphoinositide-3-kinase, catalytic, gamma polypeptide MRAS 206538_at muscle RAS oncogene homolog CD28 206545_at CD28 antigen (Tp44) CBL 206607_at Cas-Br-M (murine) ecotropic retroviral transforming sequence PDK1 206686_at pyruvate dehydrogenase kinase, isoenzyme 1 PTPN6 206687_s_at protein tyrosine phosphatase, non-receptor type 6 CD3G 206804_at CD3G antigen, gamma polypeptide (TiT3 complex) PPP3CC 207000_s_at protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform PIK3R2 207105_s_at phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) TNF 207113_s_at tumor necrosis factor (TNF superfamily, member 2) AKT1 207163_s_at v-akt murine thymoma viral oncogene homolog 1 PTPRC 207238_s_at protein tyrosine phosphatase, receptor type, C NFATC3 207416_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 IL10 207433_at interleukin 10 NFKB2 207535_s_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) IL4 207538_at interleukin 4 IL4 207539_s_at interleukin 4 PDCD1 207634_at programmed cell death 1 IL2 207849_at interleukin 2 CD40LG 207892_at CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome) IL5 207952_at interleukin 5 (colony-stimulating factor, eosinophil) CD8B1 207979_s_at CD8 antigen, beta polypeptide 1 (p37) CHP 207993_s_at calcium binding protein P22 NFAT5 208003_s_at nuclear factor of activated T-cells 5, tonicity-responsive NFATC1 208196_x_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 MALT1 208309_s_at mucosa associated lymphoid tissue lymphoma translocation gene 1 CBLB 208348_s_at Cas-Br-M (murine) ecotropic retroviral transforming sequence b GRAP2 208406_s_at GRB2-related adaptor protein 2 RRAS2 208456_s_at related RAS viral (r-ras) oncogene homolog 2 CDC42 208727_s_at cell division cycle 42 (GTP binding protein, 25 kDa) CDC42 208728_s_at cell division cycle 42 (GTP binding protein, 25 kDa) PAK2 208875_s_at p21 (CDKN1A)-activated kinase 2 PAK2 208876_s_at p21 (CDKN1A)-activated kinase 2 PAK2 208877_at p21 (CDKN1A)-activated kinase 2 PAK2 208878_s_at p21 (CDKN1A)-activated kinase 2 FOS 209189_at v-fos FBJ murine osteosarcoma viral oncogene homolog NFKB1 209239_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) IKBKB 209341_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta IKBKB 209342_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta NFKB2 209636_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) NFATC1 209664_x_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 CHUK 209666_s_at conserved helix-loop-helix ubiquitous kinase CBLB 209682_at Cas-Br-M (murine) ecotropic retroviral transforming sequence b PPP3CC 209697_at protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform (calcineurin A gamma) PPP3CB 209817_at protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform (calcineurin A beta) LAT 209881_s_at linker for activation of T cells IKBKG 209929_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma MALT1 210017_at mucosa associated lymphoid tissue lymphoma translocation gene 1 MALT1 210018_x_at mucosa associated lymphoid tissue lymphoma translocation gene 1 CD3Z 210031_at CD3Z antigen, zeta polypeptide (TiT3 complex) PRKCQ 210038_at protein kinase C, theta PRKCQ 210039_s_at protein kinase C, theta FYN 210105_s_at FYN oncogene related to SRC, FGR, YES NFATC1 210162_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 CSF2 210228_at colony stimulating factor 2 (granulocyte-macrophage) CSF2 210229_s_at colony stimulating factor 2 (granulocyte-macrophage) CDC42 210232_at cell division cycle 42 (GTP binding protein, 25 kDa) IFNG 210354_at interferon, gamma ICOS 210439_at inducible T-cell co-stimulator NFATC3 210555_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 NFATC3 210556_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 PAK7 210721_s_at p21(CDKN1A)-activated kinase 7 LAT 211005_at linker for activation of T cells IKBKB 211027_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta NCK1 211063_s_at NCK adaptor protein 1 /// NCK adaptor protein 1 NFATC1 211105_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 PIK3CD 211230_s_at phosphoinositide-3-kinase, catalytic, delta polypeptide ITK 211339_s_at IL2-inducible T-cell kinase AKT2 211453_s_at v-akt murine thymoma viral oncogene homolog 2 NFKB2 211524_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) PIK3R3 211580_s_at phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) SOS2 211665_s_at son of sevenless homolog 2 (Drosophila) /// son of sevenless homolog 2 (Drosophila) CD28 211856_x_at CD28 antigen (Tp44) CD28 211861_x_at CD28 antigen (Tp44) PIK3R1 212239_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3R1 212240_s_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) PIK3R1 212249_at phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) FYN 212486_s_at FYN oncogene related to SRC, FGR, YES PTPRC 212587_s_at protein tyrosine phosphatase, receptor type, C PTPRC 212588_at protein tyrosine phosphatase, receptor type, C RRAS2 212590_at related RAS viral (r-ras) oncogene homolog 2 AKT3 212607_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) AKT3 212609_s_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) RRAS 212647_at related RAS viral (r-ras) oncogene homolog PIK3CB 212688_at phosphoinositide-3-kinase, catalytic, beta polypeptide PIK3R4 212740_at phosphoinositide-3-kinase, regulatory subunit 4, p150 SOS1 212777_at son of sevenless homolog 1 (Drosophila) SOS1 212780_at son of sevenless homolog 1 (Drosophila) HRAS 212983_at v-Ha-ras Harvey rat sarcoma viral oncogene homolog NFATC4 213345_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 CD3D 213539_at CD3D antigen, delta polypeptide (TiT3 complex) PPP3CC 213950_s_at Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform PAK7 213990_s_at p21(CDKN1A)-activated kinase 7 ZAP70 214032_at zeta-chain (TCR) associated protein kinase 70 kDa NFKBIB 214062_x_at nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta PAK3 214078_at P21 (CDKN1A)-activated kinase 3
CDC42 214230_at cell division cycle 42 (GTP binding protein, 25 kDa) KRAS 214352_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog NFKBIB 214448_x_at nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta PAK3 214607_at p21 (CDKN1A)-activated kinase 3 CHP 214665_s_at calcium binding protein P22 GRB2 215075_s_at growth factor receptor-bound protein 2 NFAT5 215092_s_at nuclear factor of activated T-cells 5, tonicity-responsive CD8B1 215332_s_at CD8 antigen, beta polypeptide 1 (p37) FYN 216033_s_at FYN oncogene related to SRC, FGR, YES CD4 216424_at CD4 antigen (p55) PIK3R4 216436_at Phosphoinositide-3-kinase, regulatory subunit 4, p150 PLCG1 216551_x_at phospholipase C, gamma 1 PIK3R4 216752_at Phosphoinositide-3-kinase, regulatory subunit 4, p150 SOS2 217575_s_at Son of sevenless homolog 2 (Drosophila) SOS2 217576_x_at son of sevenless homolog 2 (Drosophila) PIK3CB 217620_s_at phosphoinositide-3-kinase, catalytic, beta polypeptide SOS2 217644_s_at son of sevenless homolog 2 (Drosophila) FYN 217697_at FYN oncogene related to SRC, FGR, YES VAV3 218806_s_at vav 3 oncogene VAV3 218807_at vav 3 oncogene AKT3 219393_s_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) PAK6 219461_at p21(CDKN1A)-activated kinase 6 PIK3R5 220566_at phosphoinositide-3-kinase, regulatory subunit 5, p101 CBLC 220638_s_at Cas-Br-M (murine) ecotropic retroviral transforming sequence c CTLA4 221331_x_at cytotoxic T-lymphocyte-associated protein 4 AKT3 222880_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) GRB2 223049_at growth factor receptor-bound protein 2 CARD11 223514_at caspase recruitment domain family, member 11 CBLC 223668_at Cas-Br-M (murine) ecotropic retroviral transforming sequence c VAV3 224221_s_at vav 3 oncogene AKT3 224229_s_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) NFATC2 224542_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 NFAT5 224984_at nuclear factor of activated T-cells 5, tonicity-responsive MRAS 225185_at muscle RAS oncogene homolog CBL 225231_at Cas-Br-M (murine) ecotropic retroviral transforming sequence CBL 225234_at Cas-Br-M (murine) ecotropic retroviral transforming sequence AKT2 225471_s_at v-akt murine thymoma viral oncogene homolog 2 VAV2 226063_at vav 2 oncogene CDC42 226400_at Cell division cycle 42 (GTP binding protein, 25 kDa) PDK1 226452_at pyruvate dehydrogenase kinase, isoenzyme 1 NFATC2 226991_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 SOS1 227426_at Son of sevenless homolog 1 (Drosophila) PIK3R5 227645_at phosphoinositide-3-kinase, regulatory subunit 5, p101 CBLB 227900_at Cas-Br-M (murine) ecotropic retroviral transforming sequence b NFKBIB 228388_at nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta NFATC2 228442_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 GRB2 228572_at growth factor receptor-bound protein 2 CBL 229010_at Cas-Br-M (murine) ecotropic retroviral transforming sequence NFATC3 229223_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 SOS1 229261_at Son of sevenless homolog 1 (Drosophila) PIK3R2 229392_s_at Phosphoinositide-3-kinase, regulatory subunit 2 (p85 beta) PPP3CA 229606_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) NCK1 229895_s_at NCK adaptor protein 1 CD8B1 230037_at CD8 antigen, beta polypeptide 1 (p37) SOS1 230337_at son of sevenless homolog 1 (Drosophila) PPP3R2 231304_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, beta isoform NFKBIA 231699_at Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha CTLA4 231794_at cytotoxic T-lymphocyte-associated protein 4 NFATC2 231801_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 NFATC2 233706_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 NFATC2 233708_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 RASGRP1 233926_at RAS guanyl releasing protein 1 (calcium and DAG-regulated) CBLB 234112_at Cas-Br-M (murine) ecotropic retroviral transforming sequence b CTLA4 234362_s_at cytotoxic T-lymphocyte-associated protein 4 NCK2 234595_at NCK adaptor protein 2 NCK2 234705_at NCK adaptor protein 2 CTLA4 234895_at cytotoxic T-lymphocyte-associated protein 4 MAP3K8 235421_at Mitogen-activated protein kinase kinase kinase 8 NFATC4 236270_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 PAK3 236277_at P21 (CDKN1A)-activated kinase 3 PAK2 236283_x_at p21 (CDKN1A)-activated kinase 2 CTLA4 236341_at cytotoxic T-lymphocyte-associated protein 4 PPP3CA 236545_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha) PRKCQ 237542_at Protein kinase C, theta SOS2 238830_at Son of sevenless homolog 2 (Drosophila) PAK6 239470_at P21(CDKN1A)-activated kinase 6 NFKB1 239876_at Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) RHOA 240337_at Ras homolog gene family, member A AKT3 240568_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) RHOA 241097_at Ras homolog gene family, member A PPP3R1 241786_at Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform SOS1 242018_at Son of sevenless homolog 1 (Drosophila) SOS1 242682_at Son of sevenless homolog 1 (Drosophila) AKT3 242876_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) AKT3 242879_x_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) FYN 243006_at FYN oncogene related to SRC, FGR, YES CBL 243475_at Cas-Br-M (murine) ecotropic retroviral transforming sequence PIK3R1 244181_at Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) LCP2 244251_at Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa) PAK2 244268_x_at p21 (CDKN1A)-activated kinase 2 LCP2 244556_at Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa) LCP2 244578_at lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa) PPP3R2 244782_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, beta isoform PPP3CC 32540_at Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform PPP3CC 32541_at protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform PAK4 33814_at p21(CDKN1A)-activated kinase 4 IKBKG 36004_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma
TABLE-US-00006 TABLE 6 Pathway 6: Mitogen activated protein kinase Gene Symbol Probe Set ID Gene Title MAPK1 1552263_at mitogen-activated protein kinase 1 MAPK1 1552264_a_at mitogen-activated protein kinase 1 ACVR1C 1552519_at activin A receptor, type IC CACNG5 1552602_at calcium channel, voltage-dependent, gamma subunit 5 MAP3K6 1552631_a_at mitogen-activated protein kinase kinase kinase 6 CASP1 /// 1552703_s_at caspase 1, apoptosis-related cysteine peptidase COP1 (interleukin 1, beta, convertase) FGF1 1552721_a_at fibroblast growth factor 1 (acidic) CACNG6 1552863_a_at calcium channel, voltage-dependent, gamma subunit 6 FGF4 1552982_a_at fibroblast growth factor 4 (heparin secretory transforming protein 1) CASP8 1553306_at caspase 8, apoptosis-related cysteine peptidase RPS6KA5 1554319_at ribosomal protein S6 kinase, 90 kDa, polypeptide 5 FGF7 /// 1554741_s_at fibroblast growth factor 7 (keratinocyte growth factor) FLJ30435 PDGFRA 1554828_at platelet-derived growth factor receptor, alpha polypeptide PTPN7 1554860_at protein tyrosine phosphatase, non-receptor type 7 FGFR4 1554961_at fibroblast growth factor receptor 4 FGFR4 1554962_a_at fibroblast growth factor receptor 4 RASGRF1 1554992_at Ras protein-specific guanine nucleotide-releasing factor 1 CACNB2 1555098_a_at calcium channel, voltage-dependent, beta 2 subunit FGF7 1555102_at fibroblast growth factor 7 (keratinocyte growth factor) FGF7 1555103_s_at fibroblast growth factor 7 (keratinocyte growth factor) ATF2 1555146_at activating transcription factor 2 GNG12 1555240_s_at guanine nucleotide binding protein (G protein), gamma 12 ZAK 1555259_at Hypothetical protein LOC339751 RAP1A 1555339_at RAP1A, member of RAS oncogene family RAP1A 1555340_x_at RAP1A, member of RAS oncogene family DUSP16 1555399_a_at dual specificity phosphatase 16 TGFB3 1555540_at transforming growth factor, beta 3 CACNA1D 1555993_at Calcium channel, voltage-dependent, L type, alpha 1D subunit RASGRF2 1556128_a_at Ras protein-specific guanine nucleotide-releasing factor 2 MAPK12 1556340_at Mitogen-activated protein kinase 12 MAPK12 1556341_s_at Mitogen-activated protein kinase 12 NLK 1556568_a_at Nemo-like kinase CDC42 1556931_at Cell division cycle 42 (GTP binding protein, 25 kDa) EEF1A1 1557120_at WD repeats and SOF1 domain containing DUSP16 1557343_at Dual specificity phosphatase 16 PPP3CA 1557637_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform RAF1 1557675_at V-raf-1 murine leukemia viral oncogene homolog 1 PRKCB1 1557811_a_at Protein kinase C, beta 1 DUSP16 1558739_at Dual specificity phosphatase 16 DUSP16 1558740_s_at Dual specificity phosphatase 16 PAK2 1559052_s_at p21 (CDKN1A)-activated kinase 2 KRAS 1559203_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 1559204_x_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog CACNB2 1559419_at calcium channel, voltage-dependent, beta 2 subunit CACNB2 1559420_x_at calcium channel, voltage-dependent, beta 2 subunit ARRB2 1559436_x_at Arrestin, beta 2 FGFR1 1559449_a_at Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) CACNA1G 1559948_at Calcium channel, voltage-dependent, alpha 1G subunit MAX 1560012_at MYC associated factor X PRKCA 1560074_at protein kinase C, alpha STK4 1560214_at Serine/threonine kinase 4 PPP3CA 1560552_a_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform AKT2 1560689_s_at V-akt murine thymoma viral oncogene homolog 2 FGFR2 1560859_at Fibroblast growth factor receptor 2 (bacteria-expressed kinase. MAP4K4 1560868_s_at Mitogen-activated protein kinase kinase kinase kinase 4 FLNB 1561834_a_at Filamin B, beta (actin binding protein 278) MAPK1 1562283_at Mitogen-activated protein kinase 1 FGF12 1562794_at Fibroblast growth factor 12 DUSP16 1563505_at Dual specificity phosphatase 16 RUNX1T1 1564642_at runt-related transcription factor 1; translocated to, 1 (cyclin D-related) BDNF 1565265_at Brain-derived neurotrophic factor opposite strand EGFR 1565483_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) EGFR 1565484_x_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) FUS 1565715_at Fusion (involved in t(12; 16) in malignant liposarcoma) FUS 1565717_s_at fusion (involved in t(12; 16) in malignant liposarcoma) PAK1 1565772_at p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) PPP3R1 1565810_at Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform PPP3R1 1565811_at Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform MAP3K7IP2 1565888_at Mitogen-activated protein kinase kinase kinase 7 interacting protein 2 MAP3K7IP2 1565889_at Mitogen-activated protein kinase kinase kinase 7 interacting protein 2 PPP3CA 1566201_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform PPP3CA 1566202_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform MAPK10 1566596_at Mitogen-activated protein kinase 10 MAPK10 1566597_at Mitogen-activated protein kinase 10 TPM3 1567105_at tropomyosin 3 TPM3 /// 1567107_s_at tropomyosin 3 /// tropomyosin 4 TPM4 BDNF 1567359_at Brain-derived neurotrophic factor opposite strand RAC1 1567457_at Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein) RAC1 1567458_s_at ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein) BDNF 1567575_at Brain-derived neurotrophic factor opposite strand BDNF 1567576_at Brain-derived neurotrophic factor opposite strand RPS6KA3 1568448_at Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 RPS6KA3 1568449_at Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 TRIM24 1569316_at Tripartite motif-containing 24 NLK 1569540_at Nemo-like kinase STK4 1569791_at serine/threonine kinase 4 RUNX1 1570350_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) NFKB1 1570362_at Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) MAP3K4 1570439_at Mitogen-activated protein kinase kinase kinase 4 HSPA9B 200690_at heat shock 70 kDa protein 9B (mortalin-2) HSPA9B 200691_s_at heat shock 70 kDa protein 9B (mortalin-2) HSPA9B 200692_s_at heat shock 70 kDa protein 9B (mortalin-2) ATF4 200779_at activating transcription factor 4 (tax-responsive enhancer element B67) STMN1 200783_s_at stathmin 1/oncoprotein 18 HSPA1A 200799_at heat shock 70 kDa protein 1A HSPA1A /// 200800_s_at heat shock 70 kDa protein 1A /// heat shock 70 kDa protein 1B HSPA1B RAP1B 200833_s_at RAP1B, member of RAS oncogene family FLNA 200859_x_at filamin A, alpha (actin binding protein 280) FUS 200959_at fusion (involved in t(12; 16) in malignant liposarcoma) DUSP1 201041_s_at dual specificity phosphatase 1 DUSP1 201044_x_at dual specificity phosphatase 1 RAF1 201244_s_at v-raf-1 murine leukemia viral oncogene homolog 1 MAPKAPK2 201460_at mitogen-activated protein kinase-activated protein kinase 2 MAPKAPK2 201461_s_at mitogen-activated protein kinase-activated protein kinase 2 JUN 201464_x_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 201465_s_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 201466_s_at v-jun sarcoma virus 17 oncogene homolog (avian) DUSP3 201536_at dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) DUSP3 201537_s_at dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) DUSP3 201538_s_at dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related) CD14 201743_at CD14 antigen /// CD14 antigen TP53 201746_at tumor protein p53 (Li-Fraumeni syndrome) DAXX 201763_s_at death-associated protein 6 HSPB1 201841_s_at heat shock 27 kDa protein 1 CDC25B 201853_s_at cell division cycle 25B PPP5C 201979_s_at protein phosphatase 5, catalytic subunit EGFR 201983_s_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) EGFR 201984_s_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) CRK 202224_at v-crk sarcoma virus CT10 oncogene homolog (avian) CRK 202225_at V-crk sarcoma virus CT10 oncogene homolog (avian) CRK 202226_s_at v-crk sarcoma virus CT10 oncogene homolog (avian) PDGFRB 202273_at platelet-derived growth factor receptor, beta polypeptide NR4A1 202340_x_at nuclear receptor subfamily 4, group A, member 1 RAP1A 202362_at RAP1A, member of RAS oncogene family SRF 202400_s_at serum response factor (c-fos serum response element-binding transcription factor) SRF 202401_s_at serum response factor (c-fos serum response element-binding transcription factor) MAP2K2 202424_at mitogen-activated protein kinase kinase 2 PPP3CA 202425_x_at protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform PPP3CA 202429_s_at protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform MYC 202431_s_at v-myc myelocytomatosis viral oncogene homolog (avian) PPP3CB 202432_at protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform PPP3CA 202457_s_at protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform MAPK14 202530_at mitogen-activated protein kinase 14 HSPA1B 202581_at heat shock 70 kDa protein 1B NRAS 202647_s_at neuroblastoma RAS viral (v-ras) oncogene homolog MAP2K1 202670_at mitogen-activated protein kinase kinase 1 RASA1 202677_at RAS p21 protein activator (GTPase activating protein) 1 PRKACB 202741_at protein kinase, cAMP-dependent, catalytic, beta PRKACB 202742_s_at protein kinase, cAMP-dependent, catalytic, beta CASP3 202763_at caspase 3, apoptosis-related cysteine peptidase PRKACA 202801_at protein kinase, cAMP-dependent, catalytic, alpha IL1R1 202948_at interleukin 1 receptor, type I TGFB1 203084_at transforming growth factor, beta 1 (Camurati-Engelmann disease) TGFB1 203085_s_at transforming growth factor, beta 1 (Camurati-Engelmann disease) PDGFRA 203131_at platelet-derived growth factor receptor, alpha polypeptide MAPK9 203218_at mitogen-activated protein kinase 9 MAP2K4 203265_s_at mitogen-activated protein kinase kinase 4 MAP2K4 203266_s_at mitogen-activated protein kinase kinase 4 DUSP14 203367_at dual specificity phosphatase 14 RPS6KA1 203379_at ribosomal protein S6 kinase, 90 kDa, polypeptide 1 ARRB2 203388_at arrestin, beta 2 MAP3K3 203514_at mitogen-activated protein kinase kinase kinase 3 ELK1 203617_x_at ELK1, member of ETS oncogene family FGFR2 203638_s_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGFR2 203639_s_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) PLA2G2A 203649_s_at phospholipase A2, group IIA (platelets, synovial fluid) GADD45A 203725_at growth arrest and DNA-damage-inducible, alpha JUND 203751_x_at jun D proto-oncogene JUND 203752_s_at jun D proto-oncogene AKT2 203808_at v-akt murine thymoma viral oncogene homolog 2 AKT2 203809_s_at v-akt murine thymoma viral oncogene homolog 2 MAP3K5 203836_s_at mitogen-activated protein kinase kinase kinase 5 MAP3K5 203837_at mitogen-activated protein kinase kinase kinase 5 RPS6KA3 203843_at ribosomal protein S6 kinase, 90 kDa, polypeptide 3 MAP3K7IP1 203901_at mitogen-activated protein kinase kinase kinase 7 interacting protein 1 MAPT 203928_x_at microtubule-associated protein tau MAPT 203929_s_at microtubule-associated protein tau MAPT 203930_s_at microtubule-associated protein tau PPM1A 203966_s_at protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform CASP9 203984_s_at caspase 9, apoptosis-related cysteine peptidase KRAS 204009_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 204010_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog DUSP4 204014_at dual specificity phosphatase 4 DUSP4 204015_s_at dual specificity phosphatase 4 PRKX /// 204060_s_at protein kinase, X-linked /// protein kinase, Y-linked PRKY PRKX 204061_at protein kinase, X-linked STK3 204068_at serine/threonine kinase 3 (STE20 homolog, yeast) MAP3K4 204089_x_at mitogen-activated protein kinase kinase kinase 4 GADD45G 204121_at growth arrest and DNA-damage-inducible, gamma PDGFB 204200_s_at platelet-derived growth factor beta polypeptide (simian sarcoma viral oncogene) NF1 204323_x_at neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) NF1 204325_s_at neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) FGFR3 204379_s_at fibroblast growth factor receptor 3
(achondroplasia, thanatophoric dwarfism) FGFR3 204380_s_at fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) TRIM24 204391_x_at tripartite motif-containing 24 TRAF2 204413_at TNF receptor-associated factor 2 FGF2 204421_s_at fibroblast growth factor 2 (basic) FGF2 204422_s_at fibroblast growth factor 2 (basic) PPP3R1 204506_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform PPP3R1 204507_s_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform IKBKE 204549_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon FGFR4 204579_at fibroblast growth factor receptor 4 RPS6KA4 204632_at ribosomal protein S6 kinase, 90 kDa, polypeptide 4 RPS6KA5 204633_s_at ribosomal protein S6 kinase, 90 kDa, polypeptide 5 RPS6KA5 204635_at ribosomal protein S6 kinase, 90 kDa, polypeptide 5 PLA2G6 204691_x_at phospholipase A2, group VI (cytosolic, calcium-independent) MAP2K5 204756_at mitogen-activated protein kinase kinase 5 FAS 204780_s_at Fas (TNF receptor superfamily, member 6) FAS 204781_s_at Fas (TNF receptor superfamily, member 6) DUSP2 204794_at dual specificity phosphatase 2 MAPK10 204813_at mitogen-activated protein kinase 10 PTPN7 204852_s_at protein tyrosine phosphatase, non-receptor type 7 TAOK2 204877_s_at TAO kinase 2 TAOK2 204878_s_at TAO kinase 2 EEF1A1 204892_x_at eukaryotic translation elongation factor 1 alpha 1 MAP4K2 204936_at mitogen-activated protein kinase kinase kinase kinase 2 TAOK2 204986_s_at TAO kinase 2 MAP3K8 205027_s_at mitogen-activated protein kinase kinase kinase 8 IL1B 205067_at interleukin 1, beta FGF13 205110_s_at fibroblast growth factor 13 FGF1 205117_at fibroblast growth factor 1 (acidic) MAP3K14 205192_at mitogen-activated protein kinase kinase kinase 14 ACVR1B 205209_at activin A receptor, type IB IL1R2 205403_at interleukin 1 receptor, type II STK4 205411_at serine/threonine kinase 4 ATF2 205446_s_at activating transcription factor 2 MAP3K12 205447_s_at mitogen-activated protein kinase kinase kinase 12 MAP3K12 205448_s_at mitogen-activated protein kinase kinase kinase 12 CASP10 205467_at caspase 10, apoptosis-related cysteine peptidase RUNX1T1 205528_s_at runt-related transcription factor 1; translocated to, 1 (cyclin D-related) RUNX1T1 205529_s_at runt-related transcription factor 1; translocated to, 1 (cyclin D-related) TRAF6 205558_at TNF receptor-associated factor 6 RASGRP1 205590_at RAS guanyl releasing protein 1 (calcium and DAG-regulated) MAP2K6 205698_s_at mitogen-activated protein kinase kinase 6 MAP2K6 205699_at mitogen-activated protein kinase kinase 6 DUSP9 205777_at dual specificity phosphatase 9 FGF7 205782_at fibroblast growth factor 7 (keratinocyte growth factor) RASGRP3 205801_s_at RAS guanyl releasing protein 3 (calcium and DAG-regulated) HSPB2 205824_at heat shock 27 kDa protein 2 CACNA1H 205845_at calcium channel, voltage-dependent, alpha 1H subunit NFATC4 205897_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 PAK2 205962_at p21 (CDKN1A)-activated kinase 2 ELK4 205994_at ELK4, ETS-domain protein (SRF accessory protein 1) CASP1 206011_at caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) MAPK11 206040_s_at mitogen-activated protein kinase 11 BRAF 206044_s_at v-raf murine sarcoma viral oncogene homolog B1 PTPRR 206084_at protein tyrosine phosphatase, receptor type, R RAC3 206103_at ras-related C3 botulinum toxin substrate 3 (rho family) MAPK12 206106_at mitogen-activated protein kinase 12 PLA2G5 206178_at phospholipase A2, group V CRKL 206184_at v-crk sarcoma virus CT10 oncogene homolog (avian)-like MAP3K13 206249_at mitogen-activated protein kinase kinase kinase 13 EGF 206254_at epidermal growth factor (beta-urogastrone) PRKCG 206270_at protein kinase C, gamma PRKY 206279_at protein kinase, Y-linked MAP4K1 206296_x_at mitogen-activated protein kinase kinase kinase kinase 1 PLA2G1B 206311_s_at phospholipase A2, group IB (pancreas) MAP3K10 206362_x_at mitogen-activated protein kinase kinase kinase 10 DUSP8 206374_at dual specificity phosphatase 8 BDNF 206382_s_at brain-derived neurotrophic factor CACNG3 206384_at calcium channel, voltage-dependent, gamma subunit 3 CACNA1A 206399_x_at calcium channel, voltage-dependent, P/Q type, alpha 1A subunit MAPT 206401_s_at microtubule-associated protein tau FGF9 206404_at fibroblast growth factor 9 (glia-activating factor) MRAS 206538_at muscle RAS oncogene homolog EEF1A1 206559_x_at eukaryotic translation elongation factor 1 alpha 1 MAP4K4 206571_s_at mitogen-activated protein kinase kinase kinase kinase 4 CACNG1 206612_at calcium channel, voltage-dependent, gamma subunit 1 RASA2 206636_at RAS p21 protein activator 2 NTF3 206706_at neurotrophin 3 FGF4 206783_at fibroblast growth factor 4 (heparin secretory transforming protein 1) NGFB 206814_at nerve growth factor, beta polypeptide MAP3K7 206853_s_at Mitogen-activated protein kinase kinase kinase 7 MAP3K7 206854_s_at mitogen-activated protein kinase kinase kinase 7 ELK4 206919_at ELK4, ETS-domain protein (SRF accessory protein 1) PRKCA 206923_at protein kinase C, alpha TGFBR1 206943_at transforming growth factor, beta receptor I (activin A receptor type II-like kinase) FGF18 206986_at fibroblast growth factor 18 FGF18 206987_x_at fibroblast growth factor 18 CCR5 206991_s_at chemokine (C-C motif) receptor 5 CACNB1 206996_x_at calcium channel, voltage-dependent, beta 1 subunit PPP3CC 207000_s_at protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform CACNA2D1 207050_at calcium channel, voltage-dependent, alpha 2/delta subunit 1 TNF 207113_s_at tumor necrosis factor (TNF superfamily, member 2) NTRK2 207152_at neurotrophic tyrosine kinase, receptor, type 2 CACNA1B 207162_s_at calcium channel, voltage-dependent, L type, alpha 1B subunit CASP7 207181_s_at caspase 7, apoptosis-related cysteine peptidase PLA2G10 207222_at phospholipase A2, group X PRKACG 207228_at protein kinase, cAMP-dependent, catalytic, gamma MAPK7 207292_s_at mitogen-activated protein kinase 7 TGFBR2 207334_s_at transforming growth factor, beta receptor II (70/80 kDa) RAC2 207419_s_at ras-related C3 botulinum toxin substrate 2 (rho family, Rac 2) CASP5 207500_at caspase 5, apoptosis-related cysteine peptidase FGF12 207501_s_at fibroblast growth factor 12 NFKB2 207535_s_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) GADD45B 207574_s_at growth arrest and DNA-damage-inducible, beta TNFRSF1A 207643_s_at tumor necrosis factor receptor superfamily, member 1A MAP2K3 207667_s_at mitogen-activated protein kinase kinase 3 CASP8 207686_s_at caspase 8, apoptosis-related cysteine peptidase CACNB4 207693_at calcium channel, voltage-dependent, beta 4 subunit CACNB2 207776_s_at calcium channel, voltage-dependent, beta 2 subunit FGFR1 207822_at fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) CACNA1G 207869_s_at calcium channel, voltage-dependent, alpha 1G subunit FLNC 207876_s_at filamin C, gamma (actin binding protein 280) FGFR1 207937_x_at fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) MEF2C 207968_s_at MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer 2C) CHP 207993_s_at calcium binding protein P22 CACNA1D 207998_s_at calcium channel, voltage-dependent, L type, alpha 1D subunit CASP2 208050_s_at caspase 2, apoptosis-related cysteine peptidase RUNX1 208129_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) IL1A 208200_at interleukin 1, alpha RASGRP2 208206_s_at RAS guanyl releasing protein 2 (calcium and DAG-regulated) ACVR1B 208218_s_at activin A receptor, type IB ACVR1B 208219_at activin A receptor, type IB ACVR1B 208222_at activin A receptor, type IB ACVR1B 208223_s_at activin A receptor, type IB FGFR2 208225_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGFR2 208228_s_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGFR2 208229_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGFR2 208234_x_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGF1 208240_s_at fibroblast growth factor 1 (acidic) CACNA1I 208299_at calcium channel, voltage-dependent, alpha 1I subunit MAPK1 208351_s_at mitogen-activated protein kinase 1 CACNA1F 208377_s_at calcium channel, voltage-dependent, alpha 1F subunit FGF5 208378_x_at fibroblast growth factor 5 MAX 208403_x_at MYC associated factor X FGF6 208417_at fibroblast growth factor 6 MDS1 208434_at myelodysplasia syndrome 1 FGF8 208449_s_at fibroblast growth factor 8 (androgen-induced) RRAS2 208456_s_at related RAS viral (r-ras) oncogene homolog 2 NTRK1 208605_s_at neurotrophic tyrosine kinase, receptor, type 1 FLNB 208613_s_at filamin B, beta (actin binding protein 278) FLNB 208614_s_at filamin B, beta (actin binding protein 278) RAC1 208640_at ras-related C3 botulinum toxin substrate 1 (rho family) RAC1 208641_s_at ras-related C3 botulinum toxin substrate 1 (rho family) HSPA8 208687_x_at heat shock 70 kDa protein 8 CDC42 208727_s_at cell division cycle 42 (GTP binding protein, 25 kDa) CDC42 208728_s_at cell division cycle 42 (GTP binding protein, 25 kDa) PAK2 208875_s_at p21 (CDKN1A)-activated kinase 2 PAK2 208876_s_at p21 (CDKN1A)-activated kinase 2 PAK2 208877_at p21 (CDKN1A)-activated kinase 2 PAK2 208878_s_at p21 (CDKN1A)-activated kinase 2 DUSP6 208891_at dual specificity phosphatase 6 DUSP6 208892_s_at dual specificity phosphatase 6 DUSP6 208893_s_at dual specificity phosphatase 6 TGFBR2 208944_at transforming growth factor, beta receptor II (70/80 kDa) FOS 209189_at v-fos FBJ murine osteosarcoma viral oncogene homolog MEF2C 209199_s_at MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer 2C) MEF2C 209200_at MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer 2C) NFKB1 209239_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) MINK1 209241_x_at misshapen-like kinase 1 (zebrafish) PPM1B 209296_at protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform GADD45B 209304_x_at growth arrest and DNA-damage-inducible, beta GADD45B 209305_s_at growth arrest and DNA-damage-inducible, beta CASP4 209310_s_at caspase 4, apoptosis-related cysteine peptidase MAX 209331_s_at MYC associated factor X MAX 209332_s_at MYC associated factor X IKBKB 209341_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta IKBKB 209342_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta RUNX1 209359_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) RUNX1 209360_s_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) DDIT3 209383_at DNA-damage-inducible transcript 3 DUSP5 209457_at dual specificity phosphatase 5 MKNK1 209467_s_at MAP kinase interacting serine/threonine kinase 1 CACNB3 209530_at calcium channel, voltage-dependent, beta 3 subunit PAK1 209615_s_at p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) NFKB2 209636_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) CHUK 209666_s_at conserved helix-loop-helix ubiquitous kinase PRKCB1 209685_s_at protein kinase C, beta 1 PPP3CC 209697_at protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform TGFB3 209747_at transforming growth factor, beta 3 CASP6 209790_s_at caspase 6, apoptosis-related cysteine peptidase CASP2 209811_at caspase 2, apoptosis-related cysteine peptidase (neural precursor cell expressed) CASP2 209812_x_at caspase 2, apoptosis-related cysteine peptidase (neural precursor cell expressed) PPP3CB 209817_at protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform TGFB2 209908_s_at Transforming growth factor, beta 2 TGFB2 209909_s_at transforming growth factor, beta 2 IKBKG 209929_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma MAP2K7 209951_s_at mitogen-activated protein kinase kinase 7 MAP2K7 209952_s_at mitogen-activated protein kinase kinase 7 CASP1 209970_x_at caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) MAPK13 210058_at mitogen-activated protein kinase 13 MAPK13 210059_s_at mitogen-activated protein kinase 13 CACNA1D 210108_at calcium channel, voltage-dependent, L type, alpha 1D subunit
IL1A 210118_s_at interleukin 1, alpha PLA2G4A 210145_at phospholipase A2, group IVA (cytosolic, calcium-dependent) CACNB1 210185_at calcium channel, voltage-dependent, beta 1 subunit HSPA1L 210189_at heat shock 70 kDa protein 1-like NR4A1 210226_at nuclear receptor subfamily 4, group A, member 1 CDC42 210232_at cell division cycle 42 (GTP binding protein, 25 kDa) MAP3K7IP2 210284_s_at mitogen-activated protein kinase kinase kinase 7 interacting protein 2 FGF5 210310_s_at fibroblast growth factor 5 FGF5 210311_at fibroblast growth factor 5 HSPA8 210338_s_at heat shock 70 kDa protein 8 RUNX1 210365_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) ELK1 210376_x_at ELK1, member of ETS oncogene family CACNA1G 210380_s_at calcium channel, voltage-dependent, alpha 1G subunit PPM1A 210407_at protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform MAPK14 210449_x_at mitogen-activated protein kinase 14 MAPK8 210477_x_at mitogen-activated protein kinase 8 MAP2K5 210482_x_at mitogen-activated protein kinase kinase 5 RASGRF1 210550_s_at Ras protein-specific guanine nucleotide-releasing factor 1 MAPK9 210570_x_at mitogen-activated protein kinase 9 RASA1 210621_s_at RAS p21 protein activator (GTPase activating protein) 1 NF1 210631_at neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) PLA2G6 210647_x_at phospholipase A2, group VI (cytosolic, calcium-independent) MAPK8 210671_x_at mitogen-activated protein kinase 8 PTPRR 210675_s_at protein tyrosine phosphatase, receptor type, R CASP10 210708_x_at caspase 10, apoptosis-related cysteine peptidase MAX 210734_x_at MYC associated factor X CACNA1A 210770_s_at calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CASP9 210775_x_at caspase 9, apoptosis-related cysteine peptidase RUNX1 210805_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) ELK1 210850_s_at ELK1, member of ETS oncogene family FASLG 210865_at Fas ligand (TNF superfamily, member 6) CASP10 210955_at caspase 10, apoptosis-related cysteine peptidase CACNB1 210967_x_at calcium channel, voltage-dependent, beta 1 subunit FGFR1 210973_s_at fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) EGFR 210984_x_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) IKBKB 211027_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta cells) FGF18 211029_x_at fibroblast growth factor 18 /// fibroblast growth factor 18 STK3 211078_s_at serine/threonine kinase 3 (STE20 homolog, yeast) MAP3K13 211083_s_at mitogen-activated protein kinase kinase kinase STK4 211085_s_at serine/threonine kinase 4 /// serine/threonine kinase 4 MAPK14 211087_x_at mitogen-activated protein kinase 14 /// mitogen-activated protein kinase 14 NF1 211094_s_at neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) NF1 211095_at neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) CASP2 211140_s_at caspase 2, apoptosis-related cysteine peptidase NR4A1 211143_x_at nuclear receptor subfamily 4, group A, member 1 RUNX1 211179_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) RUNX1 211180_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) RUNX1 211181_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) RUNX1 211182_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) FGFR4 211237_s_at fibroblast growth factor receptor 4 TP53 211300_s_at tumor protein p53 (Li-Fraumeni syndrome) CACNA1G 211314_at calcium channel, voltage-dependent, alpha 1G subunit CACNA1G 211315_s_at calcium channel, voltage-dependent, alpha 1G subunit FASLG 211333_s_at Fas ligand (TNF superfamily, member 6) CASP1 211366_x_at caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) CASP1 211367_s_at caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) CASP1 211368_s_at caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) MAP2K5 211370_s_at mitogen-activated protein kinase kinase 5 MAP2K5 211371_at mitogen-activated protein kinase kinase 5 IL1R2 211372_s_at interleukin 1 receptor, type II FGFR2 211398_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGFR2 211399_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGFR2 211400_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGFR2 211401_s_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) MAP3K4 211437_at Mitogen-activated protein kinase kinase kinase AKT2 211453_s_at v-akt murine thymoma viral oncogene homolog 2 CASP6 211464_x_at caspase 6, apoptosis-related cysteine peptidase FGF18 211485_s_at fibroblast growth factor 18 MAPK11 211499_s_at mitogen-activated protein kinase 11 MAPK11 211500_at mitogen-activated protein kinase 11 NFKB2 211524_at nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) PDGFRA 211533_at platelet-derived growth factor receptor, alpha polypeptide FGFR1 211535_s_at fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) MAP3K7 211536_x_at mitogen-activated protein kinase kinase kinase 7 MAP3K7 211537_x_at mitogen-activated protein kinase kinase kinase 7 EGFR 211550_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) EGFR 211551_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) MAPK14 211561_x_at mitogen-activated protein kinase 14 EGFR 211607_x_at epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) RUNX1 211620_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) SOS2 211665_s_at son of sevenless homolog 2 (Drosophila) /// son of sevenless homolog 2 CACNA1G 211802_x_at calcium channel, voltage-dependent, alpha 1G subunit CACNA1I 211830_s_at calcium channel, voltage-dependent, alpha 1I subunit CASP10 211888_x_at caspase 10, apoptosis-related cysteine peptidase NF1 211914_x_at neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) HSPA5 211936_at heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) MAPK3 212046_x_at mitogen-activated protein kinase 3 CRKL 212180_at v-crk sarcoma virus CT10 oncogene homolog (avian)-like MAP3K7IP2 212184_s_at mitogen-activated protein kinase kinase kinase 7 interacting protein 2 MAPK1 212271_at mitogen-activated protein kinase 1 GNG12 212294_at guanine nucleotide binding protein (G protein), gamma 12 RRAS2 212590_at related RAS viral (r-ras) oncogene homolog 2 AKT3 212607_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) AKT3 212609_s_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) RRAS 212647_at related RAS viral (r-ras) oncogene homolog NF1 212676_at Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) NF1 212678_at Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) SOS1 212777_at son of sevenless homolog 1 (Drosophila) SOS1 212780_at son of sevenless homolog 1 (Drosophila) MAPKAPK5 212871_at mitogen-activated protein kinase-activated protein kinase 5 HRAS 212983_at v-Ha-ras Harvey rat sarcoma viral oncogene homolog ATF2 212984_at Activating transcription factor 2 MAPK8IP1 213013_at mitogen-activated protein kinase 8 interacting protein 1 MAPK8IP1 213014_at mitogen-activated protein kinase 8 interacting protein 1 PRKCA 213093_at protein kinase C, alpha MAPK8IP3 213177_at mitogen-activated protein kinase 8 interacting protein 3 MAPK8IP3 213178_s_at mitogen-activated protein kinase 8 interacting protein 3 ACVR1B 213198_at activin A receptor, type IB PPM1B 213225_at protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform TRIM24 213301_x_at tripartite motif-containing 24 NFATC4 213345_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 CASP8 213373_s_at caspase 8, apoptosis-related cysteine peptidase EEF1A1 213477_x_at eukaryotic translation elongation factor 1 alpha 1 MAP2K2 213487_at Mitogen-activated protein kinase kinase 2 MAP2K2 213490_s_at mitogen-activated protein kinase kinase 2 GADD45B 213560_at Growth arrest and DNA-damage-inducible, beta EEF1A1 /// 213583_x_at eukaryotic translation elongation factor 1 alpha LOC387845 /// LOC389223 /// LOC440595 /// LOC441032 CASP4 213596_at caspase 4, apoptosis-related cysteine peptidase RAC2 213603_s_at ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding Rac2) EEF1A1 213614_x_at eukaryotic translation elongation factor 1 alpha 1 CACNB2 213714_at calcium channel, voltage-dependent, beta 2 subunit FLNA 213746_s_at filamin A, alpha (actin binding protein 280) DUSP7 213848_at Dual specificity phosphatase 7 PPP3CC 213950_s_at Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform MAX 214108_at MYC associated factor X MAP4K1 214219_x_at mitogen-activated protein kinase kinase kinase kinase 1 CDC42 214230_at cell division cycle 42 (GTP binding protein, 25 kDa) MINK1 214246_x_at misshapen-like kinase 1 (zebrafish) FGF18 214284_s_at Fibroblast growth factor 18 JUND 214326_x_at jun D proto-oncogene MAP4K1 214339_s_at mitogen-activated protein kinase kinase kinase kinase 1 KRAS 214352_s_at v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog TPM3 214365_at tropomyosin 3 RASGRP2 214367_at RAS guanyl releasing protein 2 (calcium and DAG-regulated) RASGRP2 214368_at RAS guanyl releasing protein 2 (calcium and DAG-regulated) RASGRP2 214369_s_at RAS guanyl releasing protein 2 (calcium and DAG-regulated) IKBKE 214398_s_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon CACNG2 214495_at calcium channel, voltage-dependent, gamma subunit 2 FGF3 214571_at fibroblast growth factor 3 (murine mammary tumor virus integration site oncogene) FGF12 214589_at fibroblast growth factor 12 MAP2K1 214592_s_at Mitogen-activated protein kinase kinase 1 MINK1 214625_s_at misshapen-like kinase 1 (zebrafish) CHP 214665_s_at calcium binding protein P22 NTRK2 214680_at neurotrophic tyrosine kinase, receptor, type 2 FLNA 214752_x_at filamin A, alpha (actin binding protein 280) MAP3K1 214786_at mitogen-activated protein kinase kinase kinase 1 DUSP7 214793_at dual specificity phosphatase 7 CACNA1A 214933_at calcium channel, voltage-dependent, P/Q type, alpha 1A subunit MAPKAPK2 215050_x_at mitogen-activated protein kinase-activated protein kinase 2 GRB2 215075_s_at growth factor receptor-bound protein 2 PRKCA 215194_at protein kinase C, alpha PRKCA 215195_at protein kinase C, alpha PDGFRA 215305_at platelet-derived growth factor receptor, alpha polypeptide CACNB2 215365_at calcium channel, voltage-dependent, beta 2 subunit FGFR1 215404_x_at fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) MAP2K3 215498_s_at mitogen-activated protein kinase kinase 3 /// mitogen-activated protein kinase kinase 3 MAP2K3 215499_at mitogen-activated protein kinase kinase 3 /// mitogen-activated protein kinase kinase 3 DUSP10 215501_s_at dual specificity phosphatase 10 IL1R1 215561_s_at interleukin 1 receptor, type I RASGRF1 215688_at Ras protein-specific guanine nucleotide-releasing factor 1 PPP5C 215705_at protein phosphatase 5, catalytic subunit FAS 215719_x_at Fas (TNF receptor superfamily, member 6) FUS 215744_at fusion (involved in t(12; 16) in malignant liposarcoma) EVI1 215851_at ecotropic viral integration site 1 PLA2G5 215870_s_at phospholipase A2, group V PLA2G5 215871_at phospholipase A2, group V MINK1 215909_x_at misshapen-like kinase 1 (zebrafish) PLA2G6 215938_s_at phospholipase A2, group VI (cytosolic, calcium-independent) DAXX 216038_x_at death-associated protein 6 PDGFB 216055_at Platelet-derived growth factor beta polypeptide (simian sarcoma viral oncogene) PDGFB 216061_x_at platelet-derived growth factor beta polypeptide (simian sarcoma viral oncogene) NF1 216115_at Neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease)
MAPK8IP3 216137_s_at Mitogen-activated protein kinase 8 interacting protein 3 MAPK8IP3 216139_s_at mitogen-activated protein kinase 8 interacting protein 3 MAP3K4 216199_s_at mitogen-activated protein kinase kinase kinase 4 MAP2K7 216206_x_at mitogen-activated protein kinase kinase 7 PRKACA 216234_s_at protein kinase, cAMP-dependent, catalytic, alpha FAS 216252_x_at Fas (TNF receptor superfamily, member 6) MAP2K5 216435_at Mitogen-activated protein kinase kinase 5 MAP2K5 216765_at Mitogen-activated protein kinase kinase 5 RUNX1T1 216831_s_at runt-related transcription factor 1; translocated to, 1 (cyclin D-related) RUNX1T1 216832_at runt-related transcription factor 1; translocated to, 1 (cyclin D-related) PDGFB 217112_at platelet-derived growth factor beta polypeptide (simian sarcoma viral oncogene) STMN1 217253_at Stathmin 1/oncoprotein 18 STMN1 217257_at Stathmin 1/oncoprotein 18 RUNX1 217263_x_at runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) FUS 217370_x_at fusion (involved in t(12; 16) in malignant liposarcoma) CACNA1S 217515_s_at calcium channel, voltage-dependent, L type, alpha 1S subunit SOS2 217575_s_at Son of sevenless homolog 2 (Drosophila) SOS2 217576_x_at son of sevenless homolog 2 (Drosophila) SOS2 217644_s_at son of sevenless homolog 2 (Drosophila) STMN1 217714_x_at stathmin 1/oncoprotein 18 TFG 217839_at TRK-fused gene MAP2K1IP1 217971_at mitogen-activated protein kinase kinase 1 interacting protein 1 MAP4K4 218181_s_at mitogen-activated protein kinase kinase kinase kinase 4 MKNK2 218205_s_at MAP kinase interacting serine/threonine kinase 2 SITPEC 218225_at signaling intermediate in Toll pathway, evolutionarily conserved MAP4K3 218311_at mitogen-activated protein kinase kinase kinase kinase 3 NLK 218318_s_at nemo like kinase ARRB1 218832_x_at arrestin, beta 1 ZAK 218833_at sterile alpha motif and leucine zipper containing kinase AZK MAP3K6 219278_at mitogen-activated protein kinase kinase kinase 6 AKT3 219393_s_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) FGF20 220394_at fibroblast growth factor 20 TGFB2 220406_at transforming growth factor, beta 2 TGFB2 220407_s_at transforming growth factor, beta 2 PLA2G2D 220423_at phospholipase A2, group IID PLA2G3 220780_at phospholipase A2, group III PLA2G12A 221027_s_at phospholipase A2, group XIIA /// phospholipase A2, group XIIA FGF23 221166_at fibroblast growth factor 23 FGF14 221310_at fibroblast growth factor 14 FGF22 221315_s_at fibroblast growth factor 22 MOS 221367_at v-mos Moloney murine sarcoma viral oncogene homolog FGF16 221374_at fibroblast growth factor 16 FGF17 221376_at fibroblast growth factor 17 PLA2G2E 221389_at phospholipase A2, group IIE CACNG5 221401_at calcium channel, voltage-dependent, gamma subunit 5 FGF21 221433_at fibroblast growth factor 21 DUSP10 221563_at dual specificity phosphatase 10 CACNG4 221585_at calcium channel, voltage-dependent, gamma subunit 4 CACNA1I 221631_at calcium channel, voltage-dependent, alpha 1I subunit MAP3K2 221695_s_at mitogen-activated protein kinase kinase kinase 2 GNA12 221737_at guanine nucleotide binding protein (G protein) alpha 12 NTRK2 221795_at neurotrophic tyrosine kinase, receptor, type 2 NTRK2 221796_at neurotrophic tyrosine kinase, receptor, type 2 TFG 221871_s_at TRK-fused gene EVI1 221884_at ecotropic viral integration site 1 HSPA8 221891_x_at heat shock 70 kDa protein 8 FGFR3 222006_at Fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) FGFR1 222164_at Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) MAP4K4 222547_at mitogen-activated protein kinase kinase kinase kinase 4 MAP4K4 222548_s_at mitogen-activated protein kinase kinase kinase kinase 4 NLK 222589_at nemo like kinase NLK 222590_s_at nemo like kinase ARRB1 222756_s_at arrestin, beta 1 ZAK 222757_s_at sterile alpha motif and leucine zipper containing kinase AZK GNG12 222834_s_at guanine nucleotide binding protein (G protein), gamma 12 AKT3 222880_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) ARRB1 222912_at arrestin, beta 1 CACNA1H 222960_at calcium channel, voltage-dependent, alpha 1H subunit TPM3 222976_s_at tropomyosin 3 GRB2 223049_at growth factor receptor-bound protein 2 MKNK2 223199_at MAP kinase interacting serine/threonine kinase 2 PLA2G12A 223373_s_at phospholipase A2, group XIIA ZAK 223519_at sterile alpha motif and leucine zipper containing kinase AZK STK4 223746_at serine/threonine kinase 4 MAP2K5 224114_at Mitogen-activated protein kinase kinase 5 CACNG7 224137_at calcium channel, voltage-dependent, gamma subunit 7 TPM3 224164_at tropomyosin 3 HSPA8 224187_x_at heat shock 70 kDa protein 8 AKT3 224229_s_at v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) CACNG6 224291_at calcium channel, voltage-dependent, gamma subunit 6 DUSP16 224336_s_at dual specificity phosphatase 16 /// dual specificity phosphatase 16 NFATC2 224542_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 MAPK1 224621_at mitogen-activated protein kinase 1 GNA12 224681_at guanine nucleotide binding protein (G protein) alpha 12 TGFBR1 224793_s_at transforming growth factor, beta receptor I (activin A receptor type II-like kinase) DUSP16 224832_at dual specificity phosphatase 16 EGFR 224999_at Epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) MRAS 225185_at muscle RAS oncogene homolog PRKCA 225225_at Homo sapiens, clone IMAGE: 4103364, mRNA /// Protein kinase C, alpha PRKCA 225332_at Homo sapiens, clone IMAGE: 4103364, mRNA /// Protein kinase C, alpha STK4 225364_at serine/threonine kinase 4 MAPT 225379_at microtubule-associated protein tau AKT2 225471_s_at v-akt murine thymoma viral oncogene homolog 2 ZAK 225662_at sterile alpha motif and leucine zipper containing kinase AZK ZAK 225665_at sterile alpha motif and leucine zipper containing kinase AZK MAPK9 225781_at Mitogen-activated protein kinase 9 MAP3K1 225927_at mitogen-activated protein kinase kinase kinase 1 MAP2K7 226023_at mitogen-activated protein kinase kinase 7 CASP2 226032_at caspase 2, apoptosis-related cysteine peptidase (neural precursor cell expressed) DUSP4 226034_at Dual specificity phosphatase 4 CASP2 226036_x_at caspase 2, apoptosis-related cysteine peptidase (neural precursor cell expressed) MAPK8 226046_at mitogen-activated protein kinase 8 MAPK8 226048_at mitogen-activated protein kinase 8 MAP2K7 226053_at mitogen-activated protein kinase kinase 7 RPS6KA3 226335_at ribosomal protein S6 kinase, 90 kDa, polypeptide 3 BRAF 226391_at V-raf murine sarcoma viral oncogene homolog B1 RASA2 226392_at RAS p21 protein activator 2 CDC42 226400_at Cell division cycle 42 (GTP binding protein, 25 kDa) EVI1 226420_at ecotropic viral integration site 1 MAP3K2 226441_at Mitogen-activated protein kinase kinase kinase 2 PAK1 226507_at p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) DUSP1 226578_s_at Dual specificity phosphatase 1 FGFR1 226705_at Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) MAP3K2 226979_at mitogen-activated protein kinase kinase kinase 2 NFATC2 226991_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 MAP3K2 227073_at Mitogen-activated protein kinase kinase kinase 2 MAP3K3 227131_at mitogen-activated protein kinase kinase kinase 3 FGF11 227271_at fibroblast growth factor 11 SOS1 227426_at Son of sevenless homolog 1 (Drosophila) MAP2K1IP1 227562_at Mitogen-activated protein kinase kinase 1 interacting protein 1 CACNA2D1 227623_at Calcium channel, voltage-dependent, alpha 2/delta subunit 1 EEF1A1 227708_at eukaryotic translation elongation factor 1 alpha 1 PPM1A 227728_at Protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform PRKCB1 227817_at Protein kinase C, beta 1 RASGRF2 228109_at Ras protein-specific guanine nucleotide-releasing factor 2 TGFB2 228121_at Transforming growth factor, beta 2 NFATC2 228442_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 CACNA1D 228560_at Calcium channel, voltage-dependent, L type, alpha 1D subunit GRB2 228572_at growth factor receptor-bound protein 2 RUNX1T1 228827_at Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) PPM1A 229027_at Protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform JUND 229117_s_at Jun D proto-oncogene SOS1 229261_at Son of sevenless homolog 1 (Drosophila) NTRK2 229463_at neurotrophic tyrosine kinase, receptor, type 2 PPP3CA 229606_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform MAPK8 229664_at Mitogen-activated protein kinase 8 MAPK1 229847_at Mitogen-activated protein kinase 1 MAP3K6 229960_at mitogen-activated protein kinase kinase kinase 6 HSPA5 230031_at heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) PAK1 230100_x_at p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) MAPK8IP3 230162_s_at Mitogen-activated protein kinase 8 interacting protein 3 FGF14 230288_at Fibroblast growth factor 14 SOS1 230337_at son of sevenless homolog 1 (Drosophila) PRKCB1 230437_s_at Protein kinase C, beta 1 RPS6KA4 230544_at Ribosomal protein S6 kinase, 90 kDa, polypeptide 4 ELK4 230549_at ELK4, ETS-domain protein (SRF accessory protein 1) RASA2 230669_at RAS p21 protein activator 2 FGFR2 230842_at Fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGF7 230918_at Fibroblast growth factor 7 (keratinocyte growth factor) FUS 231108_at Fusion (involved in t(12; 16) in malignant liposarcoma) RAP1B 231127_at RAP1B, member of RAS oncogene family CASP8 231218_at Caspase 8, apoptosis-related cysteine peptidase PPP3R2 231304_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, beta isoform RASGRP4 231328_s_at RAS guanyl releasing protein 4 PPM1A 231370_at Protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform FGF18 231382_at Fibroblast growth factor 18 FGF14 231523_at fibroblast growth factor 14 CASP14 231722_at caspase 14, apoptosis-related cysteine peptidase CACNG4 231737_at calcium channel, voltage-dependent, gamma subunit 4 FGF10 231762_at fibroblast growth factor 10 NTF5 231785_at neurotrophin 5 (neurotrophin 4/5) NFATC2 231801_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 FGF11 231803_at fibroblast growth factor 11 MAPK8IP3 232085_at mitogen-activated protein kinase 8 interacting protein 3 HSPA9B 232200_at heat shock 70 kDa protein 9B (mortalin-2) EGFR 232541_at Epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog PPM1B 232580_x_at Protein phosphatase 1B (formerly 2C), magnesium-dependent, beta isoform MAX 233283_at MYC associated factor X PTPN5 233470_at Protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) PTPN5 233471_at protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) MEF2C 233522_at MADS box transcription enhancer factor 2, polypeptide C MAP3K7IP1 233679_at Mitogen-activated protein kinase kinase kinase 7 interacting protein 1 NFATC2 233706_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 NFATC2 233708_at Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 STK3 233779_x_at Serine/threonine kinase 3 (STE20 homolog, yeast) RASGRP1 233926_at RAS guanyl releasing protein 1 (calcium and DAG-regulated) MAP3K7IP2 233957_at Mitogen-activated protein kinase kinase kinase 7 interacting protein 2 IL1R1 234516_at Interleukin 1 receptor, type I IL1R1 234523_at Interleukin 1 receptor, type I CACNG8 234750_at calcium channel, voltage-dependent, gamma subunit 8 CACNG8 234756_at calcium channel, voltage-dependent, gamma subunit 8 MAP3K2 235011_at Mitogen-activated protein kinase kinase kinase 2 PPM1A 235344_at Protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform MAP3K8 235421_at Mitogen-activated protein kinase kinase kinase 8 MAP3K7IP1 235480_at Mitogen-activated protein kinase kinase kinase 7 interacting protein 1 MAP2K5 235601_at Mitogen-activated protein kinase kinase 5
STMN1 235669_at Stathmin 1/oncoprotein 18 PRKACB 235780_at protein kinase, cAMP-dependent, catalytic, beta CACNA1B 235781_at calcium channel, voltage-dependent, L type, alpha 1B subunit MAP3K7IP1 235827_at mitogen-activated protein kinase kinase kinase 7 interacting protein 1 NTRK2 236095_at neurotrophic tyrosine kinase, receptor, type 2 RUNX1 236114_at Runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) PRKCG 236195_x_at protein kinase C, gamma STK4 236259_at serine/threonine kinase 4 NFATC4 236270_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 PAK2 236283_x_at p21 (CDKN1A)-activated kinase 2 MEF2C 236395_at MADS box transcription enhancer factor 2, polypeptide C TGFBR2 236419_at Transforming growth factor, beta receptor II (70/80 kDa) PTPN5 236456_at protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) DUSP16 236511_at Dual specificity phosphatase 16 PPP3CA 236545_at Protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform i TGFBR1 236561_at Transforming growth factor, beta receptor I (activin A receptor type II-like kinase) CASP3 236729_at Caspase 3, apoptosis-related cysteine peptidase ZAK 237133_at Hypothetical protein LOC339751 MDS1 237269_at Myelodysplasia syndrome 1 MAPK10 237413_at Mitogen-activated protein kinase 10 ZAK 237548_at Hypothetical protein LOC339751 CACNB2 237698_at Calcium channel, voltage-dependent, beta 2 subunit PLA2G6 237726_at Phospholipase A2, group VI (cytosolic, calcium-independent) MAP2K2 237878_at Mitogen-activated protein kinase kinase 2 EGFR 237938_at Epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) TPM3 238079_at Tropomyosin 3 RASA1 238243_at RAS p21 protein activator (GTPase activating protein) 1 MDS1 238370_x_at Myelodysplasia syndrome 1 MDS1 238375_at Myelodysplasia syndrome 1 DUSP8 238594_x_at Dual specificity phosphatase 8 ZAK 238613_at sterile alpha motif and leucine zipper containing kinase AZK NLK 238624_at Nemo-like kinase MAP4K4 238769_at Mitogen-activated protein kinase kinase kinase kinase 4 SOS2 238830_at Son of sevenless homolog 2 (Drosophila) RASA1 239301_at RAS p21 protein activator (GTPase activating protein) 1 BDNF 239367_at brain-derived neurotrophic factor TFG 239385_at TRK-fused gene TGFBR1 239605_x_at Transforming growth factor, beta receptor I (activin A receptor type II-like kinase) NFKB1 239876_at Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) MEF2C 239938_x_at MADS box transcription enhancer factor 2, polypeptide C MEF2C 239966_at MADS box transcription enhancer factor 2, polypeptide C FGF12 240067_at Fibroblast growth factor 12 RAP1A 240215_at RAP1A, member of RAS oncogene family FGF2 240243_at Fibroblast growth factor 2 (basic) AKT3 240568_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) RASGRP4 240862_at RAS guanyl releasing protein 4 FGFR2 240913_at fibroblast growth factor receptor 2 (bacteria-expressed kinase) FGF12 241323_at Fibroblast growth factor 12 CASP4 241340_at Caspase 4, apoptosis-related cysteine peptidase RPS6KA3 241460_at Ribosomal protein S6 kinase, 90 kDa, polypeptide 3 MDS1 241628_at Myelodysplasia syndrome 1 MDS1 241635_at Myelodysplasia syndrome 1 FGFR1 241724_x_at Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) PPP3R1 241786_at Protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, alpha isoform) HSPA9B 241840_at Heat shock 70 kDa protein 9B (mortalin-2) TNFRSF1A 241944_x_at Tumor necrosis factor receptor superfamily, member 1A SOS1 242018_at Son of sevenless homolog 1 (Drosophila) RAF1 242425_at V-raf-1 murine leukemia viral oncogene homolog 1 MAP3K5 242461_at Mitogen-activated protein kinase kinase kinase 5 SOS1 242682_at Son of sevenless homolog 1 (Drosophila) AKT3 242876_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) AKT3 242879_x_at V-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) MAP3K1 243030_at Mitogen-activated protein kinase kinase kinase 1 CACNB4 243244_at Calcium channel, voltage-dependent, beta 4 subunit MKNK1 243256_at MAP kinase interacting serine/threonine kinase 1 EVI1 243277_x_at Ecotropic viral integration site 1 EGFR 243327_at Epidermal growth factor receptor (erythroblastic leukemia viral oncogene homolog) CACNA1D 243334_at Calcium channel, voltage-dependent, L type, alpha 1D subunit MAP3K7IP2 243557_at Mitogen-activated protein kinase kinase kinase 7 interacting protein 2 BRAF 243829_at v-raf murine sarcoma viral oncogene homolog B1 STK4 243981_at serine/threonine kinase 4 MYC 244089_at V-myc myelocytomatosis viral oncogene homolog (avian) MEF2C 244230_at MADS box transcription enhancer factor 2, polypeptide C PAK2 244268_x_at p21 (CDKN1A)-activated kinase 2 MAP2K5 244298_at Mitogen-activated protein kinase kinase 5 RAF1 244373_at V-raf-1 murine leukemia viral oncogene homolog 1 RUNX1T1 244420_at Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) BDNF 244503_at Brain-derived neurotrophic factor opposite strand TFG 244614_at TRK-fused gene PPP3R2 244782_at protein phosphatase 3 (formerly 2B), regulatory subunit B, 19 kDa, beta isoform MAP4K4 244846_at Mitogen-activated protein kinase kinase kinase kinase 4 PPP3CC 32540_at Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform PPP3CC 32541_at protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform CASP2 34449_at caspase 2, apoptosis-related cysteine peptidase (neural precursor cell expressed) CACNB3 34726_at calcium channel, voltage-dependent, beta 3 subunit MAPK7 35617_at mitogen-activated protein kinase 7 IKBKG 36004_at inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma IL1B 39402_at interleukin 1, beta CACNG4 62987_r_at calcium channel, voltage-dependent, gamma subunit 4
TABLE-US-00007 TABLE 7 Pathway 7: Cell adhesion molecules Gene Gene Symbol Probe Set ID Title ITGAL 1554240_a_at integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) CD80 1554519_at CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) HLA-DOB 1554984_a_at major histocompatibility complex, class II, DO beta ITGB2 1555349_a_at integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) CD80 1555689_at CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) ALCAM 1563958_at Activated leukocyte cell adhesion molecule ALCAM 1569362_at Activated leukocyte cell adhesion molecule HLA-E 200904_at major histocompatibility complex, class I, E HLA-E 200905_x_at major histocompatibility complex, class I, E HLA-DPB1 201137_s_at major histocompatibility complex, class II, DP beta 1 ALCAM 201951_at activated leukocyte cell adhesion molecule ALCAM 201952_at activated leukocyte cell adhesion molecule ICAM1 202637_s_at intercellular adhesion molecule 1 (CD54), human rhinovirus receptor ICAM1 202638_s_at intercellular adhesion molecule 1 (CD54), human rhinovirus receptor ITGB2 202803_s_at integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) HLA-DQA1 203290_at major histocompatibility complex, class II, DQ alpha 1 /// major histocompatibility complex, class II, DQ alpha 1 HLA-DMB 203932_at major histocompatibility complex, class II, DM beta /// major histocompatibility complex, class II, DM beta CD22 /// 204581_at CD22 antigen /// myelin associated glycoprotein MAG HLA-DRB1 204670_x_at major histocompatibility complex, class II, DR beta 1 ICAM2 204683_at intercellular adhesion molecule 2 HLA-F 204806_x_at major histocompatibility complex, class I, F ICAM3 204949_at intercellular adhesion molecule 3 CD40 205153_s_at CD40 antigen (TNF receptor superfamily member 5) CD58 205173_x_at CD58 antigen, (lymphocyte function-associated antigen 3) HLA-DOB 205671_s_at major histocompatibility complex, class II, DO beta CD86 205685_at CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) CD86 205686_s_at CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) HLA-DOA 206313_at major histocompatibility complex, class II, DO alpha CD80 207176_s_at CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) HLA-DRB5 208306_x_at Major histocompatibility complex, class II, DR beta 3 HLA-B 208729_x_at major histocompatibility complex, class I, B HLA-C 208812_x_at major histocompatibility complex, class I, C HLA-DRA 208894_at major histocompatibility complex, class II, DR alpha /// major histocompatibility complex, class II, DR alpha HLA-B 209140_x_at major histocompatibility complex, class I, B HLA-DRB1 209312_x_at major histocompatibility complex, class II, DR beta 1 /// major histocompatibility complex, class II, DR beta 1 HLA-DQB1 209480_at Major histocompatibility complex, class II, DQ beta 1 /// Major histocompatibility complex, class II, DQ beta 1 HLA-DRB4 209728_at major histocompatibility complex, class II, DR beta 4 /// major histocompatibility complex, class II, DR beta 4 HLA-DQB1 209823_x_at major histocompatibility complex, class II, DQ beta 1 HLA-G 210514_x_at HLA-G histocompatibility antigen, class I, G HLA-DQB1 210747_at major histocompatibility complex, class II, DQ beta 1 CD86 210895_s_at CD86 antigen (CD28 antigen ligand 2, B7-2 antigen) HLA-DRA 210982_s_at major histocompatibility complex, class II, DR alpha HLA-DOA 211142_x_at major histocompatibility complex, class II, DO alpha ICOSLG 211197_s_at inducible T-cell co-stimulator ligand ICOSLG 211198_s_at inducible T-cell co-stimulator ligand ICOSLG 211199_s_at inducible T-cell co-stimulator ligand HLA-G 211528_x_at HLA-G histocompatibility antigen, class I, G HLA-G 211529_x_at HLA-G histocompatibility antigen, class I, G HLA-G 211530_x_at HLA-G histocompatibility antigen, class I, G HLA-DQB1 211654_x_at major histocompatibility complex, class II, DQ beta 1 /// major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 211656_x_at major histocompatibility complex, class II, DQ beta 1 /// major histocompatibility complex, class II, DQ beta 1 CD58 211744_s_at CD58 antigen, (lymphocyte function-associated antigen 3) /// CD58 antigen, (lymphocyte function-associated antigen 3) HLA-C 211799_x_at major histocompatibility complex, class I, C HLA-B 211911_x_at major histocompatibility complex, class I, B /// major histocompatibility complex, class I, B HLA-DPA1 211990_at major histocompatibility complex, class II, DP alpha 1 HLA-DPA1 211991_s_at major histocompatibility complex, class II, DP alpha 1 HLA-DQA1 212671_s_at major histocompatibility complex, class II, DQ alpha 1 /// HLA- /// major histocompatibility complex, class II, DQ alpha 2 DQA2 HLA-DQB1 212998_x_at major histocompatibility complex, class II, DQ beta 1 /// major histocompatibility complex, class II, DQ beta 1 HLA-DQB1 212999_x_at Major histocompatibility complex, class II, DQ beta 1 /// Major histocompatibility complex, class II, DQ beta 1 ICOSLG 213450_s_at inducible T-cell co-stimulator ligand ITGAL 213475_s_at integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) HLA-DPA1 213537_at major histocompatibility complex, class II, DP alpha 1 ICAM2 213620_s_at intercellular adhesion molecule 2 HLA-DQA1 213831_at major histocompatibility complex, class II, DQ alpha 1 HLA-A 213932_x_at Major histocompatibility complex, class I, A HLA-C 214459_x_at major histocompatibility complex, class I, C HLA-DRB1 215193_x_at major histocompatibility complex, class II, DR beta 1 HLA-A 215313_x_at major histocompatibility complex, class I, A CD40 215346_at CD40 antigen (TNF receptor superfamily member 5) ICAM1 215485_s_at intercellular adhesion molecule 1 (CD54), human rhinovirus receptor HLA-DQB2 215536_at major histocompatibility complex, class II, DQ beta 2 HLA-DRB4 215666_at major histocompatibility complex, class II, DR beta 4 HLA-DRB4 215669_at major histocompatibility complex, class II, DR beta 4 CD58 216322_at CD58 antigen, (lymphocyte function-associated antigen 3) HLA-C 216526_x_at major histocompatibility complex, class I, C CD58 216942_s_at CD58 antigen, (lymphocyte function-associated antigen 3) HLA-DOA 216946_at major histocompatibility complex, class II, DO alpha HLA-DOA 217001_x_at major histocompatibility complex, class II, DO alpha CD22 /// 217422_s_at CD22 antigen /// myelin associated glycoprotein MAG HLA-G /// 217436_x_at HLA-G histocompatibility antigen, class I, G HLA-H /// major histocompatibility complex, class I, H (pseudogene) HLA-E 217456_x_at major histocompatibility complex, class I, E HLA-DMA 217478_s_at major histocompatibility complex, class II, DM alpha SN 219519_s_at Sialoadhesin /// Sialoadhesin PDCD1LG2 220049_s_at programmed cell death 1 ligand 2 HLA-DRB1 221491_x_at major histocompatibility complex, class II, DR beta 1 /// major histocompatibility complex, class II, DR beta 1 HLA-F 221875_x_at major histocompatibility complex, class I, F HLA-F 221978_at major histocompatibility complex, class I, F CD58 222061_at CD58 antigen, (lymphocyte function-associated antigen 3) CD40 222292_at CD40 antigen (TNF receptor superfamily member 5) CD274 223834_at CD274 antigen PDCD1LG2 224399_at programmed cell death 1 ligand 2 /// programmed cell death 1 ligand 2 HLA-DOA 226878_at major histocompatibility complex, class II, DO alpha PDCD1LG1 227458_at CD274 antigen ICOSLG 228976_at inducible T-cell co-stimulator ligand ICAM3 229859_at Intercellular adhesion molecule 3 CD58 234128_at CD58 antigen, (lymphocyte function-associated antigen 3) HLA-DQA1 236203_at Major histocompatibility complex, class II, DQ alpha 1 ICAM3 236567_at Intercellular adhesion molecule 3 ITGB2 236988_x_at integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) HLA-DRB1 238900_at major histocompatibility complex, class II, DR beta 1 /// HLA- /// major histocompatibility complex, class II, DR beta 3 DRB3 ALCAM 240655_at Activated leukocyte cell adhesion molecule CD58 243931_at CD58 antigen, (lymphocyte function-associated antigen 3) CD40 35150_at CD40 antigen (TNF receptor superfamily member 5) SN 44673_at Sialoadhesin
TABLE-US-00008 TABLE 8 Probe set identification of 100 randomly selected gene probe sets Probe Set ID Gene Symbol Gene Title 1570227_at -- CDNA clone IMAGE: 4857625, with apparent retained intron 1570330_at -- Homo sapiens, clone IMAGE: 4151631, mRNA 201148_s_at TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory) 201159_s_at NMT1 N-myristoyltransferase 1 201280_s_at DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 202495_at TBCC tubulin folding cofactor C 202905_x_at NBN nibrin 203249_at EZH1 enhancer of zeste homolog 1 (Drosophila) 205300_s_at U1SNRNPBP U11/U12 snRNP 35K 205440_s_at NPY1R neuropeptide Y receptor Y1 205515_at PRSS12 protease, serine, 12 (neurotrypsin, motopsin) 205529_s_at RUNX1T1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related) 205533_s_at CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 205626_s_at CALB1 calbindin 1, 28 kDa 205651_x_at RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 205709_s_at CDS1 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 205729_at OSMR oncostatin M receptor 205760_s_at OGG1 8-oxoguanine DNA glycosylase 205789_at CD1D CD1d molecule 206114_at EPHA4 EPH receptor A4 206855_s_at HYAL2 hyaluronoglucosaminidase 2 206929_s_at NFIC nuclear factor I/C (CCAAT-binding transcription factor) 207087_x_at ANK1 ankyrin 1, erythrocytic 207270_x_at CD300C CD300c molecule 207319_s_at CDC2L5 cell division cycle 2-like 5 (cholinesterase-related cell division controller) 207428_x_at CDC2L1 /// LOC728642 cell division cycle 2-like 1 (PITSLRE proteins) proteins) 207618_s_at BCS1L BCS1-like (yeast) 207856_s_at FLJ41352 /// SMPD4 sphingomyelin phosphodiesterase 4, neutral membrane 209117_at WBP2 WW domain binding protein 2 209375_at XPC xeroderma pigmentosum, complementation group C 210061_at ZNF589 zinc finger protein 589 210063_at SARDH sarcosine dehydrogenase 210124_x_at SEMA4F sema domain, immunoglobulin domain (Ig),) 210157_at C19orf2 chromosome 19 open reading frame 2 210200_at WWP2 WW domain containing E3 ubiquitin protein ligase 2 210220_at FZD2 frizzled homolog 2 (Drosophila) 210234_at GRM4 glutamate receptor, metabotropic 4 210417_s_at PIK4CB phosphatidylinositol 4-kinase, catalytic, beta polypeptide 210616_s_at SEC31A SEC31 homolog A (S. cerevisiae) 214400_at INSL3 insulin-like 3 (Leydig cell) 214475_x_at CAPN3 calpain 3, (p94) 214570_x_at DKFZp434K191 /// POM121 membrane glycoprotein-like 1 (rat) DKFZP434P211 /// /// POM121-like protein LOC646074 /// LOC651452 /// LOC727983 /// LOC728418 /// LOC728451 /// 214674_at USP19 ubiquitin specific peptidase 19 219350_s_at DIABLO diablo homolog (Drosophila) 221007_s_at FIP1L1 FIP1 like 1 (S. cerevisiae) 221515_s_at LCMT1 leucine carboxyl methyltransferase 1 221522_at ANKRD27 ankyrin repeat domain 27 (VPS9 domain) 221808_at RAB9A RAB9A, member RAS oncogene family 221871_s_at TFG TRK-fused gene 221887_s_at DFNB31 deafness, autosomal recessive 31 221941_at PAOX polyamine oxidase (exo-N4-amino) 221945_at FBXO41 F-box protein 41 222042_x_at RKHD1 Ring finger and KH domain containing 1 222108_at AMIGO2 adhesion molecule with Ig-like domain 2 222727_s_at SLC24A6 solute carrier family 24 LOC727866 /// (sodium/potassium/calcium exchanger), member 6 223203_at TMEM29 transmembrane protein 29 /// similar to transmembrane protein 29 224898_at WDR26 WD repeat domain 26 225716_at -- Full-length cDNA clone CS0DK008YI09 of HeLa cells Cot 25- normalized of Homo sapiens (human) 225852_at ANKRD17 ankyrin repeat domain 17 230576_at BLOC1S3 Biogenesis of lysosome-related organelles complex-1, subunit 3 230629_s_at EP400 E1A binding protein p400 230632_at -- Full-length cDNA clone CS0DI051YA02 of Placenta Cot 25- normalized of Homo sapiens (human) 230640_at -- Transcribed locus 230651_at -- Transcribed locus 232096_x_at -- CDNA: FLJ22140 fis, clone HEP20977 232433_at KIAA1683 KIAA1683 232522_at -- CDNA: FLJ21484 fis, clone COL05256 232649_at GLDN gliomedin 232841_at -- CDNA: FLJ23097 fis, clone LNG07418 233236_at TSPAN16 tetraspanin 16 233266_at -- CDNA FLJ13844 fis, clone THYRO1000805 240117_at FBN3 fibrillin 3 240224_at -- Transcribed locus 240277_at SLC30A7 Solute carrier family 30 (zinc transporter), member 7 240280_at UFSP1 inactive Ufm1-specific protease 1 240452_at GSPT1 G1 to S phase transition 1 240617_at -- -- 240630_at -- Transcribed locus 240780_at -- -- 241485_at MYT1L myelin transcription factor 1-like 241532_at -- Transcribed locus 241566_at -- -- 241643_at TLK1 Tousled-like kinase 1 241674_s_at -- Transcribed locus 241677_x_at -- -- 241708_at DOCK1 dedicator of cytokinesis 1 241737_x_at -- Transcribed locus 241760_x_at -- -- 241861_at SYCP3 Synaptonemal complex protein 3 241864_x_at -- Transcribed locus, moderately similar to XP_517655.1 similar to KIAA0825 protein [Pan troglodytes] 241873_at -- Homo sapiens, clone IMAGE: 5209126, mRNA 241874_at LOC492311 similar to bovine IgA regulatory protein 241887_at -- CDNA FLJ41537 fis, clone BRTHA2017985 241919_x_at WDR31 WD repeat domain 31 244659_at TRIP12 Thyroid hormone receptor interactor 12 244740_at MGC9913 Hypothetical protein MGC9913 244862_at -- -- 31637_s_at NR1D1 /// THRA thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian) /// nuclear receptor subfamily 1, group D, member 1 37005_at NBL1 neuroblastoma, suppression of tumorigenicity 1 48808_at DHFR dihydrofolate reductase
Statistical Analysis
[0039]Each pre-specified pathway was assessed in the following manner: A partial least squares (PLS) regression algorithm was used to reduce the data (20, 21, 22). This supervised learning algorithm reduces the independent variables (gene probe sets) to PLS components that are mutually uncorrelated and associated with the binary dependent study variable (restenosis vs. no restenosis). The components of the PLS analysis became the independent variables for logistic regression (SAS, Cary, N.C.). The receiver operating characteristic (ROC) was used to evaluate the predictive accuracy (discrimination) of the logistic regression model. In addition, the misclassification rate (MR), defined as false positives +false negatives/all was also determined. The Wilcoxon test was also used to test for differences in Pathway expression between the patients who restenosed and those that did not, with significance set at the 0.05 level (one-sided) (SAS, Cary, N.C.).
Results
[0040]The demographic characteristics and clinical laboratory data of patients with and without restenosis were similar as shown in Tables 9 and 10. Of note, there was no significant difference in hsCRP (high sensitivity C-reactive protein) in patients who developed restenosis compared to those without restenosis.
TABLE-US-00009 TABLE 9 Clinical Variables Variable No Restenosis Group Restenosis Group Age (yrs) 61 ± 2.0 64 ± 2.3 Gender (M)(%) 82 74 Hx of Hypertension (%) 68 57 Hx of ↑ Lipids (%) 55 67 Hx of Smoking (%) 74 67 Hx of Stable Angina (%) 16 10 Hx Unstable Angina (%) 63 76
TABLE-US-00010 TABLE 10 Laboratory Values Variable No Restenosis Group Restenosis Group Hematocrit (%) 42.6 ± 0.6 43 ± 0.6 Platelets (#/ml × 1000) 226 ± 15 232 ± 14 WBC (#/ml × 1000) 7.5 ± 0.4 7.9 ± 0.4 Neutrophils (%) 63.7 ± 1.6 64.3 ± 2.0 Lymphocytes (%) 26.3 ± 1.3 27 ± 1.9 Monocytes (%) 6.8 ± 0.4 6.0 ± 0.5 Eosinophils (%) 2.6 ± 0.3 2.2 ± 0.3 hsCRP (mg %) 2.2 ± 0.3 2.2 ± 0.3 Numbers represent Values ± SEM.
[0041]The angiographic characteristics of coronary lesions in each group prior to stent placement, immediately following stent placement and at 6 month follow-up angiography are shown in Table 11.
TABLE-US-00011 TABLE 11 Angiographic Data Vessel Stented No Restenosis Group Restenosis Group Left ant. descending (%) 58 44 Left circumflex (%) 21 21 Right coronary (%) 21 35 **Vessel Diameter (mm) 3.0 ± 0.1 2.7 ± 0.1 Stent Diameter (mm) 3.0 ± 0.1 3.0 ± 0.1 Lesion Length (mm) 11.5 ± 0.8 13 ± 1.2 Stent Length (mm) 19 ± 0.9 19 ± 1.0 Post stent MLD (mm) 2.7 ± 0.1 2.5 ± 0.1 Acute Gain (mm) 1.8 ± 0.1 1.7 ± 0.1 Late Loss (mm) 0.8 ± 0.1 1.7 ± 0.1 Numbers represent values ± SEM; **p ≦ 0.05; MLD = minimum luminal diameter of stented vessel segment; Acute Gain = immediate post stent MLD minus pre stent MLD; Late Loss = Post stent MLD minus 6 month follow-up MLD.
[0042]Coronary lesions in this study were relatively discrete with lesion length being <20 mm in the majority of instances. Stent length was <23 mm in most instances. There was a significant difference in the reference diameter of the vessel chosen for intervention between those patients with and without restenosis (Table 11). Patients with restenosis had, on average, vessel sizes 0.3 mm smaller than those patients without restenosis. There was no difference in the frequency of the particular vessel stented, lesion length, stent length, or minimum lesion diameter post stenting between patients with and without restenosis. Acute gain was similar in each group immediately post stent placement. Late loss was significantly greater in patients with restenosis vs those without restenosis. The binary rate of restenosis 6 months following stent placement was 41%.
[0043]Patients with documented angiographic restenosis within six months after receiving a bare metal stent exhibited, on average, a greater extent of mRNA expression at study enrollment compared to those patients without restenosis (Table 12A). FIG. 2, demonstrates that this phenomena is a result of an apparent increase in mRNA expression in the great majority of probe sets/genes examined. All pre-specified molecular pathways and functional molecular families were significantly over expressed (activated) in those patients with restenosis compared to those patients without restenosis. These data are shown in Table 12C. Of note, a sample of 100 probe sets (Table 12B) selected in a non-systematic manner also demonstrated increased mRNA expression at the time of enrollment in those patients with subsequent restenosis compared to those without restenosis.
TABLE-US-00012 TABLE 12A 54,675 probe sets. Analysis Cases +RS Controls -RS set Number of probe sets Mean (SD) Mean (SD) All probes 54,675 200 (68) 166 (75)
TABLE-US-00013 TABLE 12B Set of 100 probe sets selected in a non-systematic manner from a set of probes corresponding to a set of named genes. Analysis Number of PLS PLS- Cases +RS Controls -RS set probe sets ROC MCR Mean (SD) Mean (SD) Pathway 100 .893 .17 115 (47) 92 (47) 100
TABLE-US-00014 TABLE 12C Pre-specified Pathways Number Cases Controls of probe PLS +RS -RS Analysis set sets ROC PLS-MCR Mean (SD) Mean (SD) Pathway 1 135 .893 .17 360 (113) 295 (136) Pathway 2 112 .952 .07 865 (284) 720 (304) Pathway 3 206 .760 .30 233 (76) 195 (83) Pathway 4 204 .942 .07 1937 (560) 1641 (642) Pathway 5 258 .857 .15 353 (116) 289 (134) Pathway 6 821 .942 .09 357 (112) 297 (122) Pathway 7 105 .956 .04 2460 (742) 2081 (816) +RS = Restenosis group; -RS = No restenosis group. PLS ROC = Partial Least Square Receiver Operating Characteristic; PLS-MCR = Partial Least Square Misclassification Rate.
Discussion
[0044]In order to carry out the studies described herein, several molecular pathways were pre-specified and tested for their ability to be predictive of bare metal stent restenosis. The results showed that each of these pathways was significantly activated in patients who experienced restenosis compared to those who did not. Thus, activation of any one of these pathways was an independent and highly accurate predictor or molecular signature of coronary restenosis following placement of a bare metal stent. The data presented herein also imply that a more generalized phenomenon, i.e., a pre-existing generalized genome activation within the mRNA-containing compartment of circulating whole blood appears to be a characteristic associated with those patients who experience restenosis following placement of a coronary artery stent. This interpretation is supported by the finding that a group of 100 genes selected in a non-systematic manner were also highly predictive of restenosis. This finding suggests that restenosis is a complex process involving multiple molecular mechanisms and is associated with either a pre-existing, general transcriptional activation of the genome and/or decreased degradation of the mRNA in the mRNA containing compartment of circulating whole blood. This is consistent with a large number of reports, each of which has identified a diverse assortment of genes up-regulated in response to coronary angioplasty and purported to be related to the restenosis process.
[0045]The following conclusions may be drawn from the experimental results presented herein: [0046]I. Non-restenosis following coronary artery stenting with a bare metal stent is a highly predictable event. [0047]II. Expression profiling using mRNA derived from the mRNA containing compartment of circulating whole blood may be used to identify patients who, with a high degree of certainty, will not experience restenosis within 6 months following coronary stenting with bare metal stents. [0048]III. Increased transcription or decreased inactivation/degradation of the mRNA representative of molecular pathways responsible for multiple cellular functions, including but not limited to, T cell function, wound healing, cellular proliferation and migration, identify patients at high risk for restenosis who may benefit from the use of drug eluting stents to reduce their probability of restenosis. [0049]IV. Subjects who do not exhibit activation of the molecular pathways described herein have a high likelihood of non-restenosis and would not be expected to derive any benefit from drug eluting stents. [0050]V. Activated specific molecular pathways appear to be singular instances of a more generalized phenomena of transcriptional activation of a significant proportion of the whole genome of cells derived from whole blood, which itself is predictive of restenosis. [0051]VI. Application of these expression profiling algorithms correctly predicted non-restenosis in 75-80% of cases that did not restenose and would be expected to significantly reduce the use of drug eluting stents and their potential excess morbidity, mortality and cost.
[0052]In summary, these results demonstrate that non-restenosis (or alternatively, the risk of restenosis) following coronary angioplasty with a bare metal stent can be accurately predicted using mRNA expression profiling of samples derived from whole blood. Further, biological pathway activation predicts which patients will restenose after placement of a bare metal stent. Finally, generalized transcriptional activation and/or decreased degradation of the products of the transcriptional process play a role in restenosis. These findings can be employed in the development of methods to predict which patients will not restenose and can therefore be offered a bare metal stent with a low risk for subsequent restenosis. Conversely, patients with a high risk of restenosis can be identified and offered a stent that includes anti-restenosis agents.
Example 2
Methods for Predicting a Patient's Propensity for Restenosis
[0053]Based on the data in Tables 12A, 12B and 12C above, the patient may be predicted to be a good candidate for a bare metal stent (one not likely to have restenosis within six months) according to the following three exemplary methods:
[0054]a) In a first embodiment, the invention provides a method for predicting a patient's propensity for bare metal stent restenosis, comprising the steps of: ai) obtaining a whole blood sample from a patient deemed to be in need of a stent; aii) measuring total mRNA from a volume of blood obtained from said blood sample using a gene probe substrate having at least a plurality of gene probes that hybridize to at least a plurality of mRNA sequences; aiii) computing an average mRNA value for said predetermined volume of blood from said total mRNA and said plurality of genes; aiv) classifying said patient as having a prognosis selected from a group consisting of a first prognosis and a second prognosis on the basis of a mRNA expression profile comprising the nucleic acid levels of expression of all genes and expressed sequence tags expressed on the Affymetrix U133+2 GeneChip®; av) determining the similarity between said patients profile and first prognosis profile comprising the average nucleic acid expression of the genes and expressed sequence tags expressed on the Affymetrix U133+2 GeneChip® and; avi) determining the similarity of said patient expression profile and second prognosis profile comprising the average nucleic acid levels of expression of all genes and expressed sequence tags expressed on the Affymetrix U133+2 GeneChip® and; avii) classifying said patient as having first prognosis if said patient average mRNA expression of all genes and expressed sequence tags present on the Affymetrix U133+2 GeneChip® is closer to the average mRNA expression of the first prognosis profile compared to the second prognosis profile and; aviii) classifying said patient as having second prognosis if said patient average mRNA expression of all genes and expressed sequence tags present on the Affymetrix U133+2 GeneChip® is closer to the average mRNA expression of the second prognosis profile as compared to the first prognosis profile.
[0055]b) The invention in another embodiment provides a method of predicting a patient's propensity for bare metal stent restenosis, comprising: (bi) from the patient who is deemed to need a coronary artery stent, taking a blood sample; (bii) from the sample, measuring the amount of mRNA present using a gene probe substrate having at least a plurality of gene probes that hybridize to at least a plurality of mRNA sequences corresponding to those genes and probe sets comprising as described herein each of the seven genomic pathways and one set of 100 non-systematically chosen genes listed in Tables 12B and 12C; biii) classifying said patient as having a prognosis selected from a group consisting of a first prognosis and a second prognosis on the basis of a mRNA expression profile comprising the nucleic acid levels of expression of any or all of the seven genomic pathways and one set of 100 non-systematically chosen genes listed in Tables 12B and 12C by a method comprising one of the following; biv) determining the similarity between said patients expression profile and first prognosis profile comprising the average nucleic acid levels of expression of the genes comprising any or all of the seven genomic pathways and set of 100 non-systematically chosen genes listed in Tables 12B and 12C and; bv) determining the similarity between said patients expression profile and second prognosis profile comprising the average nucleic acid levels of expression of the genes comprising any or all of the seven genomic pathways and set of 100 non-systematically chosen genes listed in Table 12B and 12C and; bvi) classifying said patient as having first prognosis if said patient average mRNA expression of genes present in any or all of seven genomic pathways and set of 100 non-systematically chosen genes listed in Tables 12B and 12C is closer to the average mRNA expression of the first prognosis profile compared to the second prognosis profile and; bvii) classifying said patient as having second prognosis if said patient average mRNA expression of genes present in any or all of seven genomic pathways and set of 100 non-systematically chosen genes listed in Tables 12B and 12C is closer to the average mRNA expression of the second prognosis profile as compared to the first prognosis profile.
[0056]c) The invention, in another embodiment, provides a method for predicting a patient's propensity for bare metal stent restenosis, comprising the steps of: ci) obtaining whole blood sample from a patient deemed to be in need of a coronary artery stent; cii) from the sample, measure the amount of mRNA present using a gene probe substrate having at least a plurality of genes that hybridize to at least a plurality of mRNA sequences comprising the seven genomic pathways and set of 100 non-systematically chosen genes listed in Tables 12B and 12C; ciii) classifying said patient as having a prognosis selected from a group consisting of a first prognosis and a second prognosis on the basis of nucleic acid levels of expression of any or all of the seven genomic pathways or 100 non-systematically chosen genes listed in Tables 12B and 12C by a method comprising one of the following; civ) determining the similarity between said patients expression profile and first prognosis profile as embodied in the probability output of a trained Partial Least Squares component based regression model derived from any or all of the seven genomic pathways or 100 non-systematically chosen genes listed in Tables 12B or 12C and; cv) determining the similarity between said patients mRNA expression profile and a second prognosis profile as embodied in the probability output of a Partial Least Squares component based regression model derived from any or all of the seven genomic pathways or 100 non-systematically chosen genes listed in Tables 12B and 12C and; cvi) classifying said patient as having first prognosis if said patients Partial Least Squares component based regression model probability output is ≦50% and; cvii) classifying said patient as having second prognosis if said patients Partial Least Squares component based regression model probability output is >50%.
II. Detailed Algorthims Based on Methodologies Set Forth in I Above Include the Following
[0057]a) The method of 1a, wherein said patient average mRNA expression profile comprises the average of log transformed, background corrected, variance normalized, summarized intensity profiles of all probe sets present on the Affymetrix U133+2 Gene Chip® [0058]b). The method in 1avii, wherein first prognosis comprises the average mRNA expression profile of log transformed, background corrected, variance normalized, summarized probe set intensity profiles of all probe sets (n=54,675) present on the Affymetrix U133+2 GeneChip® referred to as Controls (non-restenosis) in Table 12A. [0059]c) The method in 1avii, wherein the first prognosis value is 166. [0060]d) The method in 1aviii, wherein second prognosis comprises average mRNA expression profile of log transformed, background corrected, variance normalized, summarized probe set intensity profiles of all probe sets (n=54,675) present on the Affymetrix U133+2 GeneChip® referred to as Cases (restenosis) in Table 12A. [0061]e) The method in 1aviii, wherein the second prognosis value is 200. [0062]f) The method of 1b, wherein said patient average mRNA expression profile comprises the average of log transformed, background corrected, variance normalized, summarized intensity profiles of all probe sets present on the Affymetrix U133+2 Gene Chip® which correspond to all of the probe sets or genes listed in each or any of the seven genomic pathways or 100 non-systematically chosen genes in Tables 12B and 12C. [0063]g) The method in 1bvii, wherein first prognosis comprises the average mRNA expression profile of log transformed, background corrected, variance normalized, summarized probe set intensity profiles of all probe sets present on the Affymetrix U133+2 GeneChip® which correspond to all of the probe sets or genes listed in each or any of the seven genomic pathways or 100 non-systematically chosen genes referred to as Controls (non-restenosis) in Tables 12B and 12C. [0064]h) The method in 1bvii, wherein the first prognosis value for each of the genomic pathways listed in Tables 12B and 12C are as follows: Pathway 100: 92; Pathway 1: 295; Pathway 2: 720; Pathway 3: 195; Pathway 4: 1641; Pathway 5: 289; Pathway 6: 297; Pathway 7: 2081. [0065]i) The method in 1bviii, wherein second prognosis comprises average mRNA expression profile of log transformed, background corrected, variance normalized, summarized probe set intensity profiles of all probe sets present on the Affymetrix U133+2 GeneChip® which correspond to all of the probe sets or genes listed in any or all of the seven genomic pathways or 100 non-systematically chosen genes referred to as Cases (restenosis) in Tables 12B and 12C. [0066]j) The method in 1bvii, wherein the second prognosis value for each of the genomic pathways listed in Tables 12B and 12C are as follows: Pathway 100: 115; Pathway 1: 360; Pathway 2: 865; Pathway 3: 233; Pathway 4: 1937; Pathway 5: 353; Pathway 6: 357; Pathway 7: 2460. [0067]k) The method of 1c, wherein said patient mRNA expression profile comprises log transformed, background corrected, variance normalized, summarized intensity profiles of all probe sets present on the Affymetrix U133+2 Gene Chip® which correspond to all of the probe sets or genes comprising each or any of the seven genomic pathways or 100 non-systematically chosen genes listed in Tables 12B and 12C. [0068]1) The method in 1cvii, wherein first prognosis (no restenosis) comprises the probability output of a trained Partial Least Squares component based regression model derived from all of the probe sets or gene intensity profiles from any or all of the seven genomic pathways or 100 random genes listed in Tables 12B and 12C where the probability output is ≦50% and where the regression model using Partial Least Squares derived components is formulated as follows for each pathway: Pathway 100: Probability=B1(X)+B2(Y) . . . ; Pathway 1: Probability=β1(X)+β2(Y) . . . ; Pathway 2: Probability=β1(X)+β2(Y) . . . ; Pathway 3: Probability=β1(X)+β2(Y) . . . ; Pathway 4: Probability=β1(X)+β2(Y) . . . ; Pathway 5: Probability=β1(X)+β2(Y) . . . ; Pathway 6: Probability=β1(X)+β2(Y) . . . ; Pathway 7: Probability=β1(X)+β2(Y) . . . ; [0069]m) The method in 1cvii, wherein second prognosis (restenosis) comprises the probability output of a trained Partial Least Squares component based regression model derived from all of the probe sets or gene intensity profiles from any or all of the genomic pathways listed in Tables 12B and 12C where the probability output is >50% and where the predictive regression model using Partial Least Squares derived components is formulated as follows for each pathway: Pathway 100: Probability=β1(X)+β2(Y) . . . ; Pathway 1: Probability=β1(X)+β2(Y) . . . ; Pathway 2: Probability=β1(X)+β2(Y) . . . ; Pathway 3: Probability=β1(X)+β2(Y) . . . ; Pathway 4: Probability=β1(X)+β2(Y) . . . ; Pathway 5: Probability=β1(X)+β2(Y) . . . ; Pathway 6: Probability=β1(X)+β2(Y) . . . ; Pathway 7: Probability=β1(X)+β2(Y) . . . ;While the invention has been described in terms of its preferred embodiments, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims.
REFERENCES
[0069] [0070]1. American Heart Association. 2002 Heart and Stroke Statistical Update. 2001 [0071]2. Safian R D. Zidar J, Hermiller et al. Manual of Interventional Cardiology. 3rd Edition, p511. Physicians Press, Royal Oak, Mich. 2110. [0072]3. Betriu A, Masotti M, Serra, A et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START). A four year follow-up. J Am Coll Cardiol. 1999; 34:1498-506. [0073]4. Morphologic predictors of restenosis after coronary stenting in humans. Circ. 2002; 105:2974-2980. [0074]5. Bauters C, Hubert C, Prat A et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol. 1998; 31:1291-1298. [0075]6. Kastrati A, Schgomig A, Elezi S et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997; 30:1428-1436. [0076]7. Morice M C, Serruys P W, Sousa J E et al. A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J. Med. 200; 346:1773-1780. [0077]8. Grube E, Silber S, Hauptman K E et al. TAXUS I: six and twelve month results from a randomized, double blind trial on a slow release paclitaxel-eluting stent for de novo coronary lesions. Circ. 2003; 107:38-42. [0078]9. Windecker S, Remondino A, Eberli F R et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Eng J Med 2005; 353:653-662. [0079]10. Serruys P W, de Jaegere P, Kiemeneji F et al. A comparison of balloon expandable stent implantation and balloon angioplasty in patients with coronary artery disease. The BENESTNR Study Group. N Eng J Med 1994; 34:1498-506. [0080]11. Pfisterer M, Brunner-LaRocca H P, Buser P T et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug eluting stents Vs bare metal stents. J Am Coll Cardiol 2006; 48(12):2584-2591. [0081]12. Walter D H, Schachinger V, Elsner M et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the PI(A2) allele of the platelet glycoprotein IIIa gene. Eur Heart J. 2001; 22:587-95. [0082]13. Banters C, Lamblin N, Amouyel P. Gene polymorphisms and outcome after coronary angioplasty. Curr Interven Cardiol Rep 2001; 22:587-95. [0083]14. Mamotte C D, van Bockxmeer F M, roger R. PIa1/a2 polymorphism of glycoprotein 111a and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998; 82:13-16. [0084]15. de Maat M P, Jukema J W, Ye S et al. Effect of stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83:852-856. [0085]16. Kastrati A, Werner K, Berger P et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000; 36:2168-73. [0086]17. Zohlnhofer D, Klein C A, Richter T et al. Gene expression profiling of human stent induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: detection of FK506-binding protein 12 upregulation. Circ. 2001; 103:1396-1402. [0087]18. Irizarry R A, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4(2);249-264. [0088]19. Kyoto Encyclopedia of Genes and Genomics. www.genomejp/KEGG. [0089]20. Boulesteix A l, Strimmer K. Partial Least Squares: A versatile tool for the ananlysis of high dimensional genomic data. Briefings in Bioinformatics 2007; 8(1):32-44. [0090]21. Hoang A. Optimal multi-class classification with principal components. Proc of International Conf on Data Mining 2206. Las Vegas, Nev. [0091]22. Rosipal R, Kramer N. Overview and Recent Advances in Partial Least Squares in C. Saunders et al (eds) "Subspace, latent structure and feature selection techniques, Lecture Note in Computer Science. Spring 2006: 34-51.
Sequence CWU
1
11741492DNAHomo sapiensmisc_feature(83)..(83)n is a, c, g, or t
1agaaggtcct taacacagtc gtgaacaaac acaaggacct gaagacacac gggttcacac
60tggagtcctg ccgtagcatg atngcgctca tggatacaga tggctctgga aagctcaacc
120tgcaggagtt ccaccacctc tggaacaaga ttaaggcctg gcagaaaatt ttcaaanact
180atgacacaga ccagtccggc accatcaaca gctacgagat gcgaaatgca gtcaacgacg
240caggattcca cctcaacaac cagctctatg acatcattac catngcggta cgcagacaaa
300cacatgaaca tcgactttga cagtttcatc tgctngcttc gttaggcntg gagggcatgt
360tcagagcttt tcatgcattt gacaaggnnn gagatggtat catcaagctc aacgttctgg
420agtggctgca gctcaccatg tatnnctgaa ccaggctggc ctcatccaaa gccatgcagg
480atcactcagg at
492225DNAArtificialsynthetic oligonucleotide primer 2agaaggtcct
taacacagtc gtgaa
25325DNAArtificialsynthetic oligonucleotide primer 3gacacacggg ttcacactgg
agtcc
25425DNAArtificialsynthetic oligonucleotide primer 4gatggctctg gaaagctcaa
cctgc
25525DNAArtificialsynthetic oligonucleotide primer 5aaagctcaac ctgcaggagt
tccac
25625DNAArtificialsynthetic oligonucleotide primer 6tgcagtcaac gacgcaggat
tccac
25725DNAArtificialsynthetic oligonucleotide primer 7acctcaacaa ccagctctat
gacat
25825DNAArtificialsynthetic oligonucleotide primer 8gaacatcgac tttgacagtt
tcatc
25925DNAArtificialsynthetic oligonucleotide primer 9ggagggcatg ttcagagctt
ttcat
251025DNAArtificialsynthetic oligonucleotide primer 10ggtatcatca
agctcaacgt tctgg
251125DNAArtificialsynthetic oligonucleotide primer 11caacgttctg
gagtggctgc agctc
251225DNAArtificialsynthetic oligonucleotide primer 12aaagccatgc
aggatcactc aggat 2513457DNAHomo
sapiens 13cacggccgtg gacatgtggt cagtgggttg catcttcggg gagctgctga
ctcagaagcc 60tctgttcccc gggaagtcag aaatcgatca gatcaacaag gtgttcaagg
atctggggac 120ccctagtgag aaaatctggc ccggctacag cgagctccca gcagtcaaga
agatgacctt 180cagcgagcac ccctacaaca acctccgcaa gcgcttcggg gctctgctct
cagaccaggg 240cttcgacctc atgaacaagt tcctgaccta cttccccggg aggaggatca
gcgctgagga 300cggcctcaag catgagtatt tccgcgagac ccccctcccc atcgacccct
ccatgttccc 360cacgtggccc gccaagagcg agcagcagcg tgtgaagcgg ggcaccagcc
cgaggccccc 420tgagggaggc ctgggctaca gccagctggg tgacgac
4571425DNAArtificialsynthetic oligonucleotide primer
14cacggccgtg gacatgtggt cagtg
251525DNAArtificialsynthetic oligonucleotide primer 15agctgctgac
tcagaagcct ctgtt
251625DNAArtificialsynthetic oligonucleotide primer 16gcctctgttc
cccgggaagt cagaa
251725DNAArtificialsynthetic oligonucleotide primer 17ggtgttcaag
gatctgggga cccct
251825DNAArtificialsynthetic oligonucleotide primer 18cgagctccca
gcagtcaaga agatg
251925DNAArtificialsynthetic oligonucleotide primer 19ggcttcgacc
tcatgaacaa gttcc
252025DNAArtificialsynthetic oligonucleotide primer 20tgacctactt
ccccgggagg aggat
252125DNAArtificialsynthetic oligonucleotide primer 21gaggatcagc
gctgaggacg gcctc
252225DNAArtificialsynthetic oligonucleotide primer 22caagcatgag
tatttccgcg agacc
252325DNAArtificialsynthetic oligonucleotide primer 23gagcagcagc
gtgtgaagcg gggca
252425DNAArtificialsynthetic oligonucleotide primer 24gggctacagc
cagctgggtg acgac 2525504DNAHomo
sapiens 25gcgtacagca acctcttggt caaacaggca tgccaccatc tttttcaaag
cccaatattg 60aaggtgcccc aggggctcct attggaaata ccttccagca tgtgcagtct
ttgccaacaa 120aaaaaattac caagaaacct attccagatg agcacctcat tctaaagacc
acatttgagg 180atcttattca gcgctgcctt tcttcagcaa cagaccctca aaccaagagg
aagctagatg 240atgccagcaa acgtttggag tttctgtatg ataaacttag ggaacagaca
ctttcaccaa 300caatcaccag tggtttacac aacattgcaa ggagcattga aactcgaaac
tactcagaag 360gattgaccat gcatacccac atagttagca ccagcaactt cagtgagacc
tctgctttca 420tgccagttct caaagttgtt ctcacccagg ccaataagct gggtgtctaa
aaggacagct 480tctcttccac tcaatattgc catt
5042625DNAArtificialsynthetic oligonucleotide primer
26gcgtacagca acctcttggt caaac
252725DNAArtificialsynthetic oligonucleotide primer 27tgaaggtgcc
ccaggggctc ctatt
252825DNAArtificialsynthetic oligonucleotide primer 28ttgaggatct
tattcagcgc tgcct
252925DNAArtificialsynthetic oligonucleotide primer 29gctgcctttc
ttcagcaaca gaccc
253025DNAArtificialsynthetic oligonucleotide primer 30aacagacact
ttcaccaaca atcac
253125DNAArtificialsynthetic oligonucleotide primer 31agaaggattg
accatgcata cccac
253225DNAArtificialsynthetic oligonucleotide primer 32catacccaca
tagttagcac cagca
253325DNAArtificialsynthetic oligonucleotide primer 33gcaccagcaa
cttcagtgag acctc
253425DNAArtificialsynthetic oligonucleotide primer 34ttcagtgaga
cctctgcttt catgc
253525DNAArtificialsynthetic oligonucleotide primer 35gccagttctc
aaagttgttc tcacc
253625DNAArtificialsynthetic oligonucleotide primer 36ttctcttcca
ctcaatattg ccatt 2537546DNAHomo
sapiens 37agtgccagga cctgtgtacc gggacacgtg ggagtcctcc cagcatgatg
cttgactgac 60ccgaggaagg tcctcatgtt tcgtgcctgt cattctcgga tggctgtgag
gcattccttg 120gcaagggacg ctgcgtacca gcggtcctca ccgcatctca catggctcct
gtgatgcatg 180ttgtcgcttt cccacccggg atctccatct ctcttccctt cctgctgtca
gtaagagatc 240acatgtctgt gtagtgtgaa tgccttgtcg ctgtcctgtg cttttgcacc
attgagttga 300ctgcctctga gaagcagcac taggcctgtt gaaatgcaat gtgctgccct
gagatccagt 360ttcaagaatg ggcaggtaaa cgcagtgtgg gaaaggaatg tggaatgaga
acttggtggt 420tcaccgctgt actatttgtg taaatgttta cgtatgtgat aagctacatg
tatgtaaatg 480ttgcaatacc cctaacagtc gagtagtagt ctcccttaca ggaatttttg
acggggttcc 540tcatca
5463825DNAArtificialsynthetic oligonucleotide primer
38agtgccagga cctgtgtacc gggac
253925DNAArtificialsynthetic oligonucleotide primer 39agtcctccca
gcatgatgct tgact
254025DNAArtificialsynthetic oligonucleotide primer 40tgcctgtcat
tctcggatgg ctgtg
254125DNAArtificialsynthetic oligonucleotide primer 41ggctgtgagg
cattccttgg caagg
254225DNAArtificialsynthetic oligonucleotide primer 42tggctcctgt
gatgcatgtt gtcgc
254325DNAArtificialsynthetic oligonucleotide primer 43gtagtgtgaa
tgccttgtcg ctgtc
254425DNAArtificialsynthetic oligonucleotide primer 44gcaccattga
gttgactgcc tctga
254525DNAArtificialsynthetic oligonucleotide primer 45gctgccctga
gatccagttt caaga
254625DNAArtificialsynthetic oligonucleotide primer 46gtggttcacc
gctgtactat ttgtg
254725DNAArtificialsynthetic oligonucleotide primer 47tcgagtagta
gtctccctta cagga
254825DNAArtificialsynthetic oligonucleotide primer 48gaatttttga
cggggttcct catca 2549568DNAHomo
sapiens 49ggacttggtc acaggttttt caaagggcta cgccttcatc gaatacaagg
aggagcgtgc 60cgtgatcaaa gcttaccgag atgctgatgg cctggttatt gaccagcatg
agatatttgt 120ggactacgag ctggaaagga ctctcaaagg gtggatccct cggcgacttg
gaggcggtct 180tgggggaaaa aaggagtctg ggcaactgag atttggggga cgggaccggc
cttttcgaaa 240acctattaac ttgccagttg ttaaaaacga cctctataga gagggaaaac
gggaaaggcg 300ggagcgatct cgatcccgag aaagacactg ggactcgagg acaagggatc
gagaccatga 360caggggccgg gagaagagat ggcaagaaag agagccgacc agggtgtggc
ccgacaatga 420ctgggagaga gagagggact tcagagatga caggatcaag gggagggaga
agaaggaaag 480aggcaagtag aggcccaaca gcagaacccc aaagtgaagt tacagtggaa
atgagtggag 540ggggattgtc tttcaacgca gcgtgagt
5685025DNAArtificialsynthetic oligonucleotide primer
50ggacttggtc acaggttttt caaag
255125DNAArtificialsynthetic oligonucleotide primer 51ttcaaagggc
tacgccttca tcgaa
255225DNAArtificialsynthetic oligonucleotide primer 52aaggaggagc
gtgccgtgat caaag
255325DNAArtificialsynthetic oligonucleotide primer 53gcttaccgag
atgctgatgg cctgg
255425DNAArtificialsynthetic oligonucleotide primer 54ctcaaagggt
ggatccctcg gcgac
255525DNAArtificialsynthetic oligonucleotide primer 55ggaaaggcgg
gagcgatctc gatcc
255625DNAArtificialsynthetic oligonucleotide primer 56agggatcgag
accatgacag gggcc
255725DNAArtificialsynthetic oligonucleotide primer 57aagagagccg
accagggtgt ggccc
255825DNAArtificialsynthetic oligonucleotide primer 58gggtgtggcc
cgacaatgac tggga
255925DNAArtificialsynthetic oligonucleotide primer 59aagtagaggc
ccaacagcag aaccc
256025DNAArtificialsynthetic oligonucleotide primer 60gattgtcttt
caacgcagcg tgagt 2561377DNAHomo
sapiens 61tggactgctc aatgccttgg atggtgtggc ttccaccgag gcccgcatcg
tgttcatgac 60caccaaccac gttgacaggc tggaccctgc cctgatacgc ccggggcgag
tggacctgaa 120ggagtacgtg ggctactgct cacactggca gctgacccag atgttccaga
ggttctatcc 180agggcaggca ccttccttag ctgagaactt tgcagaacat gtccttcgag
ctacaaacca 240gatcagtcct gcccaggtgc agggatactt catgctgtat aaaaatgacc
ctgtaggggc 300aattcacaat gctgagtctc tgaggaggtg atcaggctgg gctcagctca
gctctcctcc 360tctagctcaa taaacat
3776225DNAArtificialsynthetic oligonucleotide primer
62tggactgctc aatgccttgg atggt
256325DNAArtificialsynthetic oligonucleotide primer 63cttggatggt
gtggcttcca ccgag
256425DNAArtificialsynthetic oligonucleotide primer 64tcgtgttcat
gaccaccaac cacgt
256525DNAArtificialsynthetic oligonucleotide primer 65ccaaccacgt
tgacaggctg gaccc
256625DNAArtificialsynthetic oligonucleotide primer 66gccctgatac
gcccggggcg agtgg
256725DNAArtificialsynthetic oligonucleotide primer 67gaaggagtac
gtgggctact gctca
256825DNAArtificialsynthetic oligonucleotide primer 68ctggcagctg
acccagatgt tccag
256925DNAArtificialsynthetic oligonucleotide primer 69tgttccagag
gttctatcca gggca
257025DNAArtificialsynthetic oligonucleotide primer 70gcaccttcct
tagctgagaa ctttg
257125DNAArtificialsynthetic oligonucleotide primer 71gaacatgtcc
ttcgagctac aaacc
257225DNAArtificialsynthetic oligonucleotide primer 72tctcctcctc
tagctcaata aacat 2573513DNAHomo
sapiens 73catgactgtc tgtgcaccga gaagaggcgg caggtcctgc cctggccaat
caggcgagac 60gcctttgtga gctgtgagtg cctcctgtgg tctcaggctt gcgctggacc
tggttcttag 120cccttgggca ctgcaccctg tttaacattt caccccactc tgtacagctg
ctcttaccca 180ttttttttac ctcacaccca aagcattttg cctacctggg tcagagagag
gagtcctttt 240tgtcatgccc ttaagttcag caactgttta acctgttttc agtcttattt
acgtcgtcaa 300aaatgattta gtacttgttc cctctgttgg gatgccagtt gtggcagggg
gaggggaacc 360tgtccagttt gtacgatttc tttgtatgta tttctgatgt gttctctgat
ctgcccccac 420tgtcctgtga ggacagctga ggccaaggag tgaaaaacct attactacta
agagaagggg 480tgcagagtgt ttacctggtg ctctcaacag gac
5137425DNAArtificialsynthetic oligonucleotide primer
74catgactgtc tgtgcaccga gaaga
257525DNAArtificialsynthetic oligonucleotide primer 75tgccctggcc
aatcaggcga gacgc
257625DNAArtificialsynthetic oligonucleotide primer 76cgagacgcct
ttgtgagctg tgagt
257725DNAArtificialsynthetic oligonucleotide primer 77ctgcaccctg
tttaacattt caccc
257825DNAArtificialsynthetic oligonucleotide primer 78acctcacacc
caaagcattt tgcct
257925DNAArtificialsynthetic oligonucleotide primer 79gcattttgcc
tacctgggtc agaga
258025DNAArtificialsynthetic oligonucleotide primer 80tcctttttgt
catgccctta agttc
258125DNAArtificialsynthetic oligonucleotide primer 81gttttcagtc
ttatttacgt cgtca
258225DNAArtificialsynthetic oligonucleotide primer 82gtacttgttc
cctctgttgg gatgc
258325DNAArtificialsynthetic oligonucleotide primer 83tttctgatgt
gttctctgat ctgcc
258425DNAArtificialsynthetic oligonucleotide primer 84gtttacctgg
tgctctcaac aggac 2585429DNAHomo
sapiens 85ccagctgttc caagactggg ccgtagaatt ccatgtttca ggagcctaag
accctcccag 60agcccagggg cttcaccgca gaccccaagc cattgagcac atcacccaaa
gcagtggcca 120acatcgcgga cccctgtgcc ttgtcacaga tgggtgctgg tcctcaggcg
ttggggacac 180tgctgggtcg atggggtcgg attctgccag tttctgctct gcagccaaag
atggtcagaa 240gcattgtcac ttcagtaaca tcaagtgctc aaagacatgg caaccgttca
gtggtactta 300agtattcaaa atatacaact acagattctc tgacagaaac cagcacgggg
tcttcacctt 360cattcacccc acaggcgaca cgcgagggag aacagcatct cagtggtgat
ttccaaacca 420agcctttgt
4298625DNAArtificialsynthetic oligonucleotide primer
86ccagctgttc caagactggg ccgta
258725DNAArtificialsynthetic oligonucleotide primer 87gggccgtaga
attccatgtt tcagg
258825DNAArtificialsynthetic oligonucleotide primer 88caaagcagtg
gccaacatcg cggac
258925DNAArtificialsynthetic oligonucleotide primer 89gtgccttgtc
acagatgggt gctgg
259025DNAArtificialsynthetic oligonucleotide primer 90ggtcctcagg
cgttggggac actgc
259125DNAArtificialsynthetic oligonucleotide primer 91tgggtcgatg
gggtcggatt ctgcc
259225DNAArtificialsynthetic oligonucleotide primer 92tctgctctgc
agccaaagat ggtca
259325DNAArtificialsynthetic oligonucleotide primer 93aagcattgtc
acttcagtaa catca
259425DNAArtificialsynthetic oligonucleotide primer 94gacatggcaa
ccgttcagtg gtact
259525DNAArtificialsynthetic oligonucleotide primer 95gaacagcatc
tcagtggtga tttcc
259625DNAArtificialsynthetic oligonucleotide primer 96ggtgatttcc
aaaccaagcc tttgt 2597543DNAHomo
sapiens 97atcgtggaga tcatgcagca aggttctcag cttccttgct tccatggctc
cagcaccatt 60cgaaacctca aagagaggtt ccacatgagc atgactgagg agcagctgca
gctgctggtg 120gagcagatgg tggatggcag tatgcggtct atcaccacca aactctatga
cggcttccag 180tacctcacca acggcatcat gtgacacgct cctcagccca ggagtggtgg
ggggtccagg 240gcaccctccc tagagggccc ttgtttgaga aaccccaaac caggaaaccc
cacctaccca 300accatccacc caagggaaat ggaaggcaag aaacacgaag gatcatgtgg
taactgcgag 360agcttgctga ggggtgggag agccagctgt ggggtccaga cttgttgggg
cttccctgcc 420cctcctggtc tgtgtcagta ttaccaccag actgactcca ggactcactg
ccctccagaa 480aacagaggtg acaaatgtga gggacactgg ggcctttctt ctccttgtag
gggtctctca 540gag
5439825DNAArtificialsynthetic oligonucleotide primer
98atcgtggaga tcatgcagca aggtt
259925DNAArtificialsynthetic oligonucleotide primer 99gcaaggttct
cagcttcctt gcttc
2510025DNAArtificialsynthetic oligonucleotide primer 100aagagaggtt
ccacatgagc atgac
2510125DNAArtificialsynthetic oligonucleotide primer 101atggcagtat
gcggtctatc accac
2510225DNAArtificialsynthetic oligonucleotide primer 102tcaccaccaa
actctatgac ggctt
2510325DNAArtificialsynthetic oligonucleotide primer 103gtacctcacc
aacggcatca tgtga
2510425DNAArtificialsynthetic oligonucleotide primer 104caccaacggc
atcatgtgac acgct
2510525DNAArtificialsynthetic oligonucleotide primer 105gaaggatcat
gtggtaactg cgaga
2510625DNAArtificialsynthetic oligonucleotide primer 106ccagctgtgg
ggtccagact tgttg
2510725DNAArtificialsynthetic oligonucleotide primer 107cactgccctc
cagaaaacag aggtg
2510825DNAArtificialsynthetic oligonucleotide primer 108ttctccttgt
aggggtctct cagag
25109537DNAHomo sapiens 109cccgtgggca cccacggacg tggcttggtg ctgagatagc
agagccccca gccatcactg 60ctggcagcct gggcaaaccg ggtgagcaac aggaggacga
ggggccgggg cggtgccagg 120ctaccacaag aacctgcgtc ttggaccatt gcccctcccg
gccccaaacc acaggggctc 180aggtcgtgtg ggccccagtg ctagatctct ccctcccttc
gtctctgtct gtgctgttgg 240cgacccctct gtctgtctcc agccctgtct ttctgttctc
ttatctcttt gtttcacctt 300ttccctctct ggcgtccccg gctgcttgta ctcttggcct
tttctgtgtc tcctttctgg 360ctcttgcctc cgcctctctc tctcatcctc tttgtcctca
gctcctcctg ctttcttggg 420tcccaccagt gtcacttttc tgccgttttc tttcctgttc
tcctctgctt cattctcgtc 480cagccattgc tcccctctcc ctgccaccct tccccagttc
accaaacctt acatgtt 53711025DNAArtificialsynthetic oligonucleotide
primer 110cccgtgggca cccacggacg tggct
2511125DNAArtificialsynthetic oligonucleotide primer 111acggacgtgg
cttggtgctg agata
2511225DNAArtificialsynthetic oligonucleotide primer 112tggtgctgag
atagcagagc cccca
2511325DNAArtificialsynthetic oligonucleotide primer 113cagcctgggc
aaaccgggtg agcaa
2511425DNAArtificialsynthetic oligonucleotide primer 114ggcaaaccgg
gtgagcaaca ggagg
2511525DNAArtificialsynthetic oligonucleotide primer 115agcaacagga
ggacgagggg ccggg
2511625DNAArtificialsynthetic oligonucleotide primer 116gtgccaggct
accacaagaa cctgc
2511725DNAArtificialsynthetic oligonucleotide primer 117accacaagaa
cctgcgtctt ggacc
2511825DNAArtificialsynthetic oligonucleotide primer 118cggccccaaa
ccacaggggc tcagg
2511925DNAArtificialsynthetic oligonucleotide primer 119caggggctca
ggtcgtgtgg gcccc
2512025DNAArtificialsynthetic oligonucleotide primer 120cccagttcac
caaaccttac atgtt
25121560DNAHomo sapiens 121gcaaacctcc tgaagtgggc agccaacagt tttgagagag
ccatgttcat aaactacgaa 60caggtgaaca tgggtgatcg gtttgggcag atcatgattg
aaaacctgcg gagacgccag 120tgtgacctgg cgggagtgga gacctgcaag tcattagagt
cacagaaaga acggctcctg 180tcgaatgggt gggaaacagc atcggccgtc gacatgatgg
agttgtacaa caggttacct 240cgagctgaag tgagcaggat agaatcactt gaattcctgg
atgaaatgga gctgctggag 300cagctcatgc ggcattactg cctttgctgg gcaaccaaag
gaggaaatga gcttgggctg 360aaggagataa cttattaatc tgtcgaaggc ttatgccgag
ccagaagccg aagccacttg 420ccctcctgga ggagacctgc aagctccctg agcggtgggc
gggcctcgtc cgcaggtctc 480atcccacact cttgagaagc cttggtcact acagtggtcg
cacatgttcc tcttcctgtt 540cctgttgaca tgtcgttgtt
56012225DNAArtificialsynthetic oligonucleotide
primer 122gcaaacctcc tgaagtgggc agcca
2512325DNAArtificialsynthetic oligonucleotide primer 123gaacatgggt
gatcggtttg ggcag
2512425DNAArtificialsynthetic oligonucleotide primer 124gaaaacctgc
ggagacgcca gtgtg
2512525DNAArtificialsynthetic oligonucleotide primer 125aaagaacggc
tcctgtcgaa tgggt
2512625DNAArtificialsynthetic oligonucleotide primer 126cagcatcggc
cgtcgacatg atgga
2512725DNAArtificialsynthetic oligonucleotide primer 127ggagttgtac
aacaggttac ctcga
2512825DNAArtificialsynthetic oligonucleotide primer 128cattactgcc
tttgctgggc aacca
2512925DNAArtificialsynthetic oligonucleotide primer 129gtctcatccc
acactcttga gaagc
2513025DNAArtificialsynthetic oligonucleotide primer 130agccttggtc
actacagtgg tcgca
2513125DNAArtificialsynthetic oligonucleotide primer 131actacagtgg
tcgcacatgt tcctc
2513225DNAArtificialsynthetic oligonucleotide primer 132ctgttcctgt
tgacatgtcg ttgtt
25133348DNAHomo sapiens 133caagaccgaa aagctggagc ggctcatggt gcgcatcggc
gtcttctccg tgctctacac 60agtgcccgcc accatcgtca tcgcttgcta cttctacgag
caggccttcc gcgagcactg 120ggagcgctcg tgggtgagcc agcactgcaa gagcctggcc
atcccgtgcc cggcgcacta 180cacgccgcgc atgtcgcccg acttcacggt ctacatgatc
aaatacctca tgacgctcat 240cgtgggcatc acgtcgggct tctggatctg gtcgggcaag
acgctgcact cgtggaggaa 300gttctacact cgcctcacca acagccgaca cggtgagacc
accgtgtg 34813425DNAArtificialsynthetic oligonucleotide
primer 134caagaccgaa aagctggagc ggctc
2513525DNAArtificialsynthetic oligonucleotide primer 135gtgagccagc
actgcaagag cctgg
2513625DNAArtificialsynthetic oligonucleotide primer 136gagccagcac
tgcaagagcc tggcc
2513725DNAArtificialsynthetic oligonucleotide primer 137cccgacttca
cggtctacat gatca
2513825DNAArtificialsynthetic oligonucleotide primer 138cacggtctac
atgatcaaat acctc
2513925DNAArtificialsynthetic oligonucleotide primer 139gatcaaatac
ctcatgacgc tcatc
2514025DNAArtificialsynthetic oligonucleotide primer 140caaatacctc
atgacgctca tcgtg
2514125DNAArtificialsynthetic oligonucleotide primer 141caagacgctg
cactcgtgga ggaag
2514225DNAArtificialsynthetic oligonucleotide primer 142gctgcactcg
tggaggaagt tctac
2514325DNAArtificialsynthetic oligonucleotide primer 143caacagccga
cacggtgaga ccacc
2514425DNAArtificialsynthetic oligonucleotide primer 144gccgacacgg
tgagaccacc gtgtg
25145488DNAHomo sapiens 145aaagcattct gcattagtac taaaataagc catcaatgcc
agtccaccct ctctattcat 60ggctaaatat ttaaaggtta tttatagctt ctttaatgaa
ttcttcttaa acaaagtgaa 120attatgtcct agaaaagtag aagctattcg taactagagc
agtgcaactt taaagtttta 180tgaatatgta ttttaatgac aagggggcga gcttgcatcc
ccactagtta atggataatt 240caaaccgagg actgattttg aaagatcacc taaaaatgta
gatttgttct ttagtaaatt 300tagatcaact atgcatatat tttgtaggta aatctttcag
tccatgcccc aaccctcacc 360aaaaccaaag cagaaattac acacacaaag atgctcccgt
taggaattgc tattcacatg 420aggctttctg tgctagattt ttttctcaga aacaaacttt
actgtaggac tattgtggtg 480ttcttaac
48814625DNAArtificialsynthetic oligonucleotide
primer 146aaagcattct gcattagtac taaaa
2514725DNAArtificialsynthetic oligonucleotide primer 147aaataagcca
tcaatgccag tccac
2514825DNAArtificialsynthetic oligonucleotide primer 148ccaccctctc
tattcatggc taaat
2514925DNAArtificialsynthetic oligonucleotide primer 149gacaaggggg
cgagcttgca tcccc
2515025DNAArtificialsynthetic oligonucleotide primer 150gcttgcatcc
ccactagtta atgga
2515125DNAArtificialsynthetic oligonucleotide primer 151taggtaaatc
tttcagtcca tgccc
2515225DNAArtificialsynthetic oligonucleotide primer 152acacacaaag
atgctcccgt tagga
2515325DNAArtificialsynthetic oligonucleotide primer 153gatgctcccg
ttaggaattg ctatt
2515425DNAArtificialsynthetic oligonucleotide primer 154attgctattc
acatgaggct ttctg
2515525DNAArtificialsynthetic oligonucleotide primer 155aggctttctg
tgctagattt ttttc
2515625DNAArtificialsynthetic oligonucleotide primer 156gtaggactat
tgtggtgttc ttaac
25157250DNAHomo sapiens 157gacagagagc gagaccgtga tcgggacaga gaaagagaac
gcaccagaga gagagagagg 60gagcgtgatc acagtcctac accaagtgtt ttcaacagcg
atgaagaacg atacagatac 120agggaatatg cagaaagagg ttatgagcgt cacagagcaa
gtcgagaaaa agaagaacga 180catagagaaa gacgacacag ggagaaagag gaaaccagac
ataagtcttc tcgaagtaat 240agtagacgtc
25015825DNAArtificialsynthetic oligonucleotide
primer 158gacagagagc gagaccgtga tcggg
2515925DNAArtificialsynthetic oligonucleotide primer 159gagcgagacc
gtgatcggga cagag
2516025DNAArtificialsynthetic oligonucleotide primer 160gaccgtgatc
gggacagaga aagag
2516125DNAArtificialsynthetic oligonucleotide primer 161gagaaagaga
acgcaccaga gagag
2516225DNAArtificialsynthetic oligonucleotide primer 162gagggagcgt
gatcacagtc ctaca
2516325DNAArtificialsynthetic oligonucleotide primer 163gtgttttcaa
cagcgatgaa gaacg
2516425DNAArtificialsynthetic oligonucleotide primer 164gaagaacgat
acagatacag ggaat
2516525DNAArtificialsynthetic oligonucleotide primer 165gcagaaagag
gttatgagcg tcaca
2516625DNAArtificialsynthetic oligonucleotide primer 166tgagcgtcac
agagcaagtc gagaa
2516725DNAArtificialsynthetic oligonucleotide primer 167gaaaccagac
ataagtcttc tcgaa
2516825DNAArtificialsynthetic oligonucleotide primer 168tcttctcgaa
gtaatagtag acgtc
25169550DNAHomo sapiensmisc_feature(80)..(80)n is a, c, g, or t
169ctcacccaag tgctccggag agtgacagga aacccacggc tccccgcgcc caagagcgtc
60ctgcggtctc gctggcacan cnccccgtac actagggggt cctacagcta cgtggccgtg
120ggcagtactg ggggcgacct ggacctgctg gctcagnccc tccctgcaga cggcgccggc
180gcccagctcc agatcctgtt tgcgggggaa gccacacatc gcacgtttta ctccacgacg
240cacggggctc tgctgtcggg atggagggag gccgaccgcc tcctcagtct gtgggccccg
300caggtgcagc agcccaggcc naggctctag ctnggcccag cctactctgt tccacccgtg
360tcgggggtag gctgggaccn tcatttcttc tgacagattt cagtctggct tgaaatttgg
420ggatgttaat gagggtcctc tggtttttgg taaccagggc caccttctca gttcttgtgt
480ctgttattgg agtctggcca gggttgactt gagctgagac accagatgct cacggagatg
540ctggacacat
55017025DNAArtificialsynthetic oligonucleotide primer 170ctcacccaag
tgctccggag agtga
2517125DNAArtificialsynthetic oligonucleotide primer 171gagagtgaca
ggaaacccac ggctc
2517225DNAArtificialsynthetic oligonucleotide primer 172actagggggt
cctacagcta cgtgg
2517325DNAArtificialsynthetic oligonucleotide primer 173agctacgtgg
ccgtgggcag tactg
2517425DNAArtificialsynthetic oligonucleotide primer 174gtttgcgggg
gaagccacac atcgc
2517525DNAArtificialsynthetic oligonucleotide primer 175ggctctgctg
tcgggatgga gggag
2517625DNAArtificialsynthetic oligonucleotide primer 176ttccacccgt
gtcgggggta ggctg
2517725DNAArtificialsynthetic oligonucleotide primer 177caccttctca
gttcttgtgt ctgtt
2517825DNAArtificialsynthetic oligonucleotide primer 178gtctggccag
ggttgacttg agctg
2517925DNAArtificialsynthetic oligonucleotide primer 179gagctgagac
accagatgct cacgg
2518025DNAArtificialsynthetic oligonucleotide primer 180atgctcacgg
agatgctgga cacat
25181448DNAHomo sapiens 181gcctacagcc ggacctgata gagggcagga agggggcgca
gatagtgaag cgggccagcc 60tgaaaagggg gaaacagtga ccccgagccg ctctccttgg
agtagcctct cgggaggatc 120acacctcgac acccaacccc tgaaccccac acactctctg
ccatgcacac aggaggagag 180ctggacctga gggccaccgc agcggtgcac acattcctct
gggctgacgg catgacctct 240gtaagggact cctgctagtc ccctcttggc atgaatgact
gactgtagac gcatgacctc 300caggcttcaa tcctgcctct tgcaatgaca gctgatctgt
cggaaccagg acacaaaagc 360agcaagaagc ggggagagag agggatagaa aacaagcgca
ggagagcctg cgaacgcaaa 420agtgaatgag ggctttttgt ggctgggg
44818225DNAArtificialsynthetic oligonucleotide
primer 182gcctacagcc ggacctgata gaggg
2518325DNAArtificialsynthetic oligonucleotide primer 183agatagtgaa
gcgggccagc ctgaa
2518425DNAArtificialsynthetic oligonucleotide primer 184tctccttgga
gtagcctctc gggag
2518525DNAArtificialsynthetic oligonucleotide primer 185ctctcgggag
gatcacacct cgaca
2518625DNAArtificialsynthetic oligonucleotide primer 186ctctctgcca
tgcacacagg aggag
2518725DNAArtificialsynthetic oligonucleotide primer 187gcatgacctc
tgtaagggac tcctg
2518825DNAArtificialsynthetic oligonucleotide primer 188ctagtcccct
cttggcatga atgac
2518925DNAArtificialsynthetic oligonucleotide primer 189tgactgactg
tagacgcatg acctc
2519025DNAArtificialsynthetic oligonucleotide primer 190aatcctgcct
cttgcaatga cagct
2519125DNAArtificialsynthetic oligonucleotide primer 191acagctgatc
tgtcggaacc aggac
2519225DNAArtificialsynthetic oligonucleotide primer 192gaatgagggc
tttttgtggc tgggg
25193545DNAHomo sapiens 193atgtaattta gggaggactg gtctgtaatt tctgaatgta
tatagaataa tatttatgtt 60tacaatgtaa cttttcaaaa tttacaaatc aggattatat
acataagaat tccactaaga 120aatgccaaga ttcttaaatt tgccagcgtt aaagtagaaa
ataacatttc agaagagcac 180aatatgcata aaacattttt caaaattgaa atattttcct
gggcattaaa aacctttact 240attggctaca aatttattgt acctgatgaa aacatatttt
ctggacttaa atgttattac 300aaatatctta attttcagta attgttttgc actttcaaag
attgtaaata gttcattcaa 360tcaatggtat agagttattt atttgctaca taatagatac
tgtgccaaat aattactttt 420tatttatttt atttagtacg taattttgaa gtacattttt
tcctgttttc acaattagac 480tacatttaat gtgtaggaat tgtatgtatg tatatcttct
gtaaataaca tctagtatct 540tcact
54519425DNAArtificialsynthetic oligonucleotide
primer 194atgtaattta gggaggactg gtctg
2519525DNAArtificialsynthetic oligonucleotide primer 195ggactggtct
gtaatttctg aatgt
2519625DNAArtificialsynthetic oligonucleotide primer 196agaattccac
taagaaatgc caaga
2519725DNAArtificialsynthetic oligonucleotide primer 197gattcttaaa
tttgccagcg ttaaa
2519825DNAArtificialsynthetic oligonucleotide primer 198ttgaaatatt
ttcctgggca ttaaa
2519925DNAArtificialsynthetic oligonucleotide primer 199gcattaaaaa
cctttactat tggct
2520025DNAArtificialsynthetic oligonucleotide primer 200ttcagtaatt
gttttgcact ttcaa
2520125DNAArtificialsynthetic oligonucleotide primer 201gctacataat
agatactgtg ccaaa
2520225DNAArtificialsynthetic oligonucleotide primer 202gtacattttt
tcctgttttc acaat
2520325DNAArtificialsynthetic oligonucleotide primer 203tcctgttttc
acaattagac tacat
2520425DNAArtificialsynthetic oligonucleotide primer 204gtaaataaca
tctagtatct tcact
25205586DNAHomo sapiensmisc_feature(33)..(410)n is a, c, g, or t
205catgggcatg ggagacctgc tcagtgccat gtnnnnnnnn nnnnnnnnnn nnnnnnnnnn
60nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
120nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
180nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
240nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
300nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn
360nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn aatcttattt
420atattgttat aaaatattcc aagatgagcc tctggccccc tgagccttct tgtaaatacc
480tgcctccctc ccccatcacc gaacttcccc tcctccccta tttaaaccac tctgtctccc
540ccacaaccct cccctggccc tctgatttgt tctgttcctg tctcaa
58620625DNAArtificialsynthetic oligonucleotide primer 206catgggcatg
ggagacctgc tcagt
2520725DNAArtificialsynthetic oligonucleotide primer 207tctggccccc
tgagccttct tgtaa
2520825DNAArtificialsynthetic oligonucleotide primer 208gccccctgag
ccttcttgta aatac
2520925DNAArtificialsynthetic oligonucleotide primer 209ccctgagcct
tcttgtaaat acctg
2521025DNAArtificialsynthetic oligonucleotide primer 210cctgagcctt
cttgtaaata cctgc
2521125DNAArtificialsynthetic oligonucleotide primer 211ctgagccttc
ttgtaaatac ctgcc
2521225DNAArtificialsynthetic oligonucleotide primer 212tcccctggcc
ctctgatttg ttctg
2521325DNAArtificialsynthetic oligonucleotide primer 213cccctggccc
tctgatttgt tctgt
2521425DNAArtificialsynthetic oligonucleotide primer 214ccctggccct
ctgatttgtt ctgtt
2521525DNAArtificialsynthetic oligonucleotide primer 215cctggccctc
tgatttgttc tgttc
2521625DNAArtificialsynthetic oligonucleotide primer 216ctggccctct
gatttgttct gttcc
2521725DNAArtificialsynthetic oligonucleotide primer 217tggccctctg
atttgttctg ttcct
2521825DNAArtificialsynthetic oligonucleotide primer 218ggccctctga
tttgttctgt tcctg
2521925DNAArtificialsynthetic oligonucleotide primer 219gccctctgat
ttgttctgtt cctgt
2522025DNAArtificialsynthetic oligonucleotide primer 220ccctctgatt
tgttctgttc ctgtc
2522125DNAArtificialsynthetic oligonucleotide primer 221ctgatttgtt
ctgttcctgt ctcaa
25222476DNAHomo sapiens 222ccccagctgc gacctgtggg ggagctcagt tgggccgaca
ttgaccacct gcagacacac 60ttccgctgcc agtgctactt gggctggagt ggtgagcaat
gccagtggga ccataggcag 120gcagctggag gtgccaacga ggcctgggct gggtcccacc
tcaccagtct gctggctctg 180gcagccctgg cctttacctg gaccttgtag gggtctcctg
cctagctgcc tagcaagctg 240gcctctacac aagggctctc ttaggcatgt aggaccctgc
agggggtggt caaactggag 300tctggagtgc agagccccca ggaaacccag gagggcatcc
ataccagctc gcacccccct 360gttctaaggg ggaggggaag tccctgggag gccccttctc
tccctgccag aggggaagga 420gggtacagct gggctgggga ggacctgacc ctactccctt
gccctagata gtttat 47622325DNAArtificialsynthetic oligonucleotide
primer 223ccccagctgc gacctgtggg ggagc
2522425DNAArtificialsynthetic oligonucleotide primer 224agctcagttg
ggccgacatt gacca
2522525DNAArtificialsynthetic oligonucleotide primer 225gggctggagt
ggtgagcaat gccag
2522625DNAArtificialsynthetic oligonucleotide primer 226ggtgagcaat
gccagtggga ccata
2522725DNAArtificialsynthetic oligonucleotide primer 227gcaatgccag
tgggaccata ggcag
2522825DNAArtificialsynthetic oligonucleotide primer 228acctggacct
tgtaggggtc tcctg
2522925DNAArtificialsynthetic oligonucleotide primer 229cacaagggct
ctcttaggca tgtag
2523025DNAArtificialsynthetic oligonucleotide primer 230ggctctctta
ggcatgtagg accct
2523125DNAArtificialsynthetic oligonucleotide primer 231ttaggcatgt
aggaccctgc agggg
2523225DNAArtificialsynthetic oligonucleotide primer 232gcatgtagga
ccctgcaggg ggtgg
2523325DNAArtificialsynthetic oligonucleotide primer 233tactcccttg
ccctagatag tttat
25234420DNAHomo sapiens 234ggaactggtg ctgtactggg tacacagtag gcgcccagga
caagtgggtt gcaagacagg 60aagaaaggaa aaggaagggc agagtgctgg tttctccagg
ttgggttggg ggcactgctg 120tcccccctcc agctaggacc cagcccatcc ccagatgcct
gagcctttgt ccaaagtgag 180gtcactcgag aattcatgga cacggccccc agtcaggggg
catcttgcaa gacctttagt 240gccacaaata agcatcgagc acctccccat tcacaccccc
attcctcctg gctccttatc 300ccccatggtg tttattattt atttccctcc ccatgcccct
ggggacccca aggccccagc 360ttccctctgc acccccagcc tatcccagag gccttgcagg
tgaccagcag tgtcattgta 42023525DNAArtificialsynthetic oligonucleotide
primer 235ggaactggtg ctgtactggg tacac
2523625DNAArtificialsynthetic oligonucleotide primer 236tgggtacaca
gtaggcgccc aggac
2523725DNAArtificialsynthetic oligonucleotide primer 237ggaagggcag
agtgctggtt tctcc
2523825DNAArtificialsynthetic oligonucleotide primer 238gctggtttct
ccaggttggg ttggg
2523925DNAArtificialsynthetic oligonucleotide primer 239atgcctgagc
ctttgtccaa agtga
2524025DNAArtificialsynthetic oligonucleotide primer 240gtgaggtcac
tcgagaattc atgga
2524125DNAArtificialsynthetic oligonucleotide primer 241agtcaggggg
catcttgcaa gacct
2524225DNAArtificialsynthetic oligonucleotide primer 242atcttgcaag
acctttagtg ccaca
2524325DNAArtificialsynthetic oligonucleotide primer 243cacaaataag
catcgagcac ctccc
2524425DNAArtificialsynthetic oligonucleotide primer 244tccttatccc
ccatggtgtt tatta
2524525DNAArtificialsynthetic oligonucleotide primer 245gcaggtgacc
agcagtgtca ttgta
25246531DNAHomo sapiens 246gggcttgtat gtgttctatg tggtcactgt gattctctgc
acctggatct accaacggca 60acggagagga tctctgttct gccccatgcc agttactcca
gagatcctct cagactccga 120ggaggaccgg gtatcttcta ataccaacag ctatgactac
ggtgatgagt accggccgct 180gttcttctac caggagacca cggctcagat cctggtccgg
gccctcaatc ccctggatta 240catgaagtgg agaaggaaat cagcatactg gaaagccctc
aaggtgttca agctgcctgt 300ggagttcctg ctgctcctca cagtccccgt cgtggacccg
gacaaggatg accagaactg 360gaaacggccc ctcaactgtc tgcatctggt tatcagcccc
ctggttgtgg tcctgaccct 420gcagtcgggg acctatggtg tctatgagat aggcggcctc
gttcccgtct gggtcgtggt 480ggtgatcgca ggcacagcct tggcttcagt gacctttttt
gccacatctg a 53124725DNAArtificialsynthetic oligonucleotide
primer 247gggcttgtat gtgttctatg tggtc
2524825DNAArtificialsynthetic oligonucleotide primer 248agttactcca
gagatcctct cagac
2524925DNAArtificialsynthetic oligonucleotide primer 249gactccgagg
aggaccgggt atctt
2525025DNAArtificialsynthetic oligonucleotide primer 250tacggtgatg
agtaccggcc gctgt
2525125DNAArtificialsynthetic oligonucleotide primer 251ttctaccagg
agaccacggc tcaga
2525225DNAArtificialsynthetic oligonucleotide primer 252ccctcaaggt
gttcaagctg cctgt
2525325DNAArtificialsynthetic oligonucleotide primer 253actgtctgca
tctggttatc agccc
2525425DNAArtificialsynthetic oligonucleotide primer 254accctgcagt
cggggaccta tggtg
2525525DNAArtificialsynthetic oligonucleotide primer 255ctatgagata
ggcggcctcg ttccc
2525625DNAArtificialsynthetic oligonucleotide primer 256gtcgtggtgg
tgatcgcagg cacag
2525725DNAArtificialsynthetic oligonucleotide primer 257cagtgacctt
ttttgccaca tctga
25258421DNAHomo sapiens 258gaagtaagag actcagcctg cagttaatta gcattctggc
agttttgaca tcagccagct 60gccctaaata acccttcaac gtttcttcac ttttgcaagt
tccacagagt aagacattgg 120gtctattcca gctcattcat tttatattga aaaaaataat
tttaaaaatg gtggcttcag 180ctccagcccc tttccaaaat ttttcaaccc caccctgttt
ggatttttaa ttaaaaacta 240gtagttctct tggtgttaaa acacttctgt cctgtgaggt
ttcccaatgg tgtttttctt 300gtaaatgtgt tggacaaatg tgaagatgca ttgtagttta
accatatgcc cacatttagt 360ctctttattc ctagttggtg agaaacctgt atctttctat
gctgctttta tatctgtatg 420t
42125925DNAArtificialsynthetic oligonucleotide
primer 259gaagtaagag actcagcctg cagtt
2526025DNAArtificialsynthetic oligonucleotide primer 260gcctgcagtt
aattagcatt ctggc
2526125DNAArtificialsynthetic oligonucleotide primer 261ccttcaacgt
ttcttcactt ttgca
2526225DNAArtificialsynthetic oligonucleotide primer 262gacattgggt
ctattccagc tcatt
2526325DNAArtificialsynthetic oligonucleotide primer 263gtgttaaaac
acttctgtcc tgtga
2526425DNAArtificialsynthetic oligonucleotide primer 264tgaggtttcc
caatggtgtt tttct
2526525DNAArtificialsynthetic oligonucleotide primer 265gtgaagatgc
attgtagttt aacca
2526625DNAArtificialsynthetic oligonucleotide primer 266taaccatatg
cccacattta gtctc
2526725DNAArtificialsynthetic oligonucleotide primer 267gcccacattt
agtctcttta ttcct
2526825DNAArtificialsynthetic oligonucleotide primer 268aaacctgtat
ctttctatgc tgctt
2526925DNAArtificialsynthetic oligonucleotide primer 269ctatgctgct
tttatatctg tatgt
25270525DNAHomo sapiens 270cctggccagt caaagtagtc tctcccctgg ccacagtaat
tggtcatgtg atgcaagcca 60gcttactagc actttgagaa tgagtctcct gttgagctgg
taggatgtaa gcctggagct 120aatggcgatc atctttgcca ccgcctgggg agagcctgct
tgggaatgaa attaacacaa 180aggaagtcca acctgagaaa tggccaaata tatttcctga
taacattatg tggccctctg 240gatccagcca tgcctgaggt ctacccctgg gcttttggat
tatgtgtaca gttggttcat 300ccctttttct gctaattcga gtcatggcta atttaacacc
ctttagaacc ttaaagaacc 360atcagcatca cccgggaact tttttagaaa tgcaaaatct
ctactgcttt ggatcctggg 420tcaaaaaaaa gaaaaaaaaa agaaatgcaa aactttaggc
cctgccccag atttactaaa 480tcaatctgca gtttaacaaa atcctcaggt gatttgtatg
ctcat 52527125DNAArtificialsynthetic oligonucleotide
primer 271cctggccagt caaagtagtc tctcc
2527225DNAArtificialsynthetic oligonucleotide primer 272ctcccctggc
cacagtaatt ggtca
2527325DNAArtificialsynthetic oligonucleotide primer 273aattggtcat
gtgatgcaag ccagc
2527425DNAArtificialsynthetic oligonucleotide primer 274gcaagccagc
ttactagcac tttga
2527525DNAArtificialsynthetic oligonucleotide primer 275gctaatggcg
atcatctttg ccacc
2527625DNAArtificialsynthetic oligonucleotide primer 276cctgggcttt
tggattatgt gtaca
2527725DNAArtificialsynthetic oligonucleotide primer 277tgtacagttg
gttcatccct ttttc
2527825DNAArtificialsynthetic oligonucleotide primer 278atcccttttt
ctgctaattc gagtc
2527925DNAArtificialsynthetic oligonucleotide primer 279atgcaaaatc
tctactgctt tggat
2528025DNAArtificialsynthetic oligonucleotide primer 280ccctgcccca
gatttactaa atcaa
2528125DNAArtificialsynthetic oligonucleotide primer 281atcctcaggt
gatttgtatg ctcat
25282173DNAHomo sapiensmisc_feature(146)..(146)n is a, c, g, or t
282gtggaaggtg gctgctgcga agaagctcgt tagaactgtg gtgcgccatc acgaggagaa
60gcagctccgt gaagaaaggg ggaagaagga agagcagagc agactgaggc ggatagccgc
120ctccacggcc cgggagatag agtgcntttg gtcgaatatt gaacaggttg tgg
17328325DNAArtificialsynthetic oligonucleotide primer 283gtggaaggtg
gctgctgcga agaag
2528425DNAArtificialsynthetic oligonucleotide primer 284gaaggtggct
gctgcgaaga agctc
2528525DNAArtificialsynthetic oligonucleotide primer 285gtggctgctg
cgaagaagct cgtta
2528625DNAArtificialsynthetic oligonucleotide primer 286ggctgctgcg
aagaagctcg ttaga
2528725DNAArtificialsynthetic oligonucleotide primer 287gaagctcgtt
agaactgtgg tgcgc
2528825DNAArtificialsynthetic oligonucleotide primer 288gctcgttaga
actgtggtgc gccat
2528925DNAArtificialsynthetic oligonucleotide primer 289ttagaactgt
ggtgcgccat cacga
2529025DNAArtificialsynthetic oligonucleotide primer 290gtggtgcgcc
atcacgagga gaagc
2529125DNAArtificialsynthetic oligonucleotide primer 291tgcgccatca
cgaggagaag cagct
2529225DNAArtificialsynthetic oligonucleotide primer 292cctccacggc
ccgggagata gagtg
2529325DNAArtificialsynthetic oligonucleotide primer 293tggtcgaata
ttgaacaggt tgtgg
25294523DNAHomo sapiensmisc_feature(28)..(28)n is a, c, g, or t
294gcccagaatt acaggagtta gcacaccnag ctcntacaga taagaaaaca ttgaaattca
60aagattaagg ccaaaaatat ctcacttgca attttaatat tttcatttgg atttatataa
120atgaaacata tatatgtttt ggaatggcca gagtgaggca aaggggatcc ctgaaataac
180attagaacat acaggaaaaa cgaggcnggc agatcacttt aggtcaggag ttcaagacca
240gcctgtacgt gcgtgcctgt agtcccagct actcgggagg ctgagatggg agaatcactt
300gaacctggga ggcagagttt gcagtgagct gagantntnc cactgcactc cagtctgtgt
360gacagaatga gaccttgtct tgaaacaaac acaaaaacaa aaaaccacat acaggaaaca
420agagagggat ggagtcaact gtgccccaga cattaagcgc ccttcagtga ggaggggcaa
480agtgctcagg cctgcctgtg tggcccacag gagtcagaac tcg
52329525DNAArtificialsynthetic oligonucleotide primer 295gcccagaatt
acaggagtta gcaca
2529625DNAArtificialsynthetic oligonucleotide primer 296aggccaaaaa
tatctcactt gcaat
2529725DNAArtificialsynthetic oligonucleotide primer 297gagtgaggca
aaggggatcc ctgaa
2529825DNAArtificialsynthetic oligonucleotide primer 298ctgcactcca
gtctgtgtga cagaa
2529925DNAArtificialsynthetic oligonucleotide primer 299gagaccttgt
cttgaaacaa acaca
2530025DNAArtificialsynthetic oligonucleotide primer 300gagggatgga
gtcaactgtg cccca
2530125DNAArtificialsynthetic oligonucleotide primer 301tcaactgtgc
cccagacatt aagcg
2530225DNAArtificialsynthetic oligonucleotide primer 302gacattaagc
gcccttcagt gagga
2530325DNAArtificialsynthetic oligonucleotide primer 303gaggaggggc
aaagtgctca ggcct
2530425DNAArtificialsynthetic oligonucleotide primer 304aaagtgctca
ggcctgcctg tgtgg
2530525DNAArtificialsynthetic oligonucleotide primer 305tgtggcccac
aggagtcaga actcg
25306375DNAHomo sapiens 306gcaaccccaa cagcttgaag aggacaggga cggagagctc
cagacctaac actgccttgt 60tggatccaag ctcccctgaa ttctctgctg tggtatcagt
gggcgattgg ctccaggcca 120ttaaaatgga ccggtataag gataacttca cagctgctgg
ttataccaca ctagaggctg 180tggtgcacgt gaaccaggag gacctggcaa gaattggtat
cacagccatc acgcaccaga 240ataagatttt gagcagtgtc caggcaatgc gaacccaaat
gcagcagatg cacggcagaa 300tggttcccgt ctgagccagt actgaataaa ctcaaaactc
ttgaaattag tttacctcat 360ccatgcactt taatt
37530725DNAArtificialsynthetic oligonucleotide
primer 307gcaaccccaa cagcttgaag aggac
2530825DNAArtificialsynthetic oligonucleotide primer 308tccagaccta
acactgcctt gttgg
2530925DNAArtificialsynthetic oligonucleotide primer 309ccctgaattc
tctgctgtgg tatca
2531025DNAArtificialsynthetic oligonucleotide primer 310tatcagtggg
cgattggctc caggc
2531125DNAArtificialsynthetic oligonucleotide primer 311acagctgctg
gttataccac actag
2531225DNAArtificialsynthetic oligonucleotide primer 312ggtgcacgtg
aaccaggagg acctg
2531325DNAArtificialsynthetic oligonucleotide primer 313cagccatcac
gcaccagaat aagat
2531425DNAArtificialsynthetic oligonucleotide primer 314gcagtgtcca
ggcaatgcga accca
2531525DNAArtificialsynthetic oligonucleotide primer 315tgcacggcag
aatggttccc gtctg
2531625DNAArtificialsynthetic oligonucleotide primer 316ttcccgtctg
agccagtact gaata
2531725DNAArtificialsynthetic oligonucleotide primer 317tttacctcat
ccatgcactt taatt
25318561DNAHomo sapiensmisc_feature(135)..(135)n is a, c, g, or t
318agcgccccag tgaacactac aacatacgta gctgacacag aatcagagca agcagataca
60tgggatttga gtgaaaggcc aaaagaaatc aaagtctcca aaatggaaca aaaattcaga
120atgctttcac aagangcacc cactgtaaag gagtcctgca aaacaagctc taataataat
180agtatggtat caaatacttt ggctaagatg agaatcccaa actatcagct ttcaccaact
240aaattgccaa gtataaataa aagtaaagat agggcttctc agcagcagca gaccaactcc
300atcagaaact actttcagcc gtctaccaaa aaaagggaaa gggatgaaga aaatcaagaa
360atgtcttcat gcaaatcagc aagaatagaa acgtcttgtt ctcttttaga acaaacacaa
420cctgctacac cctcattgtg gaaaaataag gagcagcatc tatctgagaa tgagcctgtg
480gacacaaact cagacaataa cttatttaca gatacagatt taaaatctat tgtgaaaaat
540tctgccagta aatctcatgc t
56131925DNAArtificialsynthetic oligonucleotide primer 319agcgccccag
tgaacactac aacat
2532025DNAArtificialsynthetic oligonucleotide primer 320gcacccactg
taaaggagtc ctgca
2532125DNAArtificialsynthetic oligonucleotide primer 321gaatcccaaa
ctatcagctt tcacc
2532225DNAArtificialsynthetic oligonucleotide primer 322agctttcacc
aactaaattg ccaag
2532325DNAArtificialsynthetic oligonucleotide primer 323aagatagggc
ttctcagcag cagca
2532425DNAArtificialsynthetic oligonucleotide primer 324gcagaccaac
tccatcagaa actac
2532525DNAArtificialsynthetic oligonucleotide primer 325tcagaaacta
ctttcagccg tctac
2532625DNAArtificialsynthetic oligonucleotide primer 326tagaaacgtc
ttgttctctt ttaga
2532725DNAArtificialsynthetic oligonucleotide primer 327tagaacaaac
acaacctgct acacc
2532825DNAArtificialsynthetic oligonucleotide primer 328cctgctacac
cctcattgtg gaaaa
2532925DNAArtificialsynthetic oligonucleotide primer 329aaattctgcc
agtaaatctc atgct
25330400DNAHomo sapiens 330gccattgact ccctgagcat tgagaaaggc taccggcact
ggcacgcgga cctgcggcca 60gacgacagcc ccctggaggc aggcctggcc ttcacctgca
agctcaagtc gccggtgccc 120ttcctgggga gggaggccct ggagcagcag cgggccgcag
gcctccgccg gcgcctggtg 180tgcttcacca tggaggacaa agtacccatg tttggcctgg
aggccatctg gaggaacggc 240caagtggtgg gccatgtccg gagggctgac tttgggttcg
ccatcgacaa gaccatcgcc 300tacggttaca tccatgaccc cagcggtggg ccggtctcgc
tggactttgt gaagagcggg 360gactatgccc tggagagaat gggggtgacc tatggtgccc
40033125DNAArtificialsynthetic oligonucleotide
primer 331gccattgact ccctgagcat tgaga
2533225DNAArtificialsynthetic oligonucleotide primer 332ttgagaaagg
ctaccggcac tggca
2533325DNAArtificialsynthetic oligonucleotide primer 333cacctgcaag
ctcaagtcgc cggtg
2533425DNAArtificialsynthetic oligonucleotide primer 334cgcctggtgt
gcttcaccat ggagg
2533525DNAArtificialsynthetic oligonucleotide primer 335aagtacccat
gtttggcctg gaggc
2533625DNAArtificialsynthetic oligonucleotide primer 336gcctggaggc
catctggagg aacgg
2533725DNAArtificialsynthetic oligonucleotide primer 337ctggaggaac
ggccaagtgg tgggc
2533825DNAArtificialsynthetic oligonucleotide primer 338tttgggttcg
ccatcgacaa gacca
2533925DNAArtificialsynthetic oligonucleotide primer 339cggtctcgct
ggactttgtg aagag
2534025DNAArtificialsynthetic oligonucleotide primer 340tgaagagcgg
ggactatgcc ctgga
2534125DNAArtificialsynthetic oligonucleotide primer 341agaatggggg
tgacctatgg tgccc
25342364DNAHomo sapiens 342cacttcagac cagccaggtg tcttcccggg ccctgccaga
ccctgctcac attccctctg 60ctggtctgtg ctggtctcag aaggccaccg cgcccgcatt
ccactcagcc agggtccagc 120tgcagccccc gccacccttc cttcccttcc ctgtcctggg
tcatgttgtt gccaccctgt 180gtgacttttg aagctgtaaa atgagcttcc agggcttggg
tggcgtcggg gcagggccgc 240cgaggctggg aggaagccct tctgcctttt gctggtgttt
ctggaatttg ctttccctca 300cctctcactt ccttctagaa ggagcttcct gactggaacc
agagaatgca tgtctgtcca 360cttg
36434325DNAArtificialsynthetic oligonucleotide
primer 343cacttcagac cagccaggtg tcttc
2534425DNAArtificialsynthetic oligonucleotide primer 344gctggtctgt
gctggtctca gaagg
2534525DNAArtificialsynthetic oligonucleotide primer 345ttccctgtcc
tgggtcatgt tgttg
2534625DNAArtificialsynthetic oligonucleotide primer 346caccctgtgt
gacttttgaa gctgt
2534725DNAArtificialsynthetic oligonucleotide primer 347gtgtgacttt
tgaagctgta aaatg
2534825DNAArtificialsynthetic oligonucleotide primer 348aaatgagctt
ccagggcttg ggtgg
2534925DNAArtificialsynthetic oligonucleotide primer 349cttttgctgg
tgtttctgga atttg
2535025DNAArtificialsynthetic oligonucleotide primer 350gctggtgttt
ctggaatttg ctttc
2535125DNAArtificialsynthetic oligonucleotide primer 351acctctcact
tccttctaga aggag
2535225DNAArtificialsynthetic oligonucleotide primer 352gcttcctgac
tggaaccaga gaatg
2535325DNAArtificialsynthetic oligonucleotide primer 353cagagaatgc
atgtctgtcc acttg
25354394DNAHomo sapiens 354aatccttatt gttcagagtt gtttgggggt tctgtttcag
agcataaaac ctaaaggtta 60tagtagaaca aggcaccttc ttaaaagaaa tcttgcttca
gaccatcagt tacagagaat 120ttcctaaagt aaaattgaag caactacaac ttctccttag
acactttgga atctaaccac 180ttaaggacct ttttaaagag atagcttctc ttctttctga
agatcaattt ctcccaaggc 240caagattgtc cttttctccc atttcttgct agctattgca
aatgagggaa gaacattatt 300catctctcct cccctttttt ttctgattct tttttcagtc
agttttgctc ctgggttcaa 360gtagtattac caccctttca caagcaacag actc
39435525DNAArtificialsynthetic oligonucleotide
primer 355aatccttatt gttcagagtt gtttg
2535625DNAArtificialsynthetic oligonucleotide primer 356gaaatcttgc
ttcagaccat cagtt
2535725DNAArtificialsynthetic oligonucleotide primer 357gaccatcagt
tacagagaat ttcct
2535825DNAArtificialsynthetic oligonucleotide primer 358aactacaact
tctccttaga cactt
2535925DNAArtificialsynthetic oligonucleotide primer 359gacactttgg
aatctaacca cttaa
2536025DNAArtificialsynthetic oligonucleotide primer 360ctgaagatca
atttctccca aggcc
2536125DNAArtificialsynthetic oligonucleotide primer 361ctcccaaggc
caagattgtc ctttt
2536225DNAArtificialsynthetic oligonucleotide primer 362ctcccatttc
ttgctagcta ttgca
2536325DNAArtificialsynthetic oligonucleotide primer 363gaagaacatt
attcatctct cctcc
2536425DNAArtificialsynthetic oligonucleotide primer 364ttttttcagt
cagttttgct cctgg
2536525DNAArtificialsynthetic oligonucleotide primer 365ccaccctttc
acaagcaaca gactc
25366408DNAHomo sapiensmisc_feature(68)..(68)n is a, c, g, or t
366gctgcctctg gtggatatgc ggaggtgggc cgagttcttt tggataaagg tgctgatgtt
60aatgcccntc cagttccctc ctcaagagat acagctttaa ccatagcagc agataaaggg
120cattacaaat tctgtgagct tcttattggc aggggagctc atattgatgt acgtaacaag
180aaggggaaca ctccattgtg gctagcagca aatggtggac acctcgatgt ggttcagtta
240ctggtgcaag caggtgcaga tgtggatgca gcagataacc gcaagataac tcctcttatg
300gcagcattta gaaagggtca tgtgaaggtg gtgcgctact tagtcaaaga agtcaatcag
360tttccatcag attctgaatg tatgagatac atagcaacca tcactgat
40836725DNAArtificialsynthetic oligonucleotide primer 367gctgcctctg
gtggatatgc ggagg
2536825DNAArtificialsynthetic oligonucleotide primer 368gaggtgggcc
gagttctttt ggata
2536925DNAArtificialsynthetic oligonucleotide primer 369agttccctcc
tcaagagata cagct
2537025DNAArtificialsynthetic oligonucleotide primer 370tgtgagcttc
ttattggcag gggag
2537125DNAArtificialsynthetic oligonucleotide primer 371ggaacactcc
attgtggcta gcagc
2537225DNAArtificialsynthetic oligonucleotide primer 372gtggacacct
cgatgtggtt cagtt
2537325DNAArtificialsynthetic oligonucleotide primer 373gcagataacc
gcaagataac tcctc
2537425DNAArtificialsynthetic oligonucleotide primer 374agataactcc
tcttatggca gcatt
2537525DNAArtificialsynthetic oligonucleotide primer 375gaaggtggtg
cgctacttag tcaaa
2537625DNAArtificialsynthetic oligonucleotide primer 376agaagtcaat
cagtttccat cagat
2537725DNAArtificialsynthetic oligonucleotide primer 377gagatacata
gcaaccatca ctgat
25378453DNAHomo sapiens 378taagccgaat atgtgggagt ccatgtcctg cagtgtggcc
tgatgtaatc aaactaccat 60atttcaacac catgaaacca aagaagcaat atcgtcgaaa
gttaagagaa gaatttgttt 120ttattcctgc agctgcgcta gacttatttg attacatgct
tgccttggat cctagtaagc 180gctgcactgc tgaacaggct cttcagtgcg agttcctccg
agatgtggaa ccctcaaaat 240gcctccacca gatctccctt tatggcaaga ttgtcatgag
ttatggagta aaaagcgaag 300aagacagaag cagatgggca tgactgatgt ttccaccatt
aaagccccca ggaaggactt 360gtctctgggc ttggatgaca gcagaaccaa cacaccccag
ggtgtgctgc catcttcaca 420gctgaaatct cagggcagct caaatgtggc acc
45337925DNAArtificialsynthetic oligonucleotide
primer 379taagccgaat atgtgggagt ccatg
2538025DNAArtificialsynthetic oligonucleotide primer 380gcagtgtggc
ctgatgtaat caaac
2538125DNAArtificialsynthetic oligonucleotide primer 381tcaaactacc
atatttcaac accat
2538225DNAArtificialsynthetic oligonucleotide primer 382ttcctgcagc
tgcgctagac ttatt
2538325DNAArtificialsynthetic oligonucleotide primer 383gcgctagact
tatttgatta catgc
2538425DNAArtificialsynthetic oligonucleotide primer 384tgccttggat
cctagtaagc gctgc
2538525DNAArtificialsynthetic oligonucleotide primer 385taagcgctgc
actgctgaac aggct
2538625DNAArtificialsynthetic oligonucleotide primer 386gaacaggctc
ttcagtgcga gttcc
2538725DNAArtificialsynthetic oligonucleotide primer 387caccagatct
ccctttatgg caaga
2538825DNAArtificialsynthetic oligonucleotide primer 388tggatgacag
cagaaccaac acacc
2538925DNAArtificialsynthetic oligonucleotide primer 389ctcagggcag
ctcaaatgtg gcacc
25390390DNAHomo sapiens 390gcagctaggt gagtttgttt tccgggtctg tcttaactgg
cagcttcctg tacatactgg 60tacttatttg ctgtaaacgt ctgtttcata catttgccat
gcagtgactg tgctcgaaag 120gtgaaatcaa tggtaaagaa gcctaggatt ttatggtatg
agaaactgat cgcaggattt 180tctgatccat agctattaat tgaaaacttc tgatagtgct
gtaggctcta tagtaggctt 240aagagtgagt cttatactat gaagccagcc acaagatact
aacaaatgta taaattgaaa 300agtaccaata ctttttgcac atagatcaaa atagagtgga
gaatttgggc tccaaaaatc 360aggttagtag gctcatttcc atgtgcttaa
39039125DNAArtificialsynthetic oligonucleotide
primer 391gcagctaggt gagtttgttt tccgg
2539225DNAArtificialsynthetic oligonucleotide primer 392ttttccgggt
ctgtcttaac tggca
2539325DNAArtificialsynthetic oligonucleotide primer 393taactggcag
cttcctgtac atact
2539425DNAArtificialsynthetic oligonucleotide primer 394ggtacttatt
tgctgtaaac gtctg
2539525DNAArtificialsynthetic oligonucleotide primer 395tttgccatgc
agtgactgtg ctcga
2539625DNAArtificialsynthetic oligonucleotide primer 396gattttctga
tccatagcta ttaat
2539725DNAArtificialsynthetic oligonucleotide primer 397aacttctgat
agtgctgtag gctct
2539825DNAArtificialsynthetic oligonucleotide primer 398gctgtaggct
ctatagtagg cttaa
2539925DNAArtificialsynthetic oligonucleotide primer 399gagtcttata
ctatgaagcc agcca
2540025DNAArtificialsynthetic oligonucleotide primer 400gaagccagcc
acaagatact aacaa
2540125DNAArtificialsynthetic oligonucleotide primer 401agtaggctca
tttccatgtg cttaa
25402512DNAHomo sapiens 402gttgacgatt ttaactggct ggcccgggat atggcctccc
caaactggag tattcttcct 60gaagaggagc gaaatatcca gtgggactaa gcagttgtca
ctctgttctt cactcctacc 120aaatactttc cacgttggac tttccccctt attgggtctc
gaagtttact tattgtcaca 180ctgtgtatgt tttcagcatt ttaaggctag agattgtaat
gggctcctac ttgtaatttc 240cattaaattc gtaacaggta taacactaaa gcatttttgc
tattttcgtc atgcctttga 300gactgagtct tactccgtcc cccagcgtgg tggcgcgctg
ggattacagg cgcgcgccac 360cacgcgaact cgtattttta gtagagacgg ggtttcgcca
tgttgtccgg gctgctctcg 420aactcctgac ctcaggtgat ccacccgctt cagcttccca
aagtgctggc attacaggcg 480tgagccacca cgccagggct ttatttattt at
51240325DNAArtificialsynthetic oligonucleotide
primer 403gttgacgatt ttaactggct ggccc
2540425DNAArtificialsynthetic oligonucleotide primer 404aactggctgg
cccgggatat ggcct
2540525DNAArtificialsynthetic oligonucleotide primer 405atggcctccc
caaactggag tattc
2540625DNAArtificialsynthetic oligonucleotide primer 406gactaagcag
ttgtcactct gttct
2540725DNAArtificialsynthetic oligonucleotide primer 407ctcctaccaa
atactttcca cgttg
2540825DNAArtificialsynthetic oligonucleotide primer 408gaagtttact
tattgtcaca ctgtg
2540925DNAArtificialsynthetic oligonucleotide primer 409gggctcctac
ttgtaatttc catta
2541025DNAArtificialsynthetic oligonucleotide primer 410tttgctattt
tcgtcatgcc tttga
2541125DNAArtificialsynthetic oligonucleotide primer 411cccccagcgt
ggtggcgcgc tggga
2541225DNAArtificialsynthetic oligonucleotide primer 412ccaccacgcg
aactcgtatt tttag
2541325DNAArtificialsynthetic oligonucleotide primer 413ccacgccagg
gctttattta tttat
25414210DNAHomo sapiens 414gtcacgtgtc agaggacaca ctcgggagaa accttcatgg
agtgagagta aggtgttggc 60tggaagtggc cccttaagag atacttggag tcaaatctat
ccactgtacg cccaccccac 120tcttgttcta agagctttgg ggacagtctt ttgacccctt
acattccttt agatgtgaag 180atgacagaga tctaacttct gagagcagag
21041525DNAArtificialsynthetic oligonucleotide
primer 415gtcacgtgtc agaggacaca ctcgg
2541625DNAArtificialsynthetic oligonucleotide primer 416cacactcggg
agaaaccttc atgga
2541725DNAArtificialsynthetic oligonucleotide primer 417tcgggagaaa
ccttcatgga gtgag
2541825DNAArtificialsynthetic oligonucleotide primer 418catggagtga
gagtaaggtg ttggc
2541925DNAArtificialsynthetic oligonucleotide primer 419tggctggaag
tggcccctta agaga
2542025DNAArtificialsynthetic oligonucleotide primer 420gtggcccctt
aagagatact tggag
2542125DNAArtificialsynthetic oligonucleotide primer 421gagatacttg
gagtcaaatc tatcc
2542225DNAArtificialsynthetic oligonucleotide primer 422gagtcaaatc
tatccactgt acgcc
2542325DNAArtificialsynthetic oligonucleotide primer 423ccaccccact
cttgttctaa gagct
2542425DNAArtificialsynthetic oligonucleotide primer 424tgacccctta
cattccttta gatgt
2542525DNAArtificialsynthetic oligonucleotide primer 425agagatctaa
cttctgagag cagag
25426520DNAHomo sapiens 426tgcagggttt ggcttgtggg ctgcttgctg ctcatctgat
ttttgtccca gtagtccctg 60cgttcttcat tcaacccctt ctgggacttc agctcagaga
gcaccatccc gggggtcagg 120gcctccccac aggagccctg cagtgtggta gcgccatggc
tgtctcaaac caagcaaagg 180aaggaccctg aggccttcac gctaaccatc ctcgagcaac
tgctgttgga aggcctccct 240gggcctggcc cccaccctct gccacccagt cctcccagct
gccatgtttc aaagacgacc 300tttacctcct gcctttggat tgactctgca tttgaccacg
gactccagtc tgtgtgtagg 360gagagagctg agtaggaggc ctccactccg gatcgaggcc
tgtatagggc tcgtttcccc 420acacatgcct atttctgaag aggcttctgt cttatttgaa
ggccagccca cacccagcta 480ctttaacacc aggtttatgg aaaatgtcag gccttcccca
52042725DNAArtificialsynthetic oligonucleotide
primer 427tgcagggttt ggcttgtggg ctgct
2542825DNAArtificialsynthetic oligonucleotide primer 428gctgctcatc
tgatttttgt cccag
2542925DNAArtificialsynthetic oligonucleotide primer 429cccttctggg
acttcagctc agaga
2543025DNAArtificialsynthetic oligonucleotide primer 430gagcaactgc
tgttggaagg cctcc
2543125DNAArtificialsynthetic oligonucleotide primer 431agctgccatg
tttcaaagac gacct
2543225DNAArtificialsynthetic oligonucleotide primer 432accacggact
ccagtctgtg tgtag
2543325DNAArtificialsynthetic oligonucleotide primer 433gagagctgag
taggaggcct ccact
2543425DNAArtificialsynthetic oligonucleotide primer 434cactccggat
cgaggcctgt atagg
2543525DNAArtificialsynthetic oligonucleotide primer 435tgtcttattt
gaaggccagc ccaca
2543625DNAArtificialsynthetic oligonucleotide primer 436acacccagct
actttaacac caggt
2543725DNAArtificialsynthetic oligonucleotide primer 437tatggaaaat
gtcaggcctt cccca
25438538DNAHomo sapiens 438ccacgagtag cagccgcaac tggacggagg acatggaagg
aggcatctcg tccccggtga 60agaagacaga gatggacaag tcaccattca acagcccgtc
cccccaggac tctccccgcc 120tctccagctt cacccagcac caccggcccg tcatcgccgt
gcacagcggg atcgcccgga 180gcccacaccc gtcctccgct ctgcatttcc ctacgacgtc
catcctaccc cagacggcct 240ccacctactt cccccacacg gccatccgct acccacctca
tctcaacccc caggacccgc 300tcaaagatct tgtctcgctg gcctgcgacc cagccagcca
gcaacctgga ccgtcctggt 360atctgggata gcaaaggtct tcttccctcg ccccttctcc
atcgtcccag gaatcccagg 420gggcagcaca gccggccccc ggcccacgtt ttcggtggaa
aattagagtg aacaagaaca 480cccctgccga ctcccagccc ggccaaaaag acaaaacaca
tagacgcaca cactcagg 53843925DNAArtificialsynthetic oligonucleotide
primer 439ccacgagtag cagccgcaac tggac
2544025DNAArtificialsynthetic oligonucleotide primer 440gtagcagccg
caactggacg gagga
2544125DNAArtificialsynthetic oligonucleotide primer 441gcaactggac
ggaggacatg gaagg
2544225DNAArtificialsynthetic oligonucleotide primer 442acatggaagg
aggcatctcg tcccc
2544325DNAArtificialsynthetic oligonucleotide primer 443gcatctcgtc
cccggtgaag aagac
2544425DNAArtificialsynthetic oligonucleotide primer 444tctcgtcccc
ggtgaagaag acaga
2544525DNAArtificialsynthetic oligonucleotide primer 445tggacaagtc
accattcaac agccc
2544625DNAArtificialsynthetic oligonucleotide primer 446gtcctggtat
ctgggatagc aaagg
2544725DNAArtificialsynthetic oligonucleotide primer 447ctgggatagc
aaaggtcttc ttccc
2544825DNAArtificialsynthetic oligonucleotide primer 448tagagtgaac
aagaacaccc ctgcc
2544925DNAArtificialsynthetic oligonucleotide primer 449aaacacatag
acgcacacac tcagg
25450534DNAHomo sapiensmisc_feature(423)..(423)n is a, c, g, or t
450tattcagcca aaattaccgt tttagaccag aatgaataga ctacactgat aaaatgtact
60ggataatgcc acatcctata tggtgttata gaaatagtgc aaggaaagta catttgtttg
120cctgtctttt cattttgtac attcttccca ttctgtattc ttgtacaaaa gatctcattg
180aaaatttaaa gtcatcataa tttgttgcca taaatatgta agtgtcaata ccaaaatgtc
240tgagtaactt cttaaatccc tgttctagca aactaatatt ggttcatgtg cttgtgtata
300tgtaaatctt aaattatgtg aactattaaa tagaccctac tgtactgtgc tttggacatt
360tgaattaatg taaatatatg taatctgtga cttgatattt tgttttattt ggctatttaa
420aancataaat ctaaaatgtc ttatgttatc agattatgct attttgtata aagcacnnnn
480nnnnncaann nnnnnncnaa annanaaant cactggaccg acgttttaac aacg
53445125DNAArtificialsynthetic oligonucleotide primer 451tattcagcca
aaattaccgt tttag
2545225DNAArtificialsynthetic oligonucleotide primer 452aatgccacat
cctatatggt gttat
2545325DNAArtificialsynthetic oligonucleotide primer 453gaaagtacat
ttgtttgcct gtctt
2545425DNAArtificialsynthetic oligonucleotide primer 454ttcattttgt
acattcttcc cattc
2545525DNAArtificialsynthetic oligonucleotide primer 455aagtcatcat
aatttgttgc cataa
2545625DNAArtificialsynthetic oligonucleotide primer 456gagtaacttc
ttaaatccct gttct
2545725DNAArtificialsynthetic oligonucleotide primer 457aaatccctgt
tctagcaaac taata
2545825DNAArtificialsynthetic oligonucleotide primer 458atattggttc
atgtgcttgt gtata
2545925DNAArtificialsynthetic oligonucleotide primer 459aatagaccct
actgtactgt gcttt
2546025DNAArtificialsynthetic oligonucleotide primer 460actgtactgt
gctttggaca tttga
2546125DNAArtificialsynthetic oligonucleotide primer 461tcactggacc
gacgttttaa caacg
25462482DNAHomo sapiens 462cttcccggat ttggcaggag ctggaggctg aggaggagcc
ggtgcctgag gggtctgggc 60ccctgggtcc ctgggggccc caagactggg tgggccccct
accacgtggc cctaccacac 120cagatgaggg ctgcctccgg tactttgtcc tgggcaccgt
ggcggctttg gtggccctcg 180tgctcaacgt gttctatcct ctggtatccc agagtcgctg
gagatgagct cgcctgcagg 240cagctgctgt gagctggcct acctgcctgc cccaggccat
gcctgccttt gttgtgggga 300acacctctgg gctttgggcc tcagcttatg catctggtgg
gagagggtgg ggaggttgtg 360gcccctgcag gggcagagta tcctagggtg tgtatccatc
tggctgtctg tccattcatc 420ctgctgctct gacccttggc ctcaggcttg gccctgccca
agctacttcc tgtacttaaa 480ag
48246325DNAArtificialsynthetic oligonucleotide
primer 463cttcccggat ttggcaggag ctgga
2546425DNAArtificialsynthetic oligonucleotide primer 464tgttctatcc
tctggtatcc cagag
2546525DNAArtificialsynthetic oligonucleotide primer 465tctggtatcc
cagagtcgct ggaga
2546625DNAArtificialsynthetic oligonucleotide primer 466agagtcgctg
gagatgagct cgcct
2546725DNAArtificialsynthetic oligonucleotide primer 467gcctcagctt
atgcatctgg tggga
2546825DNAArtificialsynthetic oligonucleotide primer 468tcagcttatg
catctggtgg gagag
2546925DNAArtificialsynthetic oligonucleotide primer 469gcccctgcag
gggcagagta tccta
2547025DNAArtificialsynthetic oligonucleotide primer 470ggggcagagt
atcctagggt gtgta
2547125DNAArtificialsynthetic oligonucleotide primer 471gagtatccta
gggtgtgtat ccatc
2547225DNAArtificialsynthetic oligonucleotide primer 472ctagggtgtg
tatccatctg gctgt
2547325DNAArtificialsynthetic oligonucleotide primer 473ccaagctact
tcctgtactt aaaag 2547488DNAHomo
sapiens 474ccggaggcga ccgtgagttg ctacagtggc tggagagacg acatctgctc
catgggctgg 60tggccgacag taatctcacg ctgggacc
8847525DNAArtificialsynthetic oligonucleotide primer
475ccggaggcga ccgtgagttg ctaca
2547625DNAArtificialsynthetic oligonucleotide primer 476gcgaccgtga
gttgctacag tggct
2547725DNAArtificialsynthetic oligonucleotide primer 477gaccgtgagt
tgctacagtg gctgg
2547825DNAArtificialsynthetic oligonucleotide primer 478cgtgagttgc
tacagtggct ggaga
2547925DNAArtificialsynthetic oligonucleotide primer 479gctggagaga
cgacatctgc tccat
2548025DNAArtificialsynthetic oligonucleotide primer 480ggagagacga
catctgctcc atggg
2548125DNAArtificialsynthetic oligonucleotide primer 481ccatgggctg
gtggccgaca gtaat
2548225DNAArtificialsynthetic oligonucleotide primer 482atgggctggt
ggccgacagt aatct
2548325DNAArtificialsynthetic oligonucleotide primer 483ctggtggccg
acagtaatct cacgc
2548425DNAArtificialsynthetic oligonucleotide primer 484gccgacagta
atctcacgct gggac
2548525DNAArtificialsynthetic oligonucleotide primer 485ccgacagtaa
tctcacgctg ggacc
25486490DNAHomo sapiensmisc_feature(195)..(198)n is a, c, g, or t
486gttacagcca catcgtgggt gcagcagggt gtaggcgatt ccaaagagca gatgattcaa
60attcgtgtgc gatgggtaca gagagatacg cttggctcca gacccacgcg tctccctgtt
120tccctctctt gtggtggggg cacagtagcc ttcgtgtgtc ttcctctagc acagacccct
180gagctgaggg taggnnnnat gaaggcagca cgagggacgc tcccacctcc cactctatcc
240tcaagaacct cggccaatga acgggccact cttgctagtt ggggtactga tcacttcctg
300tcctctctgt gaggttggag atgtggcctt ggaacacacc ttcgtgaccc ccaggagttg
360ctgtaaatcc atcggaagtg tgtcctgtga cggacgcgat gtgtctccnn ncgtcatcca
420ccagaaggta actggagatt ttgtgtgttg ccttgacaga cccctgaggg ctggtgactt
480catttttatt
49048725DNAArtificialsynthetic oligonucleotide primer 487gttacagcca
catcgtgggt gcagc
2548825DNAArtificialsynthetic oligonucleotide primer 488ggtgcagcag
ggtgtaggcg attcc
2548925DNAArtificialsynthetic oligonucleotide primer 489cagagagata
cgcttggctc cagac
2549025DNAArtificialsynthetic oligonucleotide primer 490gcacagaccc
ctgagctgag ggtag
2549125DNAArtificialsynthetic oligonucleotide primer 491atgaaggcag
cacgagggac gctcc
2549225DNAArtificialsynthetic oligonucleotide primer 492gaacctcggc
caatgaacgg gccac
2549325DNAArtificialsynthetic oligonucleotide primer 493ggccactctt
gctagttggg gtact
2549425DNAArtificialsynthetic oligonucleotide primer 494ttcctgtcct
ctctgtgagg ttgga
2549525DNAArtificialsynthetic oligonucleotide primer 495ctggagattt
tgtgtgttgc cttga
2549625DNAArtificialsynthetic oligonucleotide primer 496ccttgacaga
cccctgaggg ctggt
2549725DNAArtificialsynthetic oligonucleotide primer 497gagggctggt
gacttcattt ttatt
25498486DNAHomo sapiens 498gacgatcagt cagtacatct ggagagacag gaggacctgg
aggactgctg tcagctgctc 60agccacatcc tggaggtgct gtacaggaag gacgtggggc
caacccagag gcacgtccag 120attatcatgg agaaacttct ccggaccgtg aaccgaaccg
tcatttccat gggacgagat 180tctgaactca ttgtaagtgc ttggtgacat atgtttggat
atttaactgg ggctgacagc 240atccttctcc aactgctgtt tgaacatagc ttattatact
gcaatgtagt gagcagttga 300gatacagctt ggtatataaa atgtcctcat tttccaaatg
aatgtcaaag ttgaagggta 360agcaaaccaa ctttaaagat ggaaacattt ggctcttgtt
ttctcattac ttacttatag 420caaaagacat gtattttctg ctgagtcgtc attcttctgg
cagtttctcc atagtgttta 480cactta
48649925DNAArtificialsynthetic oligonucleotide
primer 499gacgatcagt cagtacatct ggaga
2550025DNAArtificialsynthetic oligonucleotide primer 500gaactcattg
taagtgcttg gtgac
2550125DNAArtificialsynthetic oligonucleotide primer 501taactggggc
tgacagcatc cttct
2550225DNAArtificialsynthetic oligonucleotide primer 502ctccaactgc
tgtttgaaca tagct
2550325DNAArtificialsynthetic oligonucleotide primer 503gaacatagct
tattatactg caatg
2550425DNAArtificialsynthetic oligonucleotide primer 504gtgagcagtt
gagatacagc ttggt
2550525DNAArtificialsynthetic oligonucleotide primer 505agcttggtat
ataaaatgtc ctcat
2550625DNAArtificialsynthetic oligonucleotide primer 506atggaaacat
ttggctcttg ttttc
2550725DNAArtificialsynthetic oligonucleotide primer 507ttctcattac
ttacttatag caaaa
2550825DNAArtificialsynthetic oligonucleotide primer 508acatgtattt
tctgctgagt cgtca
2550925DNAArtificialsynthetic oligonucleotide primer 509agtttctcca
tagtgtttac actta
25510487DNAHomo sapiens 510ctggaagact gttgtggcct ctcagttctc tttgagtctg
actgactgtg gccagtccct 60ggactggtag ctgctggagg ccttcttgtt tctccagtcc
ctggaagctg agctctatgt 120gtatttgatg acattgtcag ctcttaccaa acgtcaagac
ctcttcctgc ttgaccactc 180gcacatggct ctaggcttct cctgctgagt cctggtcttg
gcctgtgaat gtgcctcgtt 240catccctggt gcttgagccc ctcaagctcc agtcaatgat
ccagtccttc ccctttgaag 300ttttctgctc tactttcctt ggcagcagcc tgtgaactac
tcaaaagagt ccccttgggt 360ttggaattat cagtggcttt gccactagta aatgtgtgat
cttcggcaag taacctaacc 420tagggacatc agtttactca tctgcgaagt ggggataata
aaacctacct cagggttgct 480tcaagga
48751125DNAArtificialsynthetic oligonucleotide
primer 511ctggaagact gttgtggcct ctcag
2551225DNAArtificialsynthetic oligonucleotide primer 512gcctctcagt
tctctttgag tctga
2551325DNAArtificialsynthetic oligonucleotide primer 513tccctggact
ggtagctgct ggagg
2551425DNAArtificialsynthetic oligonucleotide primer 514gctggaggcc
ttcttgtttc tccag
2551525DNAArtificialsynthetic oligonucleotide primer 515gacattgtca
gctcttacca aacgt
2551625DNAArtificialsynthetic oligonucleotide primer 516ggtcttggcc
tgtgaatgtg cctcg
2551725DNAArtificialsynthetic oligonucleotide primer 517aagctccagt
caatgatcca gtcct
2551825DNAArtificialsynthetic oligonucleotide primer 518ttgaagtttt
ctgctctact ttcct
2551925DNAArtificialsynthetic oligonucleotide primer 519ctttccttgg
cagcagcctg tgaac
2552025DNAArtificialsynthetic oligonucleotide primer 520gggacatcag
tttactcatc tgcga
2552125DNAArtificialsynthetic oligonucleotide primer 521acctacctca
gggttgcttc aagga
25522468DNAHomo sapiens 522aactgaggca gcatgcacgg aggcggggtc aggggagacg
aggccaagct gaggaggtgc 60tgcaggtccc gtctggctcc agcccttgtc agattcaccc
agggtgaagc cttcaaagct 120ttttgctacc aaagcccact caccctttga gctacagaac
actttgctag gagatactct 180tctgcctcct agacctgttc tttccatctt tagaaacatc
agtttttgta tggaagccac 240cgggagattt ctggatggtg gtgcatccgt gaatgcgctg
atcgtttctt ccagttagag 300tcttcatctg tccgacaagt tcactcgcct cggttgcgga
cctaggacca tttctctgca 360ggccacttac cttcccctga gtcaggctta ctaatgctgc
cctcactgcc tctttgcagt 420aggggagaga gcagagaagt acaggtcatc tgctgggatc
tagttttc 46852325DNAArtificialsynthetic oligonucleotide
primer 523aactgaggca gcatgcacgg aggcg
2552425DNAArtificialsynthetic oligonucleotide primer 524aggggagacg
aggccaagct gagga
2552525DNAArtificialsynthetic oligonucleotide primer 525agcccttgtc
agattcaccc agggt
2552625DNAArtificialsynthetic oligonucleotide primer 526ttgctaggag
atactcttct gcctc
2552725DNAArtificialsynthetic oligonucleotide primer 527ggaagccacc
gggagatttc tggat
2552825DNAArtificialsynthetic oligonucleotide primer 528tgaatgcgct
gatcgtttct tccag
2552925DNAArtificialsynthetic oligonucleotide primer 529ccagttagag
tcttcatctg tccga
2553025DNAArtificialsynthetic oligonucleotide primer 530tcatctgtcc
gacaagttca ctcgc
2553125DNAArtificialsynthetic oligonucleotide primer 531tcaggcttac
taatgctgcc ctcac
2553225DNAArtificialsynthetic oligonucleotide primer 532ccctcactgc
ctctttgcag taggg
2553325DNAArtificialsynthetic oligonucleotide primer 533ggtcatctgc
tgggatctag ttttc
25534533DNAHomo sapiens 534atcctacaac ccaccttgaa ggtataactg gatccagaga
gggaaggact gacaagaagg 60aattattcag aaaaacactg acagatgttt tataaattgt
acagaaaaat agttaaaaat 120gcaataggtt gaagttttcc agatatgttt ctctctgaaa
ttactgtgaa tatttaacaa 180acacttactt gatctatgtt atgaaataag tagcaaattg
ccagcaaaat gtcttgtacc 240ttttctaaag tgtattttct gatgtgaact tccttcccct
tacttgctag gtttcaataa 300tttaaaagag tcaaacacta taaatgagta agttgacgat
gttttaagat tgcacctggc 360agtgtgcctt tttgcaacaa atatttacct ggcagtgtgc
ctttttgcaa caaatattta 420ctttgcactt ggagctgctt ttaattttag caaaatgttt
tatgcaaggc acaataggaa 480gtcagttctc ctgcacttcc tcctcatgta gtctggagta
ctttctaaag ggc 53353525DNAArtificialsynthetic oligonucleotide
primer 535atcctacaac ccaccttgaa ggtat
2553625DNAArtificialsynthetic oligonucleotide primer 536accttgaagg
tataactgga tccag
2553725DNAArtificialsynthetic oligonucleotide primer 537gatatgtttc
tctctgaaat tactg
2553825DNAArtificialsynthetic oligonucleotide primer 538taacaaacac
ttacttgatc tatgt
2553925DNAArtificialsynthetic oligonucleotide primer 539gcaaaatgtc
ttgtaccttt tctaa
2554025DNAArtificialsynthetic oligonucleotide primer 540gttttaagat
tgcacctggc agtgt
2554125DNAArtificialsynthetic oligonucleotide primer 541gcacttggag
ctgcttttaa tttta
2554225DNAArtificialsynthetic oligonucleotide primer 542gcaaaatgtt
ttatgcaagg cacaa
2554325DNAArtificialsynthetic oligonucleotide primer 543ggcacaatag
gaagtcagtt ctcct
2554425DNAArtificialsynthetic oligonucleotide primer 544cacttcctcc
tcatgtagtc tggag
2554525DNAArtificialsynthetic oligonucleotide primer 545tagtctggag
tactttctaa agggc
25546502DNAHomo sapiens 546tggctccgag actttcatga tcccattgtc gaggttgagg
tgtccgtgtt cccggccggg 60acgaccacag cctccagccc ccagagctcc atgggcacct
caggtcctcc cacgaagctg 120cccgtgcaca cctggcccag cgtgaccaga aaggacagcc
ccgaacccag cccacaccct 180ggctccctgt tcagcaatgt ccgcttcctg ctcctggtcc
tcttggagct gcccctgctc 240ctgagcatgc tgggtgccgt cctctgggtg aacagacctc
agagaagctc tagaagcagg 300cagaattggc ccaagggtga gaaccagtag catctgctgt
ccatcaaggc cctgtgctgc 360aacagagccc ctctggggac tggaatgacc tcctgaccat
caaggcctgc aacagagccc 420ctctggggga ctggaatgac ctcctgacca ctccctcccg
ggctgctctc tccaacatct 480cctggaatcc tttgtgagcc tc
50254725DNAArtificialsynthetic oligonucleotide
primer 547tggctccgag actttcatga tccca
2554825DNAArtificialsynthetic oligonucleotide primer 548atgatcccat
tgtcgaggtt gaggt
2554925DNAArtificialsynthetic oligonucleotide primer 549ccagcgtgac
cagaaaggac agccc
2555025DNAArtificialsynthetic oligonucleotide primer 550cgtcctctgg
gtgaacagac ctcag
2555125DNAArtificialsynthetic oligonucleotide primer 551ggcccaaggg
tgagaaccag tagca
2555225DNAArtificialsynthetic oligonucleotide primer 552gaaccagtag
catctgctgt ccatc
2555325DNAArtificialsynthetic oligonucleotide primer 553tcaaggccct
gtgctgcaac agagc
2555425DNAArtificialsynthetic oligonucleotide primer 554acagagcccc
tctggggact ggaat
2555525DNAArtificialsynthetic oligonucleotide primer 555tgaccatcaa
ggcctgcaac agagc
2555625DNAArtificialsynthetic oligonucleotide primer 556cagagcccct
ctgggggact ggaat
2555725DNAArtificialsynthetic oligonucleotide primer 557tctcctggaa
tcctttgtga gcctc
25558462DNAHomo sapiens 558gtcatgaggc agctttcatc acaccctttt aacatttatc
taaaagaatt taaattcttt 60ttcaaaaatt acactacaag tttataagcc caaatggctc
tgtgaaatca gaagtgcaaa 120ggtgtgcaaa cttgtatctg aagacctacc agggacaagc
aggtaagagc tgatgtgagt 180gtgtgtgatg ggatctgtaa ggaactggaa cacacatgtc
ctatccaaag gaatcagctg 240cagctgcttg ttgtcaagta taaagtcagg acctggcttg
gctttaaccg tttttcaaga 300aaactggaaa tctggatttt cagcgaacat gcctgatttt
aaaaggttga ctcaagtttt 360tacaaaatac tatgtgggac acctcaaata catacctact
gactgatgac aaacccagga 420gtttgtgtgt cttttataaa aagtttgccc tggatgtcat
at 46255925DNAArtificialsynthetic oligonucleotide
primer 559gtcatgaggc agctttcatc acacc
2556025DNAArtificialsynthetic oligonucleotide primer 560tcatcacacc
cttttaacat ttatc
2556125DNAArtificialsynthetic oligonucleotide primer 561aaaggtgtgc
aaacttgtat ctgaa
2556225DNAArtificialsynthetic oligonucleotide primer 562gtatctgaag
acctaccagg gacaa
2556325DNAArtificialsynthetic oligonucleotide primer 563ggaacacaca
tgtcctatcc aaagg
2556425DNAArtificialsynthetic oligonucleotide primer 564ctatccaaag
gaatcagctg cagct
2556525DNAArtificialsynthetic oligonucleotide primer 565taaagtcagg
acctggcttg gcttt
2556625DNAArtificialsynthetic oligonucleotide primer 566tctggatttt
cagcgaacat gcctg
2556725DNAArtificialsynthetic oligonucleotide primer 567ggacacctca
aatacatacc tactg
2556825DNAArtificialsynthetic oligonucleotide primer 568actgactgat
gacaaaccca ggagt
2556925DNAArtificialsynthetic oligonucleotide primer 569aaaaagtttg
ccctggatgt catat
25570356DNAHomo sapiens 570gatattcggt tactacacgt gcacctgtag cagtatttct
agaaacatcc ctttttgttg 60agaacctccc ttgaatgtct gtcacactca cacctgacgg
gatggttact ggattagaga 120gtagatttgg cacatctttt cttagtcttt tgattcaaat
tcaaaactta acagcacaaa 180ccaggtcaga gttactttcg gttagaattt attgccattt
attccttttt ataaatttct 240atagattata ctgttatttt tatgttattg gcctagagct
acacgtatat gggtttgtcc 300tgagtccgtt ttcaaatgac cttgtgatag ggaaatggtt
ttgtccatgt tcttgg 35657125DNAArtificialsynthetic oligonucleotide
primer 571gatattcggt tactacacgt gcacc
2557225DNAArtificialsynthetic oligonucleotide primer 572acacgtgcac
ctgtagcagt atttc
2557325DNAArtificialsynthetic oligonucleotide primer 573ttgagaacct
cccttgaatg tctgt
2557425DNAArtificialsynthetic oligonucleotide primer 574cacactcaca
cctgacggga tggtt
2557525DNAArtificialsynthetic oligonucleotide primer 575ggcacatctt
ttcttagtct tttga
2557625DNAArtificialsynthetic oligonucleotide primer 576aacttaacag
cacaaaccag gtcag
2557725DNAArtificialsynthetic oligonucleotide primer 577ccaggtcaga
gttactttcg gttag
2557825DNAArtificialsynthetic oligonucleotide primer 578gttattggcc
tagagctaca cgtat
2557925DNAArtificialsynthetic oligonucleotide primer 579gtatatgggt
ttgtcctgag tccgt
2558025DNAArtificialsynthetic oligonucleotide primer 580ctgagtccgt
tttcaaatga ccttg
2558125DNAArtificialsynthetic oligonucleotide primer 581gaaatggttt
tgtccatgtt cttgg
25582504DNAHomo sapiens 582cacactggag ggcacacacg taccccgcac ccagcaactc
ctgacagaaa gctcctccca 60cccaaatggg ccaggcccca gcatgatcct gaaatctgca
tccgccgtgg tttgtattca 120ttgtgcatat cagggatacc ctcaagctgg actgtgggtt
ccaaattact catagaggag 180aaaaccagag aaagatgaag aggaggagtt aggtctattt
gaaatgccag gggctcgctg 240tgaggaatag gtaaaaaaaa acttttcacc agcctttgag
agactagact gaccccaccc 300ttccttcagt gagcagaatc actgtggtca gtctcctgtc
ccagcttcag ttcatgaata 360ctcctgttcc tccagtttcc catcctttgt ccctgctgtc
ccccactttt aaagatgggt 420ctcaacccct ccccaccacg tcatgatgga tggggcaagg
tggtggggac taggggagcc 480tggtatacat gcggcttcat tgcc
50458325DNAArtificialsynthetic oligonucleotide
primer 583cacactggag ggcacacacg taccc
2558425DNAArtificialsynthetic oligonucleotide primer 584caactcctga
cagaaagctc ctccc
2558525DNAArtificialsynthetic oligonucleotide primer 585gcatgatcct
gaaatctgca tccgc
2558625DNAArtificialsynthetic oligonucleotide primer 586tgcatccgcc
gtggtttgta ttcat
2558725DNAArtificialsynthetic oligonucleotide primer 587gccaggggct
cgctgtgagg aatag
2558825DNAArtificialsynthetic oligonucleotide primer 588aaaacttttc
accagccttt gagag
2558925DNAArtificialsynthetic oligonucleotide primer 589tttgagagac
tagactgacc ccacc
2559025DNAArtificialsynthetic oligonucleotide primer 590acccttcctt
cagtgagcag aatca
2559125DNAArtificialsynthetic oligonucleotide primer 591gcagaatcac
tgtggtcagt ctcct
2559225DNAArtificialsynthetic oligonucleotide primer 592cagttcatga
atactcctgt tcctc
2559325DNAArtificialsynthetic oligonucleotide primer 593ctggtataca
tgcggcttca ttgcc
25594423DNAHomo sapiens 594ataagcgaac ggcaggtgtc tacagaagaa gcccaagctt
ggtgcaggga caacggcgac 60tatccttatt ttgaaacaag tgcaaaagat gccacaaatg
tggcagcagc ctttgaggaa 120gcggttcgaa gagttcttgc taccgaggat aggtcagatc
atttgattca gacagacaca 180gtcaatcttc accgaaagcc caagcctagc tcatcttgct
gttgattgtt agattgttga 240tgcattctaa ccaactcaca catatacaca aaatcaacat
ggggatggag aagagaatta 300gcgtttgcag cagtgtatca tctactaata aaattaaact
aatgttgctg cttcattagt 360tggtgggaga agggacacat ccactcttgg aggaatatat
ttactcaata atggcacctt 420aca
42359525DNAArtificialsynthetic oligonucleotide
primer 595ataagcgaac ggcaggtgtc tacag
2559625DNAArtificialsynthetic oligonucleotide primer 596caagcttggt
gcagggacaa cggcg
2559725DNAArtificialsynthetic oligonucleotide primer 597gacaacggcg
actatcctta ttttg
2559825DNAArtificialsynthetic oligonucleotide primer 598ggaagcggtt
cgaagagttc ttgct
2559925DNAArtificialsynthetic oligonucleotide primer 599gagttcttgc
taccgaggat aggtc
2560025DNAArtificialsynthetic oligonucleotide primer 600cacagtcaat
cttcaccgaa agccc
2560125DNAArtificialsynthetic oligonucleotide primer 601gatgcattct
aaccaactca cacat
2560225DNAArtificialsynthetic oligonucleotide primer 602gcgtttgcag
cagtgtatca tctac
2560325DNAArtificialsynthetic oligonucleotide primer 603gttgctgctt
cattagttgg tggga
2560425DNAArtificialsynthetic oligonucleotide primer 604agaagggaca
catccactct tggag
2560525DNAArtificialsynthetic oligonucleotide primer 605atttactcaa
taatggcacc ttaca
25606436DNAHomo sapiens 606ctgccatcct tgactttgaa ctaatgataa agtaatgatc
tcaaactatg acagaaaagt 60aatgtaaaat ccatccaatc tattatttct ctaattatgc
aattagcctc atagttatta 120tccagaggac ccaactgaac tgaactaatc cttctggcag
attcaaatcg tttatttcac 180acgctgttct aatggcactt atcattagaa tcttaccttg
tgcagtcatc agaaattcca 240gcgtactata atgaaaacat ccttgttttg aaaacctaaa
agacaggctc tgtatatata 300tatacttaag aatatgctga cttcacttat tagtcttagg
gatttatttt caattaatat 360taattttcta caaataattt tagtgtcatt tccatttggg
gatattgtca tatcagcaca 420tattttctgt ttggaa
43660725DNAArtificialsynthetic oligonucleotide
primer 607ctgccatcct tgactttgaa ctaat
2560825DNAArtificialsynthetic oligonucleotide primer 608aaaatccatc
caatctatta tttct
2560925DNAArtificialsynthetic oligonucleotide primer 609atgcaattag
cctcatagtt attat
2561025DNAArtificialsynthetic oligonucleotide primer 610agaggaccca
actgaactga actaa
2561125DNAArtificialsynthetic oligonucleotide primer 611tgaactaatc
cttctggcag attca
2561225DNAArtificialsynthetic oligonucleotide primer 612aatcgtttat
ttcacacgct gttct
2561325DNAArtificialsynthetic oligonucleotide primer 613cacgctgttc
taatggcact tatca
2561425DNAArtificialsynthetic oligonucleotide primer 614cattagaatc
ttaccttgtg cagtc
2561525DNAArtificialsynthetic oligonucleotide primer 615cttgtgcagt
catcagaaat tccag
2561625DNAArtificialsynthetic oligonucleotide primer 616ttagtgtcat
ttccatttgg ggata
2561725DNAArtificialsynthetic oligonucleotide primer 617atcagcacat
attttctgtt tggaa
25618556DNAHomo sapiens 618ggagacttga gcttgaccta aggatatgca ttaaccactc
tacagactcc cactcagtac 60tgtacagggt ggctgtggtc ctagaagttc agtttttact
gaggaaatat ttccattaac 120agcaattatt atattgaagg ctttaataaa ggccacagga
gacattacta tagcatagat 180tgtcaaatgt aaatttactg agcgtgtttt ataaaaaact
cacaggtgtt tgaggccaaa 240acagatttta gacttacctt gaacggataa gaatctatag
ttcactgaca cagtaaaatt 300aactctgtgg gtgggggcgg ggggcatagc tctaatctaa
tatataaaat gtgtgatgaa 360tcaacaagat ttccacaatt cttctgtcaa gcttactaca
gtgaaagaat gggattggca 420agtaacttct gacttactgt cagttgtact tctgctccat
agacatcagt attctgccat 480catttttgat gactacctca gaacataaaa aggaacgtat
atcacataat tccagtcaca 540gtttttggtt cctctt
55661925DNAArtificialsynthetic oligonucleotide
primer 619ggagacttga gcttgaccta aggat
2562025DNAArtificialsynthetic oligonucleotide primer 620atgcattaac
cactctacag actcc
2562125DNAArtificialsynthetic oligonucleotide primer 621ggctgtggtc
ctagaagttc agttt
2562225DNAArtificialsynthetic oligonucleotide primer 622aggccacagg
agacattact atagc
2562325DNAArtificialsynthetic oligonucleotide primer 623cggggggcat
agctctaatc taata
2562425DNAArtificialsynthetic oligonucleotide primer 624gatttccaca
attcttctgt caagc
2562525DNAArtificialsynthetic oligonucleotide primer 625ggcaagtaac
ttctgactta ctgtc
2562625DNAArtificialsynthetic oligonucleotide primer 626tactgtcagt
tgtacttctg ctcca
2562725DNAArtificialsynthetic oligonucleotide primer 627gacatcagta
ttctgccatc atttt
2562825DNAArtificialsynthetic oligonucleotide primer 628acgtatatca
cataattcca gtcac
2562925DNAArtificialsynthetic oligonucleotide primer 629ccagtcacag
tttttggttc ctctt
25630503DNAHomo sapiensmisc_feature(263)..(263)n is a, c, g, or t
630ggactggccg ccgtacaggc ggccctggag gacatgggcg acaagccccc cggcttccgg
60ggctcccggg actggatcgg ctgcgtggag gccagcctct gcctcgctca cttcggaggg
120ccccaggacg cctctgccac gtaccccggg gagtggggct gcacggggag ctggagaggc
180tttactcgca cattcgcacg gggtgggggc ccagtcatgg ttggggggga cgcagatgcc
240aggtccaagg ccttgctggg agntctgcng tngnggtcag gcacggaagc ctatgtcctg
300gtattggacc ctcactactg gggcactcca aaaagcccca gtgaactaca ggctgctggg
360tgggtgggct ggcaanaggt nagtgcagcc tttgacccca actccttcta caacctgtgc
420ttgaccagcc ttagctccca acagcagcag cgcaccttgg actgaggacg aagttacaga
480actgagattc tcgggtccca gac
50363125DNAArtificialsynthetic oligonucleotide primer 631ggactggccg
ccgtacaggc ggccc
2563225DNAArtificialsynthetic oligonucleotide primer 632tacaggcggc
cctggaggac atggg
2563325DNAArtificialsynthetic oligonucleotide primer 633tggaggacat
gggcgacaag ccccc
2563425DNAArtificialsynthetic oligonucleotide primer 634gctggagagg
ctttactcgc acatt
2563525DNAArtificialsynthetic oligonucleotide primer 635caggcacgga
agcctatgtc ctggt
2563625DNAArtificialsynthetic oligonucleotide primer 636tgtcctggta
ttggaccctc actac
2563725DNAArtificialsynthetic oligonucleotide primer 637ctcactactg
gggcactcca aaaag
2563825DNAArtificialsynthetic oligonucleotide primer 638gtgaactaca
ggctgctggg tgggt
2563925DNAArtificialsynthetic oligonucleotide primer 639ttctacaacc
tgtgcttgac cagcc
2564025DNAArtificialsynthetic oligonucleotide primer 640cagcgcacct
tggactgagg acgaa
2564125DNAArtificialsynthetic oligonucleotide primer 641gaactgagat
tctcgggtcc cagac
25642537DNAHomo sapiens 642gtattctgtg gattctatat ttcatattga gatcagcatt
caaaatagtt ctatttctat 60ctgcaaatag tttcaaatga gtttaaaaaa ataacatctg
aaaagaaatg ctaatgtaat 120catttatctt atctagcaag aagattctaa aacattcttt
aacatacatc taagtcagtt 180tcacatattt gtagctagaa tatcctatac tggttatagt
tgatatgtaa cagttggtga 240ttttagattt ctttgattgt gaaacaggga gctatgagag
atgtgtccat gtgaaattta 300cagttactgc ctaggagtta atgatcgttc tgggtcagct
tgaatgtccc cattctataa 360attcaacact tattttctga attcataaaa ataaccaaaa
aatgtgagct ataatgtttc 420cctcaagaac aaacagaaac gagatttgcc aaaaactaaa
attcaacaaa tgatgttgag 480tgggagattg gctttgcctt tagcgtgtaa atggaagcac
tgccattaga ctgaatt 53764325DNAArtificialsynthetic oligonucleotide
primer 643gtattctgtg gattctatat ttcat
2564425DNAArtificialsynthetic oligonucleotide primer 644catacatcta
agtcagtttc acata
2564525DNAArtificialsynthetic oligonucleotide primer 645gtagctagaa
tatcctatac tggtt
2564625DNAArtificialsynthetic oligonucleotide primer 646ggagctatga
gagatgtgtc catgt
2564725DNAArtificialsynthetic oligonucleotide primer 647gcctaggagt
taatgatcgt tctgg
2564825DNAArtificialsynthetic oligonucleotide primer 648gatcgttctg
ggtcagcttg aatgt
2564925DNAArtificialsynthetic oligonucleotide primer 649aatgtcccca
ttctataaat tcaac
2565025DNAArtificialsynthetic oligonucleotide primer 650gagctataat
gtttccctca agaac
2565125DNAArtificialsynthetic oligonucleotide primer 651tgagtgggag
attggctttg ccttt
2565225DNAArtificialsynthetic oligonucleotide primer 652gattggcttt
gcctttagcg tgtaa
2565325DNAArtificialsynthetic oligonucleotide primer 653ggaagcactg
ccattagact gaatt
25654151DNAHomo sapiensmisc_feature(39)..(39)n is a, c, g, or t
654gttaggcaat cattctaggg cagaaagaag tacaggatng gaagagcata atacactgtt
60tttctcaaca aggagncagt atgtacacag tcataatgat gtgactgctt agcccctaaa
120tatggtaact actctgggac aatatgggag g
15165525DNAArtificialsynthetic oligonucleotide primer 655gttaggcaat
cattctaggg cagaa
2565625DNAArtificialsynthetic oligonucleotide primer 656ggcaatcatt
ctagggcaga aagaa
2565725DNAArtificialsynthetic oligonucleotide primer 657tcattctagg
gcagaaagaa gtaca
2565825DNAArtificialsynthetic oligonucleotide primer 658cattctaggg
cagaaagaag tacag
2565925DNAArtificialsynthetic oligonucleotide primer 659atacactgtt
tttctcaaca aggag
2566025DNAArtificialsynthetic oligonucleotide primer 660tacacagtca
taatgatgtg actgc
2566125DNAArtificialsynthetic oligonucleotide primer 661acacagtcat
aatgatgtga ctgct
2566225DNAArtificialsynthetic oligonucleotide primer 662cataatgatg
tgactgctta gcccc
2566325DNAArtificialsynthetic oligonucleotide primer 663ataatgatgt
gactgcttag cccct
2566425DNAArtificialsynthetic oligonucleotide primer 664taatgatgtg
actgcttagc cccta
2566525DNAArtificialsynthetic oligonucleotide primer 665gatgtgactg
cttagcccct aaata
2566625DNAArtificialsynthetic oligonucleotide primer 666atgtgactgc
ttagccccta aatat
2566725DNAArtificialsynthetic oligonucleotide primer 667aatatggtaa
ctactctggg acaat
2566825DNAArtificialsynthetic oligonucleotide primer 668atggtaacta
ctctgggaca atatg
2566925DNAArtificialsynthetic oligonucleotide primer 669tggtaactac
tctgggacaa tatgg
2567025DNAArtificialsynthetic oligonucleotide primer 670aactactctg
ggacaatatg ggagg
25671524DNAHomo sapiens 671agagtgcttc ttattcggca gggcttcgtg agaatgccac
caagttatcc aaaaccaaag 60gatgagagag gcttccaaga gagggaagac tgtccaagtt
caaggagaag gggtttggtt 120ccctgtctgc cagggacaga aagttctttc cacatgtgtc
tcctggtccc gagagctttc 180aaaaggggat gtattctgct ccaagaaaga atcacctccc
agtaaagtag ccatgaaggg 240ctcctgtata aaatatgcac acttcccctg ccctgagttt
gtggagggaa aggctgtcgg 300aagtagggac tcttaggaga gcccgtgtgc cctgtttggt
tcagctgtca ggcgtgtgcc 360acacacatcc cacctcatct tctggtccca taattctcca
tggatgggct gcttttagct 420ccagttttcc agtagaatgc ttgagttttc cttttttccg
tacctcctgg aggatgaaac 480tcataacctg tcatcatcag tactcactgt gttttccact
ttga 52467225DNAArtificialsynthetic oligonucleotide
primer 672agagtgcttc ttattcggca gggct
2567325DNAArtificialsynthetic oligonucleotide primer 673gcagggcttc
gtgagaatgc cacca
2567425DNAArtificialsynthetic oligonucleotide primer 674gagaaggggt
ttggttccct gtctg
2567525DNAArtificialsynthetic oligonucleotide primer 675gctccaagaa
agaatcacct cccag
2567650DNAArtificialsynthetic oligonucleotide primer 676atcacctccc
agtaaagtag ccatgatcac ctcccagtaa agtagccatg
5067725DNAArtificialsynthetic oligonucleotide primer 677agggactctt
aggagagccc gtgtg
2567825DNAArtificialsynthetic oligonucleotide primer 678ttggttcagc
tgtcaggcgt gtgcc
2567925DNAArtificialsynthetic oligonucleotide primer 679atcttctggt
cccataattc tccat
2568025DNAArtificialsynthetic oligonucleotide primer 680ccatggatgg
gctgctttta gctcc
2568125DNAArtificialsynthetic oligonucleotide primer 681ttttttccgt
acctcctgga ggatg
2568225DNAArtificialsynthetic oligonucleotide primer 682gtactcactg
tgttttccac tttga
25683473DNAHomo sapiens 683actacactag tctgtttctt tgccctggtc tcaagtctct
aagacgctgg tgtgtattat 60gtgggctaag ttcatgtgtt atcctaaggc acaagagttg
aggaatgggt gagcttggtg 120tcagagcact gtgtggttgg agggtggact cttgtgatgc
tgtggggatg aaattggccc 180tcttttagca taagttgggg agtgtgcact ggctggaggc
ttccagaggc ttccagccat 240gaggtgtgag ctgaaaccaa tttttcctct ttccttatag
catgttgaga aaatctgttg 300ggttttcagc agtcagggaa ggccggagtt ctgctttaat
ctgggtaact gaggctaata 360tgagcaagac tttggttaat taactgggtt ctcagatgcc
acagactccg tgagaagtca 420ccattatttt caatggttgt gatagaattt cccccagtag
ccattatttt aag 47368425DNAArtificialsynthetic oligonucleotide
primer 684actacactag tctgtttctt tgccc
2568525DNAArtificialsynthetic oligonucleotide primer 685tgccctggtc
tcaagtctct aagac
2568625DNAArtificialsynthetic oligonucleotide primer 686gacgctggtg
tgtattatgt gggct
2568725DNAArtificialsynthetic oligonucleotide primer 687tgggtgagct
tggtgtcaga gcact
2568825DNAArtificialsynthetic oligonucleotide primer 688ggagggtgga
ctcttgtgat gctgt
2568925DNAArtificialsynthetic oligonucleotide primer 689gatgaaattg
gccctctttt agcat
2569025DNAArtificialsynthetic oligonucleotide primer 690ttcctctttc
cttatagcat gttga
2569125DNAArtificialsynthetic oligonucleotide primer 691gggttttcag
cagtcaggga aggcc
2569225DNAArtificialsynthetic oligonucleotide primer 692gaaggccgga
gttctgcttt aatct
2569325DNAArtificialsynthetic oligonucleotide primer 693gccacagact
ccgtgagaag tcacc
2569425DNAArtificialsynthetic oligonucleotide primer 694ttcccccagt
agccattatt ttaag
25695456DNAHomo sapiens 695taccccctgc tgcttttgag aaatttgtga acattttcag
aggcctcagt gtagtggaag 60tgataatcct taaatgaaca ttttctaccc taatttcact
ggagtgactt attctaagcc 120tcatctatcc cctacctatt tctcaaaatc attctatgct
gattttacaa aagatcattt 180ttacatttga actgagaacc ccttttaatt gaatcagtgg
tgtctgaaat catattaaat 240acccacattt gacataaatg cggtaccctt tactacactc
atgagtggca tatttatgct 300taggtctttt caaaagactt gacaagaaat cttcatattc
tctgtagcct ttgtcaagtg 360aggaaatcag tggttaaaga attccactat aaacttttag
gcctgaatag gagtagtaaa 420gcctcaagga catctgcctg tcacaatata ttctca
45669625DNAArtificialsynthetic oligonucleotide
primer 696taccccctgc tgcttttgag aaatt
2569725DNAArtificialsynthetic oligonucleotide primer 697gtgaacattt
tcagaggcct cagtg
2569825DNAArtificialsynthetic oligonucleotide primer 698gaacattttc
taccctaatt tcact
2569925DNAArtificialsynthetic oligonucleotide primer 699ggagtgactt
attctaagcc tcatc
2570025DNAArtificialsynthetic oligonucleotide primer 700tgaactgaga
acccctttta attga
2570125DNAArtificialsynthetic oligonucleotide primer 701gacataaatg
cggtaccctt tacta
2570225DNAArtificialsynthetic oligonucleotide primer 702gtacccttta
ctacactcat gagtg
2570325DNAArtificialsynthetic oligonucleotide primer 703gcatatttat
gcttaggtct tttca
2570425DNAArtificialsynthetic oligonucleotide primer 704aaatcttcat
attctctgta gcctt
2570525DNAArtificialsynthetic oligonucleotide primer 705taaagcctca
aggacatctg cctgt
2570625DNAArtificialsynthetic oligonucleotide primer 706atctgcctgt
cacaatatat tctca
25707565DNAHomo sapiensmisc_feature(399)..(399)n is a, c, g, or t
707caaaaccttg ggacctcagc agtcccaagg ctgccctgac aatcaggcag gctccccacc
60gtgaggccaa gcctcctctg ccactgccag catggcccaa gggaggcttg gccttgggct
120tgccagcctc agctctgccc tgacaagggt cttgtatcca gggcagaggc ctgaggtgac
180ccaggcttgc tttgtggctg atgccagcag gcttggttct agtgggcacc actggtgggc
240aacctccata actggccctt aggccctacc ttcctacaca gctaggctat aatgggcctg
300agtgagaggg tagcttcccc agccccaagc acaggcagag gggtggagag caatttttgg
360ttttattttt gtttctgaag tggtgcctgt acctccagnc cccagggggc cttccctggc
420cacacttctc tgccccaccc angcatcgcc atcccagcac tttgctccat gtcacccgta
480agatgccctt tgctgaatgt acctgagtgt atgtatttaa aaggactcac atgggcatca
540gagaatttat ggctctgtat ccaat
56570825DNAArtificialsynthetic oligonucleotide primer 708caaaaccttg
ggacctcagc agtcc
2570925DNAArtificialsynthetic oligonucleotide primer 709tgccctgaca
atcaggcagg ctccc
2571025DNAArtificialsynthetic oligonucleotide primer 710gcatggccca
agggaggctt ggcct
2571125DNAArtificialsynthetic oligonucleotide primer 711tgccctgaca
agggtcttgt atcca
2571225DNAArtificialsynthetic oligonucleotide primer 712ggtcttgtat
ccagggcaga ggcct
2571325DNAArtificialsynthetic oligonucleotide primer 713gaggcctgag
gtgacccagg cttgc
2571425DNAArtificialsynthetic oligonucleotide primer 714ccaggcttgc
tttgtggctg atgcc
2571525DNAArtificialsynthetic oligonucleotide primer 715gctttgtggc
tgatgccagc aggct
2571625DNAArtificialsynthetic oligonucleotide primer 716tttctgaagt
ggtgcctgta cctcc
2571725DNAArtificialsynthetic oligonucleotide primer 717agatgccctt
tgctgaatgt acctg
2571825DNAArtificialsynthetic oligonucleotide primer 718gagaatttat
ggctctgtat ccaat
25719514DNAHomo sapiens 719cagactgttc agtgtttgtc aagcttctgg tctaatatgt
actcgaaaga ctttccgctt 60acaatttgta gaaacacaaa tatcgttttc catacagcag
tgcctatata gtgactgatt 120ttaactttca atgtccatct ttcaaaggaa gtaacaccaa
ggtacaatgt taaaggaata 180ttcactttac ctagcaggga aaaatacaca aaaactgcag
atacttcata tagcccattt 240taacttgtat aaactgtgtg acttgtggcg tcttataaat
aatgcactgt aaagattact 300gaatagttgt gtcatgttaa tgtgcctaat ttcatgtatc
ttgtaatcat gattgagcct 360cagaatcatt tggagaaact atattttaaa gaacaagaca
tacttcaatg tattatacag 420ataaagtatt acatgtgttt gattttaaaa gggcggacat
tttattaaaa tcaatattgt 480ttttgctttt tctgaggagt ctctttcagt ttca
51472025DNAArtificialsynthetic oligonucleotide
primer 720cagactgttc agtgtttgtc aagct
2572125DNAArtificialsynthetic oligonucleotide primer 721gtgtttgtca
agcttctggt ctaat
2572225DNAArtificialsynthetic oligonucleotide primer 722agcttctggt
ctaatatgta ctcga
2572325DNAArtificialsynthetic oligonucleotide primer 723gaaagacttt
ccgcttacaa tttgt
2572425DNAArtificialsynthetic oligonucleotide primer 724atatcgtttt
ccatacagca gtgcc
2572525DNAArtificialsynthetic oligonucleotide primer 725ttaactttca
atgtccatct ttcaa
2572625DNAArtificialsynthetic oligonucleotide primer 726gatacttcat
atagcccatt ttaac
2572725DNAArtificialsynthetic oligonucleotide primer 727tgtgtgactt
gtggcgtctt ataaa
2572825DNAArtificialsynthetic oligonucleotide primer 728gttgtgtcat
gttaatgtgc ctaat
2572925DNAArtificialsynthetic oligonucleotide primer 729tgtgcctaat
ttcatgtatc ttgta
2573025DNAArtificialsynthetic oligonucleotide primer 730ttctgaggag
tctctttcag tttca
25731271DNAHomo sapiens 731aaagacactg tgtacaacgt tggacactgt gcaggatgat
gccacttcat cttggatgct 60aatctgccat gttgacttct gattaacccc aggcccagga
atgcctcaag atttctactt 120tacttactgt tgcttgtgta agccaagaca accttgatgt
tatcataaac atgtacttac 180ctaagtcctg tcctttggca aattatgggc tatgagacac
agcattcttg cctttccctg 240aggggtcaat ttcagcgatc ctacacattc c
27173225DNAArtificialsynthetic oligonucleotide
primer 732aaagacactg tgtacaacgt tggac
2573325DNAArtificialsynthetic oligonucleotide primer 733gacactgtgt
acaacgttgg acact
2573425DNAArtificialsynthetic oligonucleotide primer 734ctgtgtacaa
cgttggacac tgtgc
2573525DNAArtificialsynthetic oligonucleotide primer 735ggcaaattat
gggctatgag acaca
2573625DNAArtificialsynthetic oligonucleotide primer 736ggctatgaga
cacagcattc ttgcc
2573725DNAArtificialsynthetic oligonucleotide primer 737tgagacacag
cattcttgcc tttcc
2573825DNAArtificialsynthetic oligonucleotide primer 738tgcctttccc
tgaggggtca atttc
2573925DNAArtificialsynthetic oligonucleotide primer 739ctttccctga
ggggtcaatt tcagc
2574025DNAArtificialsynthetic oligonucleotide primer 740gaggggtcaa
tttcagcgat cctac
2574125DNAArtificialsynthetic oligonucleotide primer 741gtcaatttca
gcgatcctac acatt
2574225DNAArtificialsynthetic oligonucleotide primer 742caatttcagc
gatcctacac attcc
25743394DNAHomo sapiens 743aaggcgccgt caagtcaaat aaataaatgc cctacaacac
caacccagga ctgagatctg 60catgctggaa tgacggtggt ggtggtggct ttcagtattc
cccaggtttt gtccggagca 120ccggcacgcc ctctcttgaa gtccgctctc cgcacagtgg
ttagacggga agatccggag 180ctgtccagtg tcttgggtaa tgcacggcat cgcctgatgt
ctgacgctag aacaccacgt 240aaagtcaagc agagggaagt gaatgcgccc taggcccctg
caggccacca agaagagcta 300gagggagttg gtgcaatcct agagatgccg gcaggtgcac
caatctgtgg cacacgtacg 360ctctccaatg gaagacaact caagaccaca ccaa
39474425DNAArtificialsynthetic oligonucleotide
primer 744aaggcgccgt caagtcaaat aaata
2574525DNAArtificialsynthetic oligonucleotide primer 745ctacaacacc
aacccaggac tgaga
2574625DNAArtificialsynthetic oligonucleotide primer 746acaccaaccc
aggactgaga tctgc
2574725DNAArtificialsynthetic oligonucleotide primer 747ggactgagat
ctgcatgctg gaatg
2574825DNAArtificialsynthetic oligonucleotide primer 748tgctggaatg
acggtggtgg tggtg
2574925DNAArtificialsynthetic oligonucleotide primer 749ccaggttttg
tccggagcac cggca
2575025DNAArtificialsynthetic oligonucleotide primer 750cgctctccgc
acagtggtta gacgg
2575125DNAArtificialsynthetic oligonucleotide primer 751gctagaggga
gttggtgcaa tccta
2575225DNAArtificialsynthetic oligonucleotide primer 752acacgtacgc
tctccaatgg aagac
2575325DNAArtificialsynthetic oligonucleotide primer 753gtacgctctc
caatggaaga caact
2575425DNAArtificialsynthetic oligonucleotide primer 754ggaagacaac
tcaagaccac accaa
25755421DNAHomo sapiensmisc_feature(109)..(109)n is a, c, g, or t
755tggggagagt cttacaatga ataactcaga aaaaagtttt caaaataatc ctagattgta
60agatatctac gaccattatc catagccata tctttaaaaa aaaaaaaana aannnanaaa
120anaanaaaca aggngtttct ttacccaggn cangtgagca ctaaagcttc cngtcntaat
180gaggaggcag tgggggcnan ttngctttng agactnggag tcccagtatt acngggagtg
240ccctgacccc tcaggtaggg actngtcnnn nctccagaag acctaaggta cagtcagagc
300tgagccacgc ctttgtccat gaagagaatg gggttgaaag tggagactga ggccgaggcg
360ggtggatcac gaggtcagga gatccagacc atcctatcct ggctaataca gtgaaaccct
420g
42175625DNAArtificialsynthetic oligonucleotide primer 756tggggagagt
cttacaatga ataac
2575725DNAArtificialsynthetic oligonucleotide primer 757gattgtaaga
tatctacgac catta
2575825DNAArtificialsynthetic oligonucleotide primer 758atctacgacc
attatccata gccat
2575925DNAArtificialsynthetic oligonucleotide primer 759gaccattatc
catagccata tcttt
2576025DNAArtificialsynthetic oligonucleotide primer 760gaagacctaa
ggtacagtca gagct
2576125DNAArtificialsynthetic oligonucleotide primer 761ggtacagtca
gagctgagcc acgcc
2576225DNAArtificialsynthetic oligonucleotide primer 762ccacgccttt
gtccatgaag agaat
2576325DNAArtificialsynthetic oligonucleotide primer 763gagaatgggg
ttgaaagtgg agact
2576425DNAArtificialsynthetic oligonucleotide primer 764aaagtggaga
ctgaggccga ggcgg
2576525DNAArtificialsynthetic oligonucleotide primer 765tcaggagatc
cagaccatcc tatcc
2576625DNAArtificialsynthetic oligonucleotide primer 766tcctggctaa
tacagtgaaa ccctg
25767484DNAHomo sapiensmisc_feature(143)..(143)n is a, c, g, or t
767ctgtccgaag cggcaagtgc gtccactacc actcatgctg gagaggacag gccgcctgtc
60ttctgtggcc agggacacag gcttggggcc caccctcaga cctctgagaa ctgcctgcca
120gcccccgatg cagaaccctt gantagncaa gcctcagttt ctccacaccc cactcctctt
180tctcctctcc tcagccttac agctggaggg cagggggctg gggaaggggn tcaccccaat
240gccctggact gggccccaca gctcccccgg ctgcttgctt ccttctcctg acggccggct
300ccttcccact tcagcctcct ctgtgggcac cgaggcccag gagcttcaaa agtcagacca
360agactgtcct tggtcccaca ggggcagagg tgagatctgt gcgtgccccc tctccacact
420cacggggaca gggcgtgaga tctttgcgcc ccctccccat gatctccctt tccagatttt
480caaa
48476825DNAArtificialsynthetic oligonucleotide primer 768ctgtccgaag
cggcaagtgc gtcca
2576925DNAArtificialsynthetic oligonucleotide primer 769gtccactacc
actcatgctg gagag
2577025DNAArtificialsynthetic oligonucleotide primer 770gagaggacag
gccgcctgtc ttctg
2577125DNAArtificialsynthetic oligonucleotide primer 771caccctcaga
cctctgagaa ctgcc
2577225DNAArtificialsynthetic oligonucleotide primer 772ctctcctcag
ccttacagct ggagg
2577325DNAArtificialsynthetic oligonucleotide primer 773ccgaggccca
ggagcttcaa aagtc
2577425DNAArtificialsynthetic oligonucleotide primer 774gaccaagact
gtccttggtc ccaca
2577525DNAArtificialsynthetic oligonucleotide primer 775cagaggtgag
atctgtgcgt gcccc
2577625DNAArtificialsynthetic oligonucleotide primer 776tccacactca
cggggacagg gcgtg
2577725DNAArtificialsynthetic oligonucleotide primer 777cagggcgtga
gatctttgcg ccccc
2577825DNAArtificialsynthetic oligonucleotide primer 778tgatctccct
ttccagattt tcaaa
25779247DNAHomo sapiens 779gggtttggtt aatttgtcct gcagcagcat cgtccctgat
taacatcgtg atattaagcc 60attcactgtg tcctgtaaca gtctctaatc gttcataaac
acatagtaga aagtgggccc 120caattacccc caaaattatt ctctacaata catgtcagct
aacaaatgga actttctgga 180aattttcttc ttgtcacttc caacactgaa ttgtgatatt
tggcctttaa caggacattc 240ttgatca
24778025DNAArtificialsynthetic oligonucleotide
primer 780gggtttggtt aatttgtcct gcagc
2578125DNAArtificialsynthetic oligonucleotide primer 781cagcagcatc
gtccctgatt aacat
2578225DNAArtificialsynthetic oligonucleotide primer 782atcgtccctg
attaacatcg tgata
2578325DNAArtificialsynthetic oligonucleotide primer 783gatattaagc
cattcactgt gtcct
2578425DNAArtificialsynthetic oligonucleotide primer 784cactgtgtcc
tgtaacagtc tctaa
2578525DNAArtificialsynthetic oligonucleotide primer 785acagtctcta
atcgttcata aacac
2578625DNAArtificialsynthetic oligonucleotide primer 786acatagtaga
aagtgggccc caatt
2578725DNAArtificialsynthetic oligonucleotide primer 787tacccccaaa
attattctct acaat
2578825DNAArtificialsynthetic oligonucleotide primer 788tattctctac
aatacatgtc agcta
2578925DNAArtificialsynthetic oligonucleotide primer 789atgtcagcta
acaaatggaa ctttc
2579025DNAArtificialsynthetic oligonucleotide primer 790gcctttaaca
ggacattctt gatca
25791445DNAHomo sapiensmisc_feature(393)..(393)n is a, c, g, or t
791aacaccagca atacatcagc tttacacagc aggcaagttt cctgctctct acaagtacag
60atggaacttg tcttgtgaat taacatcctg actacttttg ttgatcatca cattttttcc
120tcatgagaga aataatagtg ttttataggc tcctgagaat aggtttacta aagtcatcga
180gatctgggtt caaatgacac tgcttaggga ggcattcact gatcaagtta cctaaaatag
240caacaatcta tcatccaaaa tatcatttgc cagctttgat tttgcatata acacttactt
300tatatatgta catatatgtg tatatatata tttgtgtgtg tgtgtgtgta tacatgtata
360tatatatgca gtctgcaata aaatgtatgc ttntcagggg agaaannnnn ttntaataca
420ttcagtgctc tatacccaga acctg
44579225DNAArtificialsynthetic oligonucleotide primer 792aacaccagca
atacatcagc tttac
2579325DNAArtificialsynthetic oligonucleotide primer 793agctttacac
agcaggcaag tttcc
2579425DNAArtificialsynthetic oligonucleotide primer 794agtttcctgc
tctctacaag tacag
2579525DNAArtificialsynthetic oligonucleotide primer 795acatcctgac
tacttttgtt gatca
2579625DNAArtificialsynthetic oligonucleotide primer 796gatcatcaca
ttttttcctc atgag
2579725DNAArtificialsynthetic oligonucleotide primer 797aatagtgttt
tataggctcc tgaga
2579825DNAArtificialsynthetic oligonucleotide primer 798gatctgggtt
caaatgacac tgctt
2579925DNAArtificialsynthetic oligonucleotide primer 799gacactgctt
agggaggcat tcact
2580025DNAArtificialsynthetic oligonucleotide primer 800ggcattcact
gatcaagtta cctaa
2580125DNAArtificialsynthetic oligonucleotide primer 801tcatttgcca
gctttgattt tgcat
2580225DNAArtificialsynthetic oligonucleotide primer 802ttcagtgctc
tatacccaga acctg
25803388DNAHomo sapiens 803atcctccctt gattcgtgga tggacaacta tggaggccaa
tctggctgag gtgaagactg 60cttgagtcta aattcctctc tcctcaaacc caattcaaac
tggcctgagc aaaatgaatg 120tattgatcca taactgaaaa gtccagaatg atcaggcatc
aggcatggtt gcatccaggg 180gcccatgtat tagaaccatc tccttccagt tctgggctct
gcttgcctcc cagttggttt 240tactgcacag aggcttattc aagtccagag agatcttatc
tttccctaca agtctgtgac 300cttgattctg aacctgcatc tatgggaagg gcttgcagtg
tctgagtgag cttggactgt 360gtaaactttc ccacttctga agctgggg
38880425DNAArtificialsynthetic oligonucleotide
primer 804atcctccctt gattcgtgga tggac
2580525DNAArtificialsynthetic oligonucleotide primer 805tgcttgagtc
taaattcctc tctcc
2580625DNAArtificialsynthetic oligonucleotide primer 806ctctcctcaa
acccaattca aactg
2580725DNAArtificialsynthetic oligonucleotide primer 807ggcatcaggc
atggttgcat ccagg
2580825DNAArtificialsynthetic oligonucleotide primer 808gggcccatgt
attagaacca tctcc
2580925DNAArtificialsynthetic oligonucleotide primer 809tgcctcccag
ttggttttac tgcac
2581025DNAArtificialsynthetic oligonucleotide primer 810gcacagaggc
ttattcaagt ccaga
2581125DNAArtificialsynthetic oligonucleotide primer 811tatctttccc
tacaagtctg tgacc
2581225DNAArtificialsynthetic oligonucleotide primer 812gattctgaac
ctgcatctat gggaa
2581325DNAArtificialsynthetic oligonucleotide primer 813gtgagcttgg
actgtgtaaa ctttc
2581425DNAArtificialsynthetic oligonucleotide primer 814aactttccca
cttctgaagc tgggg
25815395DNAHomo sapiensmisc_feature(63)..(63)n is a, c, g, or t
815tccccttatc cagatgcagg tgcctatagc tgaagccatg tgtggtacat ttggtccagc
60canagccttg catgaagctg gcacttgtgc tggtgcctgn agctgtctgc cttgccacag
120cagctagcat gcgtggctgt gcacagtggc tggaccccat gctcattcgc tcatacactc
180tttgccactc cgtgcctggc tcccccttgg caggtgtgag atcgaggcca gtagtgtgag
240ccaagcgcag cctgccaggc caagtgggtg gaacgagccc tgtgggcgcg agcaatactc
300aggcagaagg cgctgcctgc cacagaggtt tctggctggc aaatcgacat cccaagggtc
360ccgtgacaat tatagcccct gcttctggat agagt
39581625DNAArtificialsynthetic oligonucleotide primer 816tccccttatc
cagatgcagg tgcct
2581725DNAArtificialsynthetic oligonucleotide primer 817atgtgtggta
catttggtcc agcca
2581825DNAArtificialsynthetic oligonucleotide primer 818aagctggcac
ttgtgctggt gcctg
2581925DNAArtificialsynthetic oligonucleotide primer 819ctagcatgcg
tggctgtgca cagtg
2582025DNAArtificialsynthetic oligonucleotide primer 820gcaggtgtga
gatcgaggcc agtag
2582125DNAArtificialsynthetic oligonucleotide primer 821cagtagtgtg
agccaagcgc agcct
2582225DNAArtificialsynthetic oligonucleotide primer 822tgggcgcgag
caatactcag gcaga
2582325DNAArtificialsynthetic oligonucleotide primer 823ggtttctggc
tggcaaatcg acatc
2582425DNAArtificialsynthetic oligonucleotide primer 824caaatcgaca
tcccaagggt cccgt
2582525DNAArtificialsynthetic oligonucleotide primer 825gggtcccgtg
acaattatag cccct
2582625DNAArtificialsynthetic oligonucleotide primer 826tatagcccct
gcttctggat agagt
25827508DNAHomo sapiensmisc_feature(40)..(40)n is a, c, g, or t
827aattgtcgag cacctctgac acttggcagt gcctacctgn ttgtgttcca gngggcagnt
60tcagagaaaa cgggnanana cnntccaagc cnagntcaat cntcagangg ccagtaatta
120ccnattggaa ttacacagca gcaatggatn gttcatatag gataataatn ataattatac
180atgagcatcg ctgtagaata atgatgccta ttggcttatc ctgggaagac tccaaaaatg
240tgattcagtc ctgaggcctc ggcaatgggc atgatgaggg caggctcagg ggcaggaggg
300caccctgcta gagctgggtg tggggcacgt aggaaagggg tggttttcaa aaaggcttga
360gacagatccc tggccttgag gacgtgcttc gcatgcagcc tgcaacccag ggagtgcaga
420aaagaaaaag tgcatttgtt tatggagcac atatttgtgt ggcaggtacc attctagatn
480ctggagattc agaaataagc ccccctcc
50882825DNAArtificialsynthetic oligonucleotide primer 828aattgtcgag
cacctctgac acttg
2582925DNAArtificialsynthetic oligonucleotide primer 829tctgacactt
ggcagtgcct acctg
2583025DNAArtificialsynthetic oligonucleotide primer 830atgcctattg
gcttatcctg ggaag
2583125DNAArtificialsynthetic oligonucleotide primer 831aatgtgattc
agtcctgagg cctcg
2583225DNAArtificialsynthetic oligonucleotide primer 832gaggcctcgg
caatgggcat gatga
2583325DNAArtificialsynthetic oligonucleotide primer 833gagggcaccc
tgctagagct gggtg
2583425DNAArtificialsynthetic oligonucleotide primer 834gctgggtgtg
gggcacgtag gaaag
2583525DNAArtificialsynthetic oligonucleotide primer 835aggcttgaga
cagatccctg gcctt
2583625DNAArtificialsynthetic oligonucleotide primer 836tgcagcctgc
aacccaggga gtgca
2583725DNAArtificialsynthetic oligonucleotide primer 837ttgtgtggca
ggtaccattc tagat
2583825DNAArtificialsynthetic oligonucleotide primer 838gagattcaga
aataagcccc cctcc
25839508DNAHomo sapiens 839atgacatcac ttgtcagatt ttctggtgta tggaaagatt
taataatcct gcctcttttg 60aagcctgaaa cttacaattt aaagcctgaa atctaccata
aggaacttgg taaattgtgt 120cagataccat gaaaatgcat cttttcatag ttaaccacag
attgtttatg taaaggcaaa 180ttggtggtca ggttcaaggt aaaatggatt attgggttga
ttagtagcca aaaactaaat 240gcatgttcag gtcaaaatga atttgtttgt tttagttggt
gccattttcc ttttattatt 300cagaactaca gagtgtgcat tttattaata ggaatgaaag
ctcatgcttg aggatttgaa 360tagggtggat gtatatattt tataaactca agttgcaaaa
tatgtaaagt cactactttt 420taaatagaat ataaatgtta aaacagacaa atctatgtta
tatatttttt aatacatgta 480tcagacttgt tagttgaatg cagattac
50884025DNAArtificialsynthetic oligonucleotide
primer 840atgacatcac ttgtcagatt ttctg
2584125DNAArtificialsynthetic oligonucleotide primer 841ctcttttgaa
gcctgaaact tacaa
2584225DNAArtificialsynthetic oligonucleotide primer 842tttaaagcct
gaaatctacc ataag
2584325DNAArtificialsynthetic oligonucleotide primer 843gcatcttttc
atagttaacc acaga
2584425DNAArtificialsynthetic oligonucleotide primer 844ggcaaattgg
tggtcaggtt caagg
2584525DNAArtificialsynthetic oligonucleotide primer 845actaaatgca
tgttcaggtc aaaat
2584625DNAArtificialsynthetic oligonucleotide primer 846tttcctttta
ttattcagaa ctaca
2584725DNAArtificialsynthetic oligonucleotide primer 847gaactacaga
gtgtgcattt tatta
2584825DNAArtificialsynthetic oligonucleotide primer 848gaaagctcat
gcttgaggat ttgaa
2584925DNAArtificialsynthetic oligonucleotide primer 849aatacatgta
tcagacttgt tagtt
2585025DNAArtificialsynthetic oligonucleotide primer 850gacttgttag
ttgaatgcag attac
25851527DNAHomo sapiensmisc_feature(470)..(470)n is a, c, g, or t
851agagctctgc aaagaacacc gccagctctt tccttccggg tgctcttgct ggggggtcag
60gctggtcccc tctgactggc actgcccacg ctgggacatg ggaggagggc catctgggca
120ctgcaggagc agatcctggg tgcacatggg gagacaggtg tgctggcagg aacagcaggc
180ggggctgagc tcaggaggcg cctcacagcg ggtgcctcca gcctggtctg agcacgggat
240gaagaaccag gcaccgctca tcgtgcatct ccacaaggca ctgtgtgact tcatgcaagc
300cgctcaacct ctctggcccc acgtccttgt ccacaggggc agagtggact gaatggaggc
360tgaggtccct ctcagcttgg gtggtgtggc agagggtgag gaggagccca tgggccctgg
420atcaccagcc tccctccacc cagaatgccc cgtccactcc actgcccacn ancctctgtg
480caattgacaa acgtcctggn tgttaacgcc taagcataaa gagtcgg
52785225DNAArtificialsynthetic oligonucleotide primer 852agagctctgc
aaagaacacc gccag
2585325DNAArtificialsynthetic oligonucleotide primer 853aaagaacacc
gccagctctt tcctt
2585425DNAArtificialsynthetic oligonucleotide primer 854tttccttccg
ggtgctcttg ctggg
2585525DNAArtificialsynthetic oligonucleotide primer 855aggctggtcc
cctctgactg gcact
2585625DNAArtificialsynthetic oligonucleotide primer 856cagcctggtc
tgagcacggg atgaa
2585725DNAArtificialsynthetic oligonucleotide primer 857gtctgagcac
gggatgaaga accag
2585825DNAArtificialsynthetic oligonucleotide primer 858gaagaaccag
gcaccgctca tcgtg
2585925DNAArtificialsynthetic oligonucleotide primer 859gtgtgacttc
atgcaagccg ctcaa
2586025DNAArtificialsynthetic oligonucleotide primer 860tgaatggagg
ctgaggtccc tctca
2586125DNAArtificialsynthetic oligonucleotide primer 861aggtccctct
cagcttgggt ggtgt
2586225DNAArtificialsynthetic oligonucleotide primer 862ttaacgccta
agcataaaga gtcgg
25863506DNAHomo sapiensmisc_feature(44)..(44)n is a, c, g, or t
863ccttcccagc tgcaagcatg gatgcgggca tgagaagaac aagncntggc acttctgctc
60ctgcagctgc cgcagcagcc cctcccccct ccncattgaa ccccacgttg gggtcactac
120tngagtggat ngaggccctt cacatttctg ggcctcagcc acagctgcag caggtgccca
180gaggtcagaa ccagagatcn cagacctccc ggaccagctc gtgccccaaa ngaaaggcca
240tctccagctc ctacagctct acgggaggcc tcccggaacg aaagcggagg agggggccag
300cctcatccca ctgccagctg accctcagtt cctcaaacac agacccaggg tgcgtgccca
360tctccagccc agggcagctc ccctgtaagc tgggtgagct actgaagcca aggcgggagg
420cagctgacaa cacccacggc ccatgtggag gtggtggaaa ggctggactc agcagcaaca
480ccaaatcccg gaccaggcag aaacca
50686425DNAArtificialsynthetic oligonucleotide primer 864ccttcccagc
tgcaagcatg gatgc
2586525DNAArtificialsynthetic oligonucleotide primer 865aggcccttca
catttctggg cctca
2586625DNAArtificialsynthetic oligonucleotide primer 866gcaggtgccc
agaggtcaga accag
2586725DNAArtificialsynthetic oligonucleotide primer 867gaaagcggag
gagggggcca gcctc
2586825DNAArtificialsynthetic oligonucleotide primer 868aaacacagac
ccagggtgcg tgccc
2586925DNAArtificialsynthetic oligonucleotide primer 869gcagctcccc
tgtaagctgg gtgag
2587025DNAArtificialsynthetic oligonucleotide primer 870ggtgagctac
tgaagccaag gcggg
2587125DNAArtificialsynthetic oligonucleotide primer 871aggcgggagg
cagctgacaa caccc
2587225DNAArtificialsynthetic oligonucleotide primer 872cacccacggc
ccatgtggag gtggt
2587325DNAArtificialsynthetic oligonucleotide primer 873aaggctggac
tcagcagcaa cacca
2587425DNAArtificialsynthetic oligonucleotide primer 874caaatcccgg
accaggcaga aacca
25875508DNAHomo sapiens 875ggatgggccg tcaaagtcta agtcagagca tcctgatgtt
ggaggcaaag caggagagtg 60tggattaagc agctagacat tggttactgg ggcaacaacc
gtttgggtgg agaactggat 120cagaaatcaa ctggagtgga tcgaggtgtg catagaaggc
gaggaagtgg cgaggcgttt 180ggctgcgagg ggtagaacta gggtgcacca agcaggagaa
acagatggaa gtttggacat 240gattgaacac aaatgggaag agtacagaaa caagagtgga
ccaggctcat atgtgtaatc 300ccagcacttg gggaggctga ggcgggagga ttgcttgaca
ctaggagttt gaggccaacc 360tgggcaatat ggcgagaccc catctctaca aaaacattta
aaaattagcc agatgcggtg 420gcgcatacct gtggtcccag gctaagatgg gacgattgct
tgagcccagg aggtcaaggc 480ctcagtcatg ccactgcttg agtgacag
50887625DNAArtificialsynthetic oligonucleotide
primer 876ggatgggccg tcaaagtcta agtca
2587725DNAArtificialsynthetic oligonucleotide primer 877aagtctaagt
cagagcatcc tgatg
2587825DNAArtificialsynthetic oligonucleotide primer 878gattaagcag
ctagacattg gttac
2587925DNAArtificialsynthetic oligonucleotide primer 879caaccgtttg
ggtggagaac tggat
2588025DNAArtificialsynthetic oligonucleotide primer 880aatcaactgg
agtggatcga ggtgt
2588125DNAArtificialsynthetic oligonucleotide primer 881ggtagaacta
gggtgcacca agcag
2588225DNAArtificialsynthetic oligonucleotide primer 882gtgcaccaag
caggagaaac agatg
2588325DNAArtificialsynthetic oligonucleotide primer 883agtggaccag
gctcatatgt gtaat
2588425DNAArtificialsynthetic oligonucleotide primer 884tacctgtggt
cccaggctaa gatgg
2588525DNAArtificialsynthetic oligonucleotide primer 885aggtcaaggc
ctcagtcatg ccact
2588625DNAArtificialsynthetic oligonucleotide primer 886agtcatgcca
ctgcttgagt gacag
25887489DNAHomo sapiens 887gcattgtcta ctgaaaagct gtggcagcga gtggtattat
tgaccatgtg ttctcatgtc 60tttttgcaga tttaaaggtt ttattgtagt gtccatttaa
tatctgcatg tgtgtttaat 120ctctgaatac catgtaatta aactgattaa cttgtgatgg
tgatggtgat tagcacacac 180taaaaaccca atgaagcaat tgtctccctc ttcttaactg
gaaatcacac ttgtgaggta 240tggtatccat tatcaacagt ggattcatga ttgacttcat
attttgtgta tctggttata 300aattttgtat agcatttaat ttggcactta atataaatcc
atttgatttg aatagtgtgt 360gtgtgtacat ggtgtgtgtg tgtgtgtgca ctttagtttc
gtgagccttg ggaaactgat 420tctacaaata tcttatatag agataaatgt atcaggcatt
tttttgcaaa gcgatatata 480cattcctct
48988825DNAArtificialsynthetic oligonucleotide
primer 888gcattgtcta ctgaaaagct gtggc
2588925DNAArtificialsynthetic oligonucleotide primer 889gctgtggcag
cgagtggtat tattg
2589025DNAArtificialsynthetic oligonucleotide primer 890ggtattattg
accatgtgtt ctcat
2589125DNAArtificialsynthetic oligonucleotide primer 891tgtagtgtcc
atttaatatc tgcat
2589225DNAArtificialsynthetic oligonucleotide primer 892atctgcatgt
gtgtttaatc tctga
2589325DNAArtificialsynthetic oligonucleotide primer 893aatgaagcaa
ttgtctccct cttct
2589425DNAArtificialsynthetic oligonucleotide primer 894gtctccctct
tcttaactgg aaatc
2589525DNAArtificialsynthetic oligonucleotide primer 895ttgacttcat
attttgtgta tctgg
2589625DNAArtificialsynthetic oligonucleotide primer 896gtgtgcactt
tagtttcgtg agcct
2589725DNAArtificialsynthetic oligonucleotide primer 897gtgagccttg
ggaaactgat tctac
2589825DNAArtificialsynthetic oligonucleotide primer 898tgcaaagcga
tatatacatt cctct
25899533DNAHomo sapiensmisc_feature(487)..(489)n is a, c, g, or t
899agacttcctg agttcagatc tctcagccat aactagctat ctgaccttgg ccaagtatgc
60tcaaagtcac aaaaccttag tttccttatg tgcatgatga ttataatacc ttttgtacag
120ttatgaggaa acttagacaa tgcctgtgtt gtatggtaag cgttttcata aatgctgcct
180acctgtaagt agcattatag tgtgtagtta ttggttaatt tcctttttct ttaccagaag
240tgtgggtttt gcccagcctt tatacaactt cagtatttct ggttaatctg tctctctatg
300gctctaaact tttcagagtg gtgggggagt taccaacact tttgtaaaag gccagatagt
360aaatgtttta tgctttatgt agtctctgtt gcaagtactc aattctgtaa ttatagcgtg
420aaagcggcca cagacttgta aatgaatgag tacagctatg ttctaataaa atttttattt
480acaaaannna tgtggtggac tggatttggc ctttgggcca tattttgctg acc
53390025DNAArtificialsynthetic oligonucleotide primer 900agacttcctg
agttcagatc tctca
2590125DNAArtificialsynthetic oligonucleotide primer 901taactagcta
tctgaccttg gccaa
2590225DNAArtificialsynthetic oligonucleotide primer 902accttggcca
agtatgctca aagtc
2590325DNAArtificialsynthetic oligonucleotide primer 903aaccttagtt
tccttatgtg catga
2590425DNAArtificialsynthetic oligonucleotide primer 904gcgttttcat
aaatgctgcc tacct
2590525DNAArtificialsynthetic oligonucleotide primer 905tgcccagcct
ttatacaact tcagt
2590625DNAArtificialsynthetic oligonucleotide primer 906tttctggtta
atctgtctct ctatg
2590725DNAArtificialsynthetic oligonucleotide primer 907gtctctctat
ggctctaaac ttttc
2590825DNAArtificialsynthetic oligonucleotide primer 908gtagtctctg
ttgcaagtac tcaat
2590925DNAArtificialsynthetic oligonucleotide primer 909gcgtgaaagc
ggccacagac ttgta
2591025DNAArtificialsynthetic oligonucleotide primer 910gcctttgggc
catattttgc tgacc
25911380DNAHomo sapiensmisc_feature(84)..(84)n is a, c, g, or t
911gcgtggtgac tgatgtgtgc ctgtagtctc agctactcag gaggctgagg caggaggatc
60acttgagccc aggagtttga gtcnagtctg ggcnaacant agnaaacccc atctctaaaa
120taaataaaat aaatgactga gctgttgtga aagggttagt gatagaganc cagaactctt
180aactgtcagg ccaatgtctt tnccacttcc tcacactgat cccacataac tctgggtatg
240atagtgagtg tcaggggtca gacatgggtc tgntnnngct gagctgcctg attgttcctt
300ataaagtttg tcaacctctt cttttttttg aacaagttaa gaggaaagga attaaagctt
360tatggatgat cacttttcaa
38091225DNAArtificialsynthetic oligonucleotide primer 912gcgtggtgac
tgatgtgtgc ctgta
2591325DNAArtificialsynthetic oligonucleotide primer 913atgactgagc
tgttgtgaaa gggtt
2591425DNAArtificialsynthetic oligonucleotide primer 914ccagaactct
taactgtcag gccaa
2591525DNAArtificialsynthetic oligonucleotide primer 915tcttaactgt
caggccaatg tcttt
2591625DNAArtificialsynthetic oligonucleotide primer 916tcacactgat
cccacataac tctgg
2591725DNAArtificialsynthetic oligonucleotide primer 917tcccacataa
ctctgggtat gatag
2591825DNAArtificialsynthetic oligonucleotide primer 918ggtatgatag
tgagtgtcag gggtc
2591925DNAArtificialsynthetic oligonucleotide primer 919gtgtcagggg
tcagacatgg gtctg
2592025DNAArtificialsynthetic oligonucleotide primer 920agctgcctga
ttgttcctta taaag
2592125DNAArtificialsynthetic oligonucleotide primer 921ttataaagtt
tgtcaacctc ttctt
2592225DNAArtificialsynthetic oligonucleotide primer 922agctttatgg
atgatcactt ttcaa
25923472DNAHomo sapiensmisc_feature(154)..(154)n is a, c, g, or t
923tgggcttggg gacatctcaa tggccataga taggtagcct gggtttgggg acacctcagt
60gggctgatat gaataggctg cacttgggga cacctcagtg agctgatatg ggtgggctgg
120gcttggagat acctcagtgg gctgaaatgg ctgngccagg gttgggtact ccctaatggc
180ctgagatggg taggttggac ttggggacac ctcagtgggc tgaaatggct gagccagcat
240tgggtactcc ccaacagact gagatgggta gtctggactt ggagacaccc cnnanngctt
300gagatggctg ggccagattt gaggttaccc caggggcttg agatggctgg gctaggcttg
360agggctcccc actgtccata gatggctggg ctaggttttg ggacccccag ttagccattg
420attggtgacc ttggtctgag gccactctaa aggtccttga tgggtgtcct cg
47292425DNAArtificialsynthetic oligonucleotide primer 924tgggcttggg
gacatctcaa tggcc
2592525DNAArtificialsynthetic oligonucleotide primer 925tgggctgggc
ttggagatac ctcag
2592625DNAArtificialsynthetic oligonucleotide primer 926gccagggttg
ggtactccct aatgg
2592725DNAArtificialsynthetic oligonucleotide primer 927tggctgagcc
agcattgggt actcc
2592825DNAArtificialsynthetic oligonucleotide primer 928ggtactcccc
aacagactga gatgg
2592925DNAArtificialsynthetic oligonucleotide primer 929gatttgaggt
taccccaggg gcttg
2593025DNAArtificialsynthetic oligonucleotide primer 930gggcttgaga
tggctgggct aggct
2593125DNAArtificialsynthetic oligonucleotide primer 931gatggctggg
ctaggttttg ggacc
2593225DNAArtificialsynthetic oligonucleotide primer 932gacccccagt
tagccattga ttggt
2593325DNAArtificialsynthetic oligonucleotide primer 933ttggtgacct
tggtctgagg ccact
2593425DNAArtificialsynthetic oligonucleotide primer 934taaaggtcct
tgatgggtgt cctcg
25935398DNAHomo sapiens 935acaatgggag cccttcatca cagctttgta gttacctcaa
ctctggctgt tgagtaattt 60gctcagttaa atctgtttgt gggtgtagtg aattacaacc
tcctctggtt ccctcgagat 120caagtctaac ctggtgattg cgtcatctgg tgggagagca
cggctacaac agcaggtgga 180aaccatgctc gggtcctggc cactttgcct aggatgaaag
ctgttgtggc aaacagggga 240aagagcttca agctttgtag taaaaggaat ctgggcttaa
attcctctta tcagcactgt 300gaccttggag aattaatcat tcttggttgt ggtgagggtt
aattgagatc aggtatttaa 360aggacatctg acagtgcctg gcacgggata ggtgctcc
39893625DNAArtificialsynthetic oligonucleotide
primer 936acaatgggag cccttcatca cagct
2593725DNAArtificialsynthetic oligonucleotide primer 937gctttgtagt
tacctcaact ctggc
2593825DNAArtificialsynthetic oligonucleotide primer 938agtgaattac
aacctcctct ggttc
2593925DNAArtificialsynthetic oligonucleotide primer 939gttccctcga
gatcaagtct aacct
2594025DNAArtificialsynthetic oligonucleotide primer 940gtctaacctg
gtgattgcgt catct
2594125DNAArtificialsynthetic oligonucleotide primer 941ggtgggagag
cacggctaca acagc
2594225DNAArtificialsynthetic oligonucleotide primer 942tcctggccac
tttgcctagg atgaa
2594325DNAArtificialsynthetic oligonucleotide primer 943atctgggctt
aaattcctct tatca
2594425DNAArtificialsynthetic oligonucleotide primer 944cctcttatca
gcactgtgac cttgg
2594525DNAArtificialsynthetic oligonucleotide primer 945aaggacatct
gacagtgcct ggcac
2594625DNAArtificialsynthetic oligonucleotide primer 946gtgcctggca
cgggataggt gctcc 2594799DNAHomo
sapiens 947ttttttttac caactattgt cacatacata taacgcatat agacatatgg
acacacagaa 60gatacttctt acctggagtt atatactagc aatattttc
9994825DNAArtificialsynthetic oligonucleotide primer
948ttttttttac caactattgt cacat
2594925DNAArtificialsynthetic oligonucleotide primer 949ttttaccaac
tattgtcaca tacat
2595025DNAArtificialsynthetic oligonucleotide primer 950taccaactat
tgtcacatac atata
2595125DNAArtificialsynthetic oligonucleotide primer 951actattgtca
catacatata acgca
2595225DNAArtificialsynthetic oligonucleotide primer 952gtcacataca
tataacgcat ataga
2595325DNAArtificialsynthetic oligonucleotide primer 953aacgcatata
gacatatgga cacac
2595425DNAArtificialsynthetic oligonucleotide primer 954catatggaca
cacagaagat acttc
2595525DNAArtificialsynthetic oligonucleotide primer 955gaagatactt
cttacctgga gttat
2595625DNAArtificialsynthetic oligonucleotide primer 956gatacttctt
acctggagtt atata
2595725DNAArtificialsynthetic oligonucleotide primer 957tcttacctgg
agttatatac tagca
2595825DNAArtificialsynthetic oligonucleotide primer 958ggagttatat
actagcaata ttttc
25959489DNAHomo sapiensmisc_feature(33)..(33)n is a, c, g, or t
959cccagccgag gaagagccgg gaaagggcgt cgncgctcat gtaggctcac ctttcgagtg
60cggagggtga cggacgcccc ccgttcaagc agcagctcag ccacctcgaa gtggncacag
120ttgagggcat cgtggagggg ggtgatgcct tcgcagccct ggccacctgg gtcgtccact
180gcggccccgt ggtccagcag gaagcggaca atttctgcag accaggagac gtaagcccag
240ctcccgatgc cccgccagga ctgactcttc gccccacgtg tccaccaagg gtctcactcc
300agcctgggtg acagagcgag actccatctc aagaaaaaaa aacaacacaa catggatggt
360gcctggctca aagtgagggc tgacggctgc caacctccaa tggtggtctc tgccatcagc
420actcctggac cacgcgtgcc atctcctctc ccaccctggg aggctagggg tacaactact
480gtctccagt
48996025DNAArtificialsynthetic oligonucleotide primer 960cccagccgag
gaagagccgg gaaag
2596125DNAArtificialsynthetic oligonucleotide primer 961tcatgtaggc
tcacctttcg agtgc
2596225DNAArtificialsynthetic oligonucleotide primer 962cgagtgcgga
gggtgacgga cgccc
2596325DNAArtificialsynthetic oligonucleotide primer 963atcgtggagg
ggggtgatgc cttcg
2596425DNAArtificialsynthetic oligonucleotide primer 964ggaagcggac
aatttctgca gacca
2596525DNAArtificialsynthetic oligonucleotide primer 965gcagaccagg
agacgtaagc ccagc
2596625DNAArtificialsynthetic oligonucleotide primer 966aacaacacaa
catggatggt gcctg
2596725DNAArtificialsynthetic oligonucleotide primer 967ggtgcctggc
tcaaagtgag ggctg
2596825DNAArtificialsynthetic oligonucleotide primer 968aaagtgaggg
ctgacggctg ccaac
2596925DNAArtificialsynthetic oligonucleotide primer 969ggaggctagg
ggtacaacta ctgtc
2597025DNAArtificialsynthetic oligonucleotide primer 970taggggtaca
actactgtct ccagt
25971397DNAHomo sapiens 971ggcagcgtat ccagaagggg gcagggaatg ggtgaagagg
ttgtgctcta gggcagagct 60gagctctgat ctagaaagga cagcaaagat acctggaagg
cctcccgatt cttgcgttgt 120tggcgtcgct cccgaagccg ggcccgctcc cgttcctcct
cctcttccct ctccaaagct 180cggatgtgct cctcaaaaca gatcagtgca tcttccttgt
ccatgtctaa agacaggcag 240gaggttccgc gggcattgtc ccagcaggat accctctcag
accccagcac ccctaatgtt 300tcaacgatgc tgtcctacag gtgctaggga tacccagggt
ggtgggggaa gggcctggag 360ggggctctgt gggagcagcc actgcaatgg tagttct
39797225DNAArtificialsynthetic oligonucleotide
primer 972ggcagcgtat ccagaagggg gcagg
2597325DNAArtificialsynthetic oligonucleotide primer 973gaggttgtgc
tctagggcag agctg
2597425DNAArtificialsynthetic oligonucleotide primer 974gagctgagct
ctgatctaga aagga
2597525DNAArtificialsynthetic oligonucleotide primer 975agcaaagata
cctggaaggc ctccc
2597625DNAArtificialsynthetic oligonucleotide primer 976cgattcttgc
gttgttggcg tcgct
2597725DNAArtificialsynthetic oligonucleotide primer 977atgtgctcct
caaaacagat cagtg
2597825DNAArtificialsynthetic oligonucleotide primer 978aacagatcag
tgcatcttcc ttgtc
2597925DNAArtificialsynthetic oligonucleotide primer 979agcaccccta
atgtttcaac gatgc
2598025DNAArtificialsynthetic oligonucleotide primer 980tgtttcaacg
atgctgtcct acagg
2598125DNAArtificialsynthetic oligonucleotide primer 981gtcctacagg
tgctagggat accca
2598225DNAArtificialsynthetic oligonucleotide primer 982gagcagccac
tgcaatggta gttct
25983234DNAHomo sapiensmisc_feature(88)..(88)n is a, c, g, or t
983acaatgataa caacagctaa cacttagaaa ggaaatacaa tgaactgttc tcttcgagat
60ccagaataaa agtctggcag ctagaacncc gtttttatac accgaacccc tcgtgctctc
120cctgcntttt ttttgttgtt gntgttgtgc ttaatgttag aaaataacat tactactatg
180aaacgaanag aatttttttt caaaaccatg tcttgccatt acagatgaga caag
23498425DNAArtificialsynthetic oligonucleotide primer 984acaatgataa
caacagctaa cactt
2598525DNAArtificialsynthetic oligonucleotide primer 985aaggaaatac
aatgaactgt tctct
2598625DNAArtificialsynthetic oligonucleotide primer 986tgaactgttc
tcttcgagat ccaga
2598725DNAArtificialsynthetic oligonucleotide primer 987aactgttctc
ttcgagatcc agaat
2598825DNAArtificialsynthetic oligonucleotide primer 988tgttctcttc
gagatccaga ataaa
2598925DNAArtificialsynthetic oligonucleotide primer 989agaataaaag
tctggcagct agaac
2599025DNAArtificialsynthetic oligonucleotide primer 990aataacatta
ctactatgaa acgaa
2599125DNAArtificialsynthetic oligonucleotide primer 991ttttttcaaa
accatgtctt gccat
2599225DNAArtificialsynthetic oligonucleotide primer 992ttcaaaacca
tgtcttgcca ttaca
2599325DNAArtificialsynthetic oligonucleotide primer 993accatgtctt
gccattacag atgag
2599425DNAArtificialsynthetic oligonucleotide primer 994gtcttgccat
tacagatgag acaag
25995437DNAHomo sapiens 995ccctaccatc cacagtatca ttttcaggaa tattggtgga
aggtcctggt tctccaggtg 60gttccaagct atccaataaa cgattcactt tatttcgaag
ttctatcagt tctcgacgga 120gatatttcac ctgacttgat tcaaggggtc ttggctggcc
attaacaaat aatgtcagtt 180tcagtatcct actgcactga attgcaaagg aaaggtcaga
actatcaaaa attgttataa 240gatctccatc ttcatcttta tactttattg ttacttcatc
attactcaga agttttcctc 300tgaaaactcg ttgcatcatt agcactaatt catcataagt
aatatcttca ttatgaatag 360gaattcgccg aatatcctcc ccaagttgag ctttgatgat
tagcttccca cttagatcca 420actgtccgtt catggtg
43799625DNAArtificialsynthetic oligonucleotide
primer 996ccctaccatc cacagtatca ttttc
2599725DNAArtificialsynthetic oligonucleotide primer 997ggtggttcca
agctatccaa taaac
2599825DNAArtificialsynthetic oligonucleotide primer 998gaagttctat
cagttctcga cggag
2599925DNAArtificialsynthetic oligonucleotide primer 999ctcgacggag
atatttcacc tgact
25100025DNAArtificialsynthetic oligonucleotide primer 1000tgattcaagg
ggtcttggct ggcca
25100125DNAArtificialsynthetic oligonucleotide primer 1001cagtatccta
ctgcactgaa ttgca
25100225DNAArtificialsynthetic oligonucleotide primer 1002tttcctctga
aaactcgttg catca
25100325DNAArtificialsynthetic oligonucleotide primer 1003taggaattcg
ccgaatatcc tcccc
25100425DNAArtificialsynthetic oligonucleotide primer 1004tatcctcccc
aagttgagct ttgat
25100525DNAArtificialsynthetic oligonucleotide primer 1005gatgattagc
ttcccactta gatcc
25100625DNAArtificialsynthetic oligonucleotide primer 1006tagatccaac
tgtccgttca tggtg
251007338DNAHomo sapiensmisc_feature(42)..(42)n is a, c, g, or t
1007aactcccagg tttctatatg ccagccaaga ggtgactttg tnaagcagga ctttnctaag
60ggtagtagtn ctatgancct gctgtgttaa ctcctttnct gcacatncgt ggtancccag
120ggaagtttgt tttcttctac ctctttatat ggaatatgaa gcatttgcac taaatcatct
180ctcttgagga aatttagtaa caaccagaac gttttgagaa tgacttgaac agtgtaactg
240ggtttaataa gtgagtttat tcacttagac atattttctc aaaaataata ctgccttgac
300agtattattc acagcctgtg ctggttgttg taatgata
338100825DNAArtificialsynthetic oligonucleotide primer 1008aactcccagg
tttctatatg ccagc
25100925DNAArtificialsynthetic oligonucleotide primer 1009tcttctacct
ctttatatgg aatat
25101025DNAArtificialsynthetic oligonucleotide primer 1010gcatttgcac
taaatcatct ctctt
25101125DNAArtificialsynthetic oligonucleotide primer 1011aaatcatctc
tcttgaggaa attta
25101225DNAArtificialsynthetic oligonucleotide primer 1012atctctcttg
aggaaattta gtaac
25101325DNAArtificialsynthetic oligonucleotide primer 1013tagtaacaac
cagaacgttt tgaga
25101425DNAArtificialsynthetic oligonucleotide primer 1014accagaacgt
tttgagaatg acttg
25101525DNAArtificialsynthetic oligonucleotide primer 1015gaatgacttg
aacagtgtaa ctggg
25101625DNAArtificialsynthetic oligonucleotide primer 1016gagtttattc
acttagacat atttt
25101725DNAArtificialsynthetic oligonucleotide primer 1017gccttgacag
tattattcac agcct
25101825DNAArtificialsynthetic oligonucleotide primer 1018gcctgtgctg
gttgttgtaa tgata
251019448DNAHomo sapiensmisc_feature(26)..(26)n is a, c, g, or t
1019gaaagcaatt gtatttgtgc aaagcntaaa caggaaaaca aagtggatga cttggcattt
60gaagaatgaa aaagccaaac agcactgtca caaccatttc tgccttcagt ctccagtgcc
120tttttctttc attataaaat ccatagaaat ggcaaggaaa gatataggaa agtttatcac
180agatacagta gctattacag aaatttggaa ttcagcagat gttttaagtc aaaattttct
240gtgtaacaga tgaatttgca aagttttgaa aacacagtcc acaaagtaat ttaaaatgtg
300ataattaaat ttgttttaaa aagcaaatta acacctttta ttttctgtga agataaaaca
360ataaaagaaa aatgttcata tatccaaacc tatgctggaa gtacacaaaa agacaatttg
420tatacattac tggcaatagt cttgtttt
448102025DNAArtificialsynthetic oligonucleotide primer 1020gaaagcaatt
gtatttgtgc aaagc
25102125DNAArtificialsynthetic oligonucleotide primer 1021aagtggatga
cttggcattt gaaga
25102225DNAArtificialsynthetic oligonucleotide primer 1022acagcactgt
cacaaccatt tctgc
25102325DNAArtificialsynthetic oligonucleotide primer 1023atcacagata
cagtagctat tacag
25102425DNAArtificialsynthetic oligonucleotide primer 1024tttggaattc
agcagatgtt ttaag
25102525DNAArtificialsynthetic oligonucleotide primer 1025ctgtgtaaca
gatgaatttg caaag
25102625DNAArtificialsynthetic oligonucleotide primer 1026gttttgaaaa
cacagtccac aaagt
25102725DNAArtificialsynthetic oligonucleotide primer 1027atgttcatat
atccaaacct atgct
25102825DNAArtificialsynthetic oligonucleotide primer 1028aaacctatgc
tggaagtaca caaaa
25102925DNAArtificialsynthetic oligonucleotide primer 1029gacaatttgt
atacattact ggcaa
25103025DNAArtificialsynthetic oligonucleotide primer 1030acattactgg
caatagtctt gtttt
251031482DNAHomo sapiens 1031ctcagaacca ggcggcaggg tcaggatcgg gagaggaacc
agatctaagg atagtggggc 60cctggtctcc gcagtagggg ttgaactata tccaatataa
agcattatcc aaggggaccg 120gattagcccc catgggtgac accaagatgg gagcgggggt
ggggggtgat aagagacaca 180ggagacagag tcaggtccca gaggcagcaa ggcctacccc
caaattgcag tcaggttggg 240aagtagaatc atggctaggc ccgcggcccc gggtctttct
caggctcggt ccctggcacg 300ccgcggatgt ccggcagcag gcggcagcca gccacgatgt
ccagacgctc ggccagcgca 360caaaggtccc cgcgcgccag gcgcacgctg tgggccgccg
ccagccccgc cgcctgggct 420gccgccagcc tactagccag ggcggccacg tcgcggcctg
cacggcggta gacaccgctc 480ac
482103225DNAArtificialsynthetic oligonucleotide
primer 1032ctcagaacca ggcggcaggg tcagg
25103325DNAArtificialsynthetic oligonucleotide primer
1033ggcagggtca ggatcgggag aggaa
25103425DNAArtificialsynthetic oligonucleotide primer 1034taaggatagt
ggggccctgg tctcc
25103525DNAArtificialsynthetic oligonucleotide primer 1035cctggtctcc
gcagtagggg ttgaa
25103625DNAArtificialsynthetic oligonucleotide primer 1036gtaggggttg
aactatatcc aatat
25103725DNAArtificialsynthetic oligonucleotide primer 1037taaagcatta
tccaagggga ccgga
25103825DNAArtificialsynthetic oligonucleotide primer 1038gggtgacacc
aagatgggag cgggg
25103925DNAArtificialsynthetic oligonucleotide primer 1039ggagacagag
tcaggtccca gaggc
25104025DNAArtificialsynthetic oligonucleotide primer 1040cctaccccca
aattgcagtc aggtt
25104125DNAArtificialsynthetic oligonucleotide primer 1041gaagtagaat
catggctagg cccgc
25104225DNAArtificialsynthetic oligonucleotide primer 1042ctgcacggcg
gtagacaccg ctcac
251043223DNAHomo sapiens 1043gtggtccgcg ctctaggaaa agatatgaat ggcctgggtg
gccggcgtgc ggcaggcggg 60acactcgggc tcgctcttgc cgcagatgcg gacggcgcag
tccatgcaga agaggttgtg 120gccgcagggg accagcgcag ccatcacctc gccctcggcg
cacaccacgc actctcgcgc 180cagggccggg gccgaggacg ccgaaggggg cttgcggctg
ttc 223104425DNAArtificialsynthetic oligonucleotide
primer 1044gtggtccgcg ctctaggaaa agata
25104525DNAArtificialsynthetic oligonucleotide primer
1045aaaagatatg aatggcctgg gtggc
25104625DNAArtificialsynthetic oligonucleotide primer 1046tatgaatggc
ctgggtggcc ggcgt
25104725DNAArtificialsynthetic oligonucleotide primer 1047ctcgctcttg
ccgcagatgc ggacg
25104825DNAArtificialsynthetic oligonucleotide primer 1048gctcttgccg
cagatgcgga cggcg
25104925DNAArtificialsynthetic oligonucleotide primer 1049tgccgcagat
gcggacggcg cagtc
25105025DNAArtificialsynthetic oligonucleotide primer 1050acggcgcagt
ccatgcagaa gaggt
25105125DNAArtificialsynthetic oligonucleotide primer 1051gcagaagagg
ttgtggccgc agggg
25105225DNAArtificialsynthetic oligonucleotide primer 1052gaggacgccg
aagggggctt gcggc
25105325DNAArtificialsynthetic oligonucleotide primer 1053gacgccgaag
ggggcttgcg gctgt
25105425DNAArtificialsynthetic oligonucleotide primer 1054cgccgaaggg
ggcttgcggc tgttc
251055159DNAHomo sapiens 1055cggccgccta ctactactat acggctgcga gaagacgaca
gaaggggcaa gaacgactgg 60agaaggaaga acaagatagg ctggagagag aggaattgaa
aagaaaggca gaggaggaaa 120ggcttcgcct agaagaggaa gcccgaaagc aggaagaag
159105625DNAArtificialsynthetic oligonucleotide
primer 1056cggccgccta ctactactat acggc
25105725DNAArtificialsynthetic oligonucleotide primer
1057cctactacta ctatacggct gcgag
25105825DNAArtificialsynthetic oligonucleotide primer 1058actactatac
ggctgcgaga agacg
25105925DNAArtificialsynthetic oligonucleotide primer 1059atacggctgc
gagaagacga cagaa
25106025DNAArtificialsynthetic oligonucleotide primer 1060gacagaaggg
gcaagaacga ctgga
25106125DNAArtificialsynthetic oligonucleotide primer 1061ggggcaagaa
cgactggaga aggaa
25106225DNAArtificialsynthetic oligonucleotide primer 1062ggaagaacaa
gataggctgg agaga
25106325DNAArtificialsynthetic oligonucleotide primer 1063gcagaggagg
aaaggcttcg cctag
25106425DNAArtificialsynthetic oligonucleotide primer 1064ggaggaaagg
cttcgcctag aagag
25106525DNAArtificialsynthetic oligonucleotide primer 1065gcctagaaga
ggaagcccga aagca
25106625DNAArtificialsynthetic oligonucleotide primer 1066gaggaagccc
gaaagcagga agaag
251067456DNAHomo sapiens 1067agctctgaga caccctagga gggcccacac ttctagtaca
acaaggctgt cttctcacag 60cctgtggaaa ctcctgaaga acagcattaa gtgatactcc
gaagagatga tgagaagcaa 120ttggccctcc aagaccatgg tgcgggagtt tgttggaacc
agctccagct gactcctctt 180cccctcccaa gcctcctagc tcatcccaaa aggagctcct
cccacaagta ccttaatagt 240cccactccat ttgattctca cagtcctgaa ggggcaggct
cctgttgcca ttgtagagat 300gaaaaaactg aggctcaaaa agaaaattgc cttcctcaac
gtcatacagc ttgtcaatgg 360cagggctggg attcaaaccc aggccaggta tggtggctca
cacctttaat tctagcactt 420tgggaggcca agatgggacg ccaggagttg cttgac
456106825DNAArtificialsynthetic oligonucleotide
primer 1068agctctgaga caccctagga gggcc
25106925DNAArtificialsynthetic oligonucleotide primer
1069ggcccacact tctagtacaa caagg
25107025DNAArtificialsynthetic oligonucleotide primer 1070tagtacaaca
aggctgtctt ctcac
25107125DNAArtificialsynthetic oligonucleotide primer 1071ctcacagcct
gtggaaactc ctgaa
25107225DNAArtificialsynthetic oligonucleotide primer 1072gatgagaagc
aattggccct ccaag
25107325DNAArtificialsynthetic oligonucleotide primer 1073gccctccaag
accatggtgc gggag
25107425DNAArtificialsynthetic oligonucleotide primer 1074ctcctcccac
aagtacctta atagt
25107525DNAArtificialsynthetic oligonucleotide primer 1075taatagtccc
actccatttg attct
25107625DNAArtificialsynthetic oligonucleotide primer 1076gattctcaca
gtcctgaagg ggcag
25107725DNAArtificialsynthetic oligonucleotide primer 1077cttcctcaac
gtcatacagc ttgtc
25107825DNAArtificialsynthetic oligonucleotide primer 1078gatgggacgc
caggagttgc ttgac
251079405DNAHomo sapiens 1079attattttgg tgggcttgat tttatagttt ctcttaaaaa
ttgtttggtt gccatccaga 60gggctctttt atgaagaatc tatataaact actaaaacat
ttcttaggac ctttttggtg 120aatttgatca taaaattaaa aagcgtgtat gtgttttata
aaggcatacc tctgttaaga 180aggctggttt tatgtttgcc ttttcttctc tactttgatc
accaccctag ctgttccttt 240ctccagacca ccttactttt caaacttgat tcttgctatc
acagctctct gtaacatcag 300ttaaaatcag ctgcctcaac tctttgagga tgtttgtgca
taggacggca ttgtgaaaca 360tagggaaatg gcagtcttac taacaaaaca ggacctatct
ctggc 405108025DNAArtificialsynthetic oligonucleotide
primer 1080attattttgg tgggcttgat tttat
25108125DNAArtificialsynthetic oligonucleotide primer
1081ttgtttggtt gccatccaga gggct
25108225DNAArtificialsynthetic oligonucleotide primer 1082ggcatacctc
tgttaagaag gctgg
25108325DNAArtificialsynthetic oligonucleotide primer 1083cagaccacct
tacttttcaa acttg
25108425DNAArtificialsynthetic oligonucleotide primer 1084cttgattctt
gctatcacag ctctc
25108525DNAArtificialsynthetic oligonucleotide primer 1085cacagctctc
tgtaacatca gttaa
25108625DNAArtificialsynthetic oligonucleotide primer 1086atcagttaaa
atcagctgcc tcaac
25108725DNAArtificialsynthetic oligonucleotide primer 1087caactctttg
aggatgtttg tgcat
25108825DNAArtificialsynthetic oligonucleotide primer 1088gtttgtgcat
aggacggcat tgtga
25108925DNAArtificialsynthetic oligonucleotide primer 1089catagggaaa
tggcagtctt actaa
25109025DNAArtificialsynthetic oligonucleotide primer 1090taacaaaaca
ggacctatct ctggc
251091269DNAHomo sapiensmisc_feature(93)..(93)n is a, c, g, or t
1091tttcctgtct tgaataatcc caacaaaacc atttgaatcc tcaagtaaaa atatatttat
60cacttaaatc agaaacaatg aattcaaaat ggnaaagtag ttaaagtcta aaatgttttt
120tcccataaac ttagaaagaa ttatcttcta cttccataaa tatattatgt tttataacga
180tgtattgtgt taccacatac aacaaacctt tatgaactgc tcatataact gtttaattgt
240tttcaatctc tggctctgaa caattctag
269109225DNAArtificialsynthetic oligonucleotide primer 1092tttcctgtct
tgaataatcc caaca
25109325DNAArtificialsynthetic oligonucleotide primer 1093gaataatccc
aacaaaacca tttga
25109425DNAArtificialsynthetic oligonucleotide primer 1094caaaaccatt
tgaatcctca agtaa
25109525DNAArtificialsynthetic oligonucleotide primer 1095gaaagaatta
tcttctactt ccata
25109625DNAArtificialsynthetic oligonucleotide primer 1096attatcttct
acttccataa atata
25109725DNAArtificialsynthetic oligonucleotide primer 1097ataacgatgt
attgtgttac cacat
25109825DNAArtificialsynthetic oligonucleotide primer 1098gttaccacat
acaacaaacc tttat
25109925DNAArtificialsynthetic oligonucleotide primer 1099caacaaacct
ttatgaactg ctcat
25110025DNAArtificialsynthetic oligonucleotide primer 1100gaactgctca
tataactgtt taatt
25110125DNAArtificialsynthetic oligonucleotide primer 1101ttaattgttt
tcaatctctg gctct
25110225DNAArtificialsynthetic oligonucleotide primer 1102aatctctggc
tctgaacaat tctag
251103395DNAHomo sapiens 1103ttcattcaaa catttcttat tatcatttat tgcacatagc
atggattaat caaataagtt 60taaaataaaa taatagacta gagaaaggtg ctttatttta
aaaacagaaa caaaaagaag 120gtacgtggat tatctgatgc tacatcacac tctgggagag
acttcccttc tttcagagag 180cctctcattt cttaatgtgg atcattttgc tctttccccc
tgataatgct cacttactct 240ctttcataat ctccccctct ttcacttgtt cttttctttc
caatcatcca atgatccatc 300aaggtacttt ggtgttcagt gctttctcat atggttcaac
tcagatcatg tagtctttct 360cacccaacca attcaactac tgtttcctga gaccc
395110425DNAArtificialsynthetic oligonucleotide
primer 1104ttcattcaaa catttcttat tatca
25110525DNAArtificialsynthetic oligonucleotide primer
1105ggtacgtgga ttatctgatg ctaca
25110625DNAArtificialsynthetic oligonucleotide primer 1106atgctacatc
acactctggg agaga
25110725DNAArtificialsynthetic oligonucleotide primer 1107ctttcagaga
gcctctcatt tctta
25110825DNAArtificialsynthetic oligonucleotide primer 1108cttttctttc
caatcatcca atgat
25110925DNAArtificialsynthetic oligonucleotide primer 1109caatgatcca
tcaaggtact ttggt
25111025DNAArtificialsynthetic oligonucleotide primer 1110gtactttggt
gttcagtgct ttctc
25111125DNAArtificialsynthetic oligonucleotide primer 1111gtgctttctc
atatggttca actca
25111225DNAArtificialsynthetic oligonucleotide primer 1112tggttcaact
cagatcatgt agtct
25111325DNAArtificialsynthetic oligonucleotide primer 1113ctcacccaac
caattcaact actgt
25111425DNAArtificialsynthetic oligonucleotide primer 1114attcaactac
tgtttcctga gaccc
251115363DNAHomo sapiensmisc_feature(57)..(57)n is a, c, g, or t
1115ggggcacgct tttcacaacg tggagatgca gggtcatggg ctgcctgcta ccacgangcn
60gaaggggatg gtgctgggca ccagnncctg ccccngggct gggtttctcc tgggcctggg
120ccgaggggtg gaggcctgtg ggtgacgtgt tcaagacggc tcagcaancc ccacctgaca
180gtgtccaggt ggggcctcnt nncccncccc caggctcccc agggagcaca gcctccactc
240ctacacactg gctactctgc cggaggggga ggccgtgctg gagtgatgcc tggcgcgtgt
300tgtgtgatgg gagaattggg tatttacagt ttaataacga gatctcgatg ccgtcgatcg
360gcc
363111625DNAArtificialsynthetic oligonucleotide primer 1116ggggcacgct
tttcacaacg tggag
25111725DNAArtificialsynthetic oligonucleotide primer 1117gcttttcaca
acgtggagat gcagg
25111825DNAArtificialsynthetic oligonucleotide primer 1118gagatgcagg
gtcatgggct gcctg
25111925DNAArtificialsynthetic oligonucleotide primer 1119tgcagggtca
tgggctgcct gctac
25112025DNAArtificialsynthetic oligonucleotide primer 1120ggcctgtggg
tgacgtgttc aagac
25112125DNAArtificialsynthetic oligonucleotide primer 1121gtgacgtgtt
caagacggct cagca
25112225DNAArtificialsynthetic oligonucleotide primer 1122aggccgtgct
ggagtgatgc ctggc
25112325DNAArtificialsynthetic oligonucleotide primer 1123ctggcgcgtg
ttgtgtgatg ggaga
25112425DNAArtificialsynthetic oligonucleotide primer 1124gagaattggg
tatttacagt ttaat
25112525DNAArtificialsynthetic oligonucleotide primer 1125taacgagatc
tcgatgccgt cgatc
25112625DNAArtificialsynthetic oligonucleotide primer 1126gagatctcga
tgccgtcgat cggcc
251127178DNAHomo sapiens 1127ggcactggga acaggcatgc tcccagctag gaagaagccg
gggacataaa gctagcagct 60gtggtgagga taccagggtg agtgctgagg gtgagggacc
tgggcttcct gtttttaatg 120attaagcctc agcctcaaaa agcttttgac agcctggaca
acatggccag accctatc 178112825DNAArtificialsynthetic oligonucleotide
primer 1128ggcactggga acaggcatgc tccca
25112925DNAArtificialsynthetic oligonucleotide primer
1129gcatgctccc agctaggaag aagcc
25113025DNAArtificialsynthetic oligonucleotide primer 1130gccggggaca
taaagctagc agctg
25113125DNAArtificialsynthetic oligonucleotide primer 1131agctagcagc
tgtggtgagg atacc
25113225DNAArtificialsynthetic oligonucleotide primer 1132gaggatacca
gggtgagtgc tgagg
25113325DNAArtificialsynthetic oligonucleotide primer 1133gtgctgaggg
tgagggacct gggct
25113425DNAArtificialsynthetic oligonucleotide primer 1134ctgggcttcc
tgtttttaat gatta
25113525DNAArtificialsynthetic oligonucleotide primer 1135ttaatgatta
agcctcagcc tcaaa
25113625DNAArtificialsynthetic oligonucleotide primer 1136aagcctcagc
ctcaaaaagc ttttg
25113725DNAArtificialsynthetic oligonucleotide primer 1137aaaaagcttt
tgacagcctg gacaa
25113825DNAArtificialsynthetic oligonucleotide primer 1138ctggacaaca
tggccagacc ctatc
251139422DNAHomo sapiensmisc_feature(207)..(208)n is a, c, g, or t
1139ggccccgtat tcatttttta tactggaaaa catttttttt gtaatttttc tttgcaaaga
60aatgagcata aaaatgaata ctccaaagaa aaggaattat tatggcaaat taaaagggac
120acggtactat gatttaatta ctgtcttgtc tttttaaaat gtcatctctt gttttaccct
180ttttttaaat aaaagcttta aaaacanntc tttgggtatt attctggagg tatgtttctt
240ttatataaga tttcaagttt aaacatttac aataagtaat aatatttaaa ttcttataac
300aagtaatgaa atatttggtt tagtaattag cntagtctat tttnaaaaat cattaaaatt
360tnctttgttt ttaagaatgc catactacaa atgatgttat ttggttttaa tggtgttttg
420tg
422114025DNAArtificialsynthetic oligonucleotide primer 1140ggccccgtat
tcatttttta tactg
25114125DNAArtificialsynthetic oligonucleotide primer 1141aagggacacg
gtactatgat ttaat
25114225DNAArtificialsynthetic oligonucleotide primer 1142tatgatttaa
ttactgtctt gtctt
25114325DNAArtificialsynthetic oligonucleotide primer 1143tactgtcttg
tctttttaaa atgtc
25114425DNAArtificialsynthetic oligonucleotide primer 1144aaaatgtcat
ctcttgtttt accct
25114525DNAArtificialsynthetic oligonucleotide primer 1145tctttgggta
ttattctgga ggtat
25114625DNAArtificialsynthetic oligonucleotide primer 1146gtattattct
ggaggtatgt ttctt
25114725DNAArtificialsynthetic oligonucleotide primer 1147tctggaggta
tgtttctttt atata
25114825DNAArtificialsynthetic oligonucleotide primer 1148tttgttttta
agaatgccat actac
25114925DNAArtificialsynthetic oligonucleotide primer 1149gaatgccata
ctacaaatga tgtta
25115025DNAArtificialsynthetic oligonucleotide primer 1150tatttggttt
taatggtgtt ttgtg
251151420DNAHomo sapiens 1151ctcttgatct ctcaaccttg tgatctgccc gcctcgacct
cccaaagtgc tgggattaca 60ggcatgagcc actgcgcctg gcctagctac agattttttt
acaatgctaa gtattttctg 120aacagtttga ctgttgccaa ataatttatt caattttttt
cccctctatg actcattact 180taccctgagc aaatcatcta tacgtccctc cttcttttcc
aggtcctggg ttttattact 240ttctaatgct gctaatttca gcattgtgag atcagtctaa
atgaaaaaaa gttattttat 300tatctccatt atatatgttg tttcaagcaa acataaaact
agattttact ccaaattcaa 360aaggtaaaga aaaatatatt tgtgtgtata tgtaaagtga
atctcaaaaa gtttgtcgac 420115225DNAArtificialsynthetic oligonucleotide
primer 1152ctcttgatct ctcaaccttg tgatc
25115325DNAArtificialsynthetic oligonucleotide primer
1153cgcctggcct agctacagat ttttt
25115425DNAArtificialsynthetic oligonucleotide primer 1154tggcctagct
acagattttt ttaca
25115525DNAArtificialsynthetic oligonucleotide primer 1155tacagatttt
tttacaatgc taagt
25115625DNAArtificialsynthetic oligonucleotide primer 1156ttctgaacag
tttgactgtt gccaa
25115725DNAArtificialsynthetic oligonucleotide primer 1157ctctatgact
cattacttac cctga
25115825DNAArtificialsynthetic oligonucleotide primer 1158atgactcatt
acttaccctg agcaa
25115925DNAArtificialsynthetic oligonucleotide primer 1159tcattactta
ccctgagcaa atcat
25116025DNAArtificialsynthetic oligonucleotide primer 1160aagttatttt
attatctcca ttata
25116125DNAArtificialsynthetic oligonucleotide primer 1161ctagatttta
ctccaaattc aaaag
25116225DNAArtificialsynthetic oligonucleotide primer 1162agtgaatctc
aaaaagtttg tcgac
251163413DNAHomo sapiens 1163gtacacggtc acagttttca tcatactaat ctctcttcaa
gaaatcttca aaatttgatt 60tacttctgaa aatacgtttc accttttctc tcctgttgct
attatctatt accatgtcag 120aacttagtct ccattaaatg ccaagcccac cgttaggcac
catgggtaaa aaatgaatag 180gaaaccatct gtttcatacg gtcttcagtc attttgcgct
tttcacaatg tactggtagt 240agatcacaat tttttttcct ttgtagttac aatagctaga
aagtaaatgt tggaatttta 300aaatatgcag gtatactaga ttttgggaat gtgggggatt
ggaagcatct agacattgtt 360tgatttgtga cattcaaaag caggtacgtc ataactcgtt
tgcttctatt ttc 413116425DNAArtificialsynthetic oligonucleotide
primer 1164gtacacggtc acagttttca tcata
25116525DNAArtificialsynthetic oligonucleotide primer
1165tttcatcata ctaatctctc ttcaa
25116625DNAArtificialsynthetic oligonucleotide primer 1166accatgtcag
aacttagtct ccatt
25116725DNAArtificialsynthetic oligonucleotide primer 1167gtctccatta
aatgccaagc ccacc
25116825DNAArtificialsynthetic oligonucleotide primer 1168gcccaccgtt
aggcaccatg ggtaa
25116925DNAArtificialsynthetic oligonucleotide primer 1169aaaccatctg
tttcatacgg tcttc
25117025DNAArtificialsynthetic oligonucleotide primer 1170tacggtcttc
agtcattttg cgctt
25117125DNAArtificialsynthetic oligonucleotide primer 1171tttgcgcttt
tcacaatgta ctggt
25117225DNAArtificialsynthetic oligonucleotide primer 1172ggaagcatct
agacattgtt tgatt
25117325DNAArtificialsynthetic oligonucleotide primer 1173gcaggtacgt
cataactcgt ttgct
25117425DNAArtificialsynthetic oligonucleotide primer 1174tcataactcg
tttgcttcta ttttc 25
User Contributions:
comments("1"); ?> comment_form("1"); ?>Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
Usenet FAQ Index |
Documents |
Other FAQs |
User Contributions:
Comment about this patent or add new information about this topic:
People who visited this patent also read: | |
Patent application number | Title |
---|---|
20160133717 | Transistors, Memory Cells and Semiconductor Constructions |
20160133716 | ALTERNATIVE GATE DIELECTRIC FILMS FOR SILICON GERMANIUM AND GERMANIUM CHANNEL MATERIALS |
20160133715 | SEMICONDUCTOR DEVICE |
20160133714 | Metal-Oxide-Semiconductor Field-Effect Transistor with Metal-Insulator-Semiconductor Contact Structure to Reduce Schottky Barrier |
20160133713 | Floating Gate NVM With Low-Moisture-Content Oxide Cap Layer |